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Abstract 
 
TRIB2 is a member of the mammalian Tribbles family of serine/threonine 
pseudokinases (TRIB1-3). In malignant haematopoiesis, Trib2 has been identified 
as an oncogene in myeloid leukaemogenesis. However, Trib2 is expressed 
physiologically at high levels in the T cell compartment of normal haematopoiesis 
and the normal haematopoietic role of TRIB2 remains elusive. Here, we studied 
murine haematopoiesis after Trib2 ablation under steady state and proliferative 
stress conditions, including genotoxic and oncogenic stress.  
 
At the steady state, we found that TRIB2 loss did not adversely affect peripheral 
blood cell counts and populations. Trib2-/- mice had similar bone marrow cellularity 
compared to wild type mice and no detectable significant differences found in the 
populations of haematopoietic stem and progenitor cells. However, Trib2-/- mice had 
significantly higher thymic cellularity due to the increased proliferation of Trib2-/- 
developing thymocytes which give rise to increased number of CD4/CD8 double 
and CD4 single positive mature thymic subsets.    
 
During stress haematopoiesis, Trib2-/- developing thymocytes undergo 
accelerated proliferation and demonstrate hypersensitivity to 5-fluorouracil-induced 
cell death. Despite the increased cell death post 5-fluorouracil-induced proliferative 
stress, Trib2-/- mice exhibit accelerated thymopoietic recovery post treatment due to 
expansion of Trib2-/- c-Kit- CD4/CD8 double negative 1 thymic progenitors and 
increased cell division kinetics of developing thymocytes. The increased 
proliferation in Trib2-/- thymocytes was exacerbated under oncogenic stress. In an 
experimental murine T-cell acute lymphoblastic leukaemia model, Trib2-/- mice had 
reduced latency in vivo which associated with aggressive phenotypes of T-cell 
acute lymphoblastic leukaemia and impaired activation of mitogen-activated protein 
10 
 
kinase. Gene set enrichment analysis showed that TRIB2 expression is elevated in 
immature subtype of human T-cell acute lymphoblastic leukaemia enriched with 
mitogen-activated protein kinase signalling. However, TRIB2 expression is 
suppressed in mature subtype of human T-cell acute lymphoblastic leukaemia 
associated with impaired mitogen-activated protein kinase signalling. Thus, TRIB2 
emerges as a novel regulator of thymocyte cellular proliferation, important for the 
thymopoietic response to genotoxic and oncogenic stress, and possessing tumour 
suppressor function. 
 
In Drosophila, Tribbles promotes degradation of String which is an orthologue of 
mammalian CDC25 phosphatases in order to arrest cell cycle during embryonic 
development. Given the anti-proliferative role we established for Trib2 in the context 
of developing thymocytes during intrathymic T-cell development, we also examined 
if the role of Tribbles-induced degradation of String is conserved in TRIB2. We 
found that TRIB2 interacts physically with CDC25B/C but not CDC25A isoform. 
Overexpression of TRIB2 promotes K48-linked polyubiquitination of CDC25C and 
degradation of CDC25C in the nucleus. Hence, this provides an insight into the 
molecular mechanism of TRIB2-mediated regulation of cell cycle. Future works are 
warranted to examine TRIB2-CDC25C interaction in the context of developing 
thymocytes and in T-cell acute lymphoblastic leukaemia, the malignant counterpart.   
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CHAPTER 1: INTRODUCTION 
  
1.1 Discovery of Tribbles family 
The Tribbles gene was first discovered in three independent Drosophila genetic 
screens. Two screens (Seher and Leptin, 2000, Grosshans and Wieschaus, 2000) 
were designed to identify mutations that affect gastrulation, the formation of ventral 
furrow by mesodermal precursor cells during Drosophila embryo development. In 
Tribbles mutants, the precursor cells have premature mitosis and this leads to 
defective gastrulation. These studies identified Tribbles as an inhibitor of mitosis 
and suggested that Tribbles inhibits String function, the Drosophila ortholog of Cell 
division cycle 25 (CDC25) phosphatase family that is required to initiate mitosis. 
The third screen discovered Tribbles as one of the genes that affect oogenesis 
when being overexpressed (Mata et al., 2000). This study investigated Tribbles in 
Drosophila wing and embryonic developments, and demonstrated that Tribbles 
coordinates mitosis and morphogenesis by promoting proteasomal dependent 
degradation of String. Another role of Tribbles in Drosophila was found to promote 
the degradation of Slbo, the Drosophila ortholog of CCAAT enhancer-binding 
protein (CEBP) family of transcription factors during oogenesis (Rorth et al., 2000).  
 
 
Figure 1.1 │ High degrees of similarity between the amino acid sequences of 
Tribbles members within the human family. TRIB1 and TRIB2 (71.3%) are more 
similar compared to TRIB3. The values in parentheses indicate similarity compared 
to the corresponded mouse Tribbles members. 
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There are three members (TRIB1-3) for mammalian Tribbles family. All the 
members are highly conserved between mouse and human (Figure 1.1) and have 
been identified as important signalling modulators and mediators in various 
diseases (Yokoyama and Nakamura, 2011). Studies of Tribbles deficient mice are 
invaluable in this aspect. Satoh and colleagues found that Trib1 knockout mice have 
diminished adipose tissue mass due to a defect in the differentiation of tissue-
resident M2-like macrophages which regulate lipolysis (Satoh et al., 2013). In 
contrast, Okamoto and colleagues did not identify any phenotypic defects in Trib3 
knockout mice (Okamoto et al., 2007). Nevertheless, Ord and colleagues showed 
that mast cells derived from bone marrow cells of Trib3 knockout mice have 
increased sensitivity to cell cycle arrest and cell death in response to interleukin 
(IL)-3 deprivation (Ord et al., 2012). Studies of Trib2 knockout mice are reviewed in 
the introduction of Chapter 3. In this chapter, we review mouse and human 
Trib2/TRIB2 in-depth.  
 
1.2 Classification of Tribbles family 
Drosophila and mammalian Tribbles consist of N-terminal, kinase-like and C-
terminal domains. Sequence analysis revealed that although the kinase-like domain 
of Tribbles is homologous to other serine/theronie kinases, it lacks one (DFG) of the 
three conserved motifs that are required for catalytic activity (Figure 1.2) (Manning 
et al., 2002). Hence, Tribbles are considered incapable to phosphorylate substrates 
and have been termed serine/threonine pseudokinases. This was supported by two 
studies where kinase activity was not detected in Drosophila Tribbles (Grosshans 
and Wieschaus, 2000) and human TRIB3 (Bowers et al., 2003) using embryo 
microinjection and in vitro kinase assays respectively. However, evidence emerges 
that pseudokinases could be catalytically active despite lacking conserved motifs. 
For example, Ca2+/calmodulin-activated serine-threonine kinase (CASK) is 
classified as pseudokinase because it lacks the DFG motif, which is crucial for Mg2+ 
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binding. Mg2+ is required for typical protein kinases to stimulate the transfer of a 
phosphate from adenosine 5’-triphosphate (ATP) to a protein substrate. However, 
further studies showed that CASK works independent of Mg2+, and is capable of 
autophosphorylation and for phosphorylating specific physiological substrate 
(neurexin-1) (Mukherjee et al., 2008, Mukherjee et al., 2010). Phylogenetic analysis 
showed that CASK and Tribbles are from the same group (Calmodulin/Calcium 
regulated kinases) of human kinase superfamily (Manning et al., 2002). Notably, a 
recent study showed that TRIB2 behaves like CASK that it binds to ATP and 
autophosphorylates in a metal-independent manner (Bailey et al., 2015). Hence, 
TRIB2 could be catalytically active and it is important to determine the physiological 
role of TRIB2 in order to identify its potential substrates which could be cell context 
specific.  
 
 
Figure 1.2 │ Tribbles lacks the key enzymatic residues in the DFG motif. 
Sequence alignment of mammalian Tribbles comparing the three conserved motifs 
(VAIK, HRD and DFG), located within the catalytic domain, which are essential for 
ATP, peptide and Mg2+ bindings respectively. The amino acid residues in these 
motifs are conserved in mouse and human orthologs of TRIB1-3. Modified from 
REF. (Zhang et al., 2012b). 
 
1.3 Cellular functions of TRIB2 
TRIB2 acts as a scaffold protein that brings enzymes and their substrates into 
critical positions to allow cellular reactions to proceed (Zhang et al., 2012b). Due to 
its scaffolding function, TRIB2 is able to modulate and mediate diverse signalling. In 
this section, we discuss the functions of TRIB2 identified in different cellular 
contexts. These studies showed that TRIB2 regulates substrates via either 
promotion (yes-associated protein (YAP), c-Jun N-terminal kinase (JNK), p38 and 
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RELB proto-oncogene, NF-kB subunit (RELB)) or inhibition (RAC-beta 
serine/threonine-protein kinase (AKT), CEBPα, CEBP, extracellular signal-
regulated kinase (ERK), forkhead box O (FOXO), JNK, myeloid cell leukaemia 1 
(MCL1) and p100) of their functions. Enzymes that are required for TRIB2 to 
regulate these substrates include beta-transducin repeat containing protein (-
TRCP), constitutive photomorphogenesis 1 (COP1), MAPK kinase 1 (MEK1), MAPK 
kinase 7 (MKK7) and tripartite motif-containing 21 (TRIM21).  
 
 
Figure 1.3 │The structure of TRIB2 protein. Catalytic loop (Keeshan et al., 2010), 
MEK1 binding (Yokoyama et al., 2010) and COP1 (Qi et al., 2006) binding motifs 
are conserved in TRIB1-3 and Drosophila Tribbles (Yokoyama and Nakamura, 
2011). Other regions are important for TRIB2 degradation (Wang et al., 2013b), 
p70S6K binding (Wang et al., 2013b) and p100 binding (Wei et al., 2012), as 
described in this chapter. Amino acid sequence of these regions and the conserved 
motifs are identical in human and mouse TRIB2 orthologs.   
 
1.3.1 Autoantigen 
TRIB2 was identified as an autoantigen in autoimmune uveitis, a group of 
inflammatory disorders in the eye by phage display and anti-TRIB2 antibody 
activities were detected in the patients (Zhang et al., 2005). However, the functional 
role and expression of TRIB2 in the eye remain unknown. Following that, TRIB2 
was implicated in narcolepsy, an excessive daytime sleepiness due to hypocretin 
deficiency with a dramatic loss in hypothalamic hypocretin-producing neurons. 
TRIB2 was found to be expressed by these neurons and hence could serve as 
potential autoimmune targets (Cvetkovic-Lopes et al., 2010). Indeed, high TRIB2-
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specific antibody titers were found in narcolepsy patient and these confirm 
narcolepsy is an autoimmune disease (Cvetkovic-Lopes et al., 2010, Kawashima et 
al., 2010, Toyoda et al., 2010). This was supported by a recent study that showed 
passive transfer of anti-TRIB2 autoantibody positive patient immunoglobuline G 
causes hypothalamic neuron loss and sleep attacks in mice (Katzav et al., 2013). 
However, the functional role of TRIB2 in hypothalamic neuron remains unknown. 
 
1.3.2 Inhibition of adipogenesis 
Activation of AKT and expression of CEBP are critical events for adipogenesis. 
TRIB2 was found to suppress adipocyte differentiation by inhibiting activation of 
AKT and promoting proteasomal degradation of CEBP (Naiki et al., 2007). As 
such, knockdown of Trib2 by small-interfering RNAs in mesenchymal stem cells in 
vitro and in vivo enhanced adipogenic differentiation (Andersen et al., 2010). 
However, expression of TRIB2 influences accumulation of pericardial (Fox et al., 
2012)  and visceral (Nakayama et al., 2013) fat. 
 
1.3.3 Inhibition of FOXO function 
In melanoma cells, TRIB2 abrogates the function of FOXO transcription factors 
which are tumour suppressive by promoting cytoplasmic sequestration of FOXO 
(Zanella et al., 2010). TRIB2 expression was found to increase in malignant 
melanoma and is a biomarker for diagnosis and progression of melanoma (Zanella 
et al., 2010, Hill et al., 2015). 
 
1.3.4 Inhibition of YAP degradation 
In liver cancer, TRIB2 overexpression stabilizes YAP, an oncogenic transcription 
factor coactivator via two mechanisms. One mechanism includes TRIB2 inhibition of 
the proteasomal dependent degradation of YAP (Wang et al., 2013a). This requires 
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binding of -TRCP, an E3 ubiquitin ligase which was found to modulate TRIB2 in a 
feedback regulation as described in section 1.4.3 (Wang et al., 2013a, Qiao et al., 
2013). Intriguingly, unlike other TRIB2 interacting E3 ligases including COP1 
(Keeshan et al., 2010) and TRIM21 (Grandinetti et al., 2011), TRIB2 interaction with 
-TRCP leads to inhibition instead of promotion of substrate degradation. It is 
unclear what influences the outcome of TRIB2 interaction with ubiqutin ligases. 
Another mechanism of TRIB2-mediated stabilization of YAP is through regulation of 
CEBPα as described in section 1.3.7 (Wang et al., 2013a). 
 
1.3.5 Modulation of MAPK pathway 
TRIB2 has been shown to modulate mitogen-activated protein kinase (MAPK) 
pathway in different cellular contexts and under different stimuli. Like other Tribbles 
members, TRIB2 contains a C-terminal conserved motif that is required for MEK1 
binding (Figure 1.3) (Yokoyama et al., 2010). In lipopolysaccharide (LPS)-stimulated 
THP-1 cells, TRIB2 was found to interact with MKK7 and MEK1 to suppress JNK 
and ERK signalling in order to inhibit IL-8 production (Eder et al., 2008b). However, 
another study found that modulation of Trib2 expression doesn’t affect low-density 
lipoprotein uptake by LPS-stimulated THP-1 cells which is regulated by MAPK 
pathway (Eder et al., 2008a). In epithelials cells stimulated with toll-like receptor 
(TLR) 5 ligand (flagellin), Trib2 was found to selectively activate p38 and JNK 
signalling but not ERK (Wei et al., 2012).  
 
1.3.6 Modulation of NFκB pathways 
TRIB2 has been shown to modulate both canonical and non-canonical nuclear 
factor kappa B (NFκB) pathways in different cellular contexts and under different 
stimuli. In TLR-5 (flagellin)-stimulated epithelial cells, TRIB2 mRNA expression is 
induced and TRIB2 protein interacts with p100 (Figure 1.3) to inhibit the canonical 
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NFκB pathway (Wei et al., 2012). In osteosarcoma cells stimulated with tumour 
necrosis factor alpha, TRIB2 mRNA expression is induced and TRIB2 protein 
upregulates non-canonical NFκB pathway by promoting nuclear retention of RELB 
(Schoolmeesters et al., 2012).  
 
1.3.7 Promotion of CEBPα degradation  
CEBPα belongs to a family of basic region leucine zipper transcription factors. It 
promotes cell cycle arrest and cell differentiation. Thus, CEBPα pathway is tumour 
suppressive in many cancers (Koschmieder et al., 2009). In a bone marrow (BM) 
transplant mouse model, enforced expression of Trib2 promotes degradation of 
CEBPα and induces a potent acute myeloid leukaemia (AML) (Keeshan et al., 
2006). This is the first study demonstrated that the functional role of Drosophila 
Tribbles is conserved in mammalian Tribbles family. Further study showed that 
TRIB2-mediated degradation of CEBPα requires COP1 binding which is an E3 
ubiquitin ligase to induce AML (Figure 1.3) (Keeshan et al., 2010). In lung cancer, 
elevated TRIB2 expression contributes to tumourigenesis by also promoting 
degradation of CEBPα and this requires interaction with a different E3 ligase, 
TRIM21 instead of COP1 (Grandinetti et al., 2011). In liver cancer, TRIB2 
overexpression downregulates CEBPα in a similar way and this in turn relieves 
CEBPα-mediated inhibition of YAP activity (Wang et al., 2013a). 
 
1.3.8 Promotion of MCL1 degradation 
TRIB2 was found to modulate apoptosis of TF-1 cells in response to deprivation of 
granulocyte-macrophage colony-stimulating factor by promoting proteasomal-
independent degradation of MCL1, a pro-survival factor (Lin et al., 2007). The 
apoptogenic activity of TRIB2 was also found in Me-1 cells when it was 
overexpressed (Gilby et al., 2010). However, the pro-apoptotic property of TRIB2 
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which was established in cell lines has yet to be shown to be of relevance in primary 
cells or in in vivo settings.    
 
1.4 Regulation of Trib2/TRIB2 and TRIB2 
 
1.4.1 Transcription factors 
Trib2/TRIB2 was identified as a target gene of several oncogenic transcription 
factors deregulated in AML, liver cancer and T-cell acute lymphoblastic leukaemia 
(T-ALL). In homeobox (HOX)-induced murine AML, Trib2 was identified as a target 
gene of myeloid ecotropic viral integration site 1 (MEIS1), a HOX co-factor 
(Argiropoulos et al., 2008) that dimerizes with pre-B-cell leukaemia homeobox 3 
(PBX3) (Garcia-Cuellar et al., 2015). In human AML, TRIB2 expression is 
upregulated by E2F transcription factor 1 (E2F1) and sustained by an E2F1-CEBPα 
positive feedback loop to promote leukaemic cell proliferation (Rishi et al., 2014). In 
liver cancer, TRIB2 was found as a downstream wingless-type MMTV integration 
site family (WNT)--Catenin target gene and its transcription is coordinated by T-cell 
factor (TCF) and FOXOA transcription factors (Wang et al., 2013a). In T-ALL, Trib2 
is a direct target of Neurogenic locus notch homolog protein 1 (NOTCH1) (Wouters 
et al., 2007), pituitary homeobox 1 (PITX1) (Nagel et al., 2011) and T-cell acute 
lymphocytic leukaemia protein 1 (TAL1) (Sanda et al., 2012). In normal 
haematopoiesis, Trib2 is regulated by friend of GATA-1 (FOG-1) which is important 
in the myelo-erythroid lineage bifurcation (Mancini et al., 2012). 
 
1.4.2 MicroRNAs 
Besides transcription factors, Trib2/TRIB2 expression is also regulated by 
microRNAs (Table 1.1). These miRNAs were found to be deregulated in different 
types of cancer and hence contributes to the elevated expression of Trib2.  
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Table 1.1 │ List of microRNAs (miRNAs) that suppress Trib2/TRIB2 expression. 
miRNAs Cellular context Functional role of miRNAs References 
let-7c lung cancer cells - Inhibition of cell proliferation (Wang et al., 
2013c) 
miR-98 Endothelial cells - not studied (Xie et al., 2012) 
miR-99 Cervical cancer cells - Inhibition of cell proliferation 
- Promotion of apoptosis 
(Xin et al., 2013) 
miR-99a AML and chronic 
myeloid leukaemia 
(CML) cells 
- Promotion of cell proliferation 
- Inhibition of apoptosis 
(Zhang et al., 
2013) 
miR-100 AML cells - Promotion of cell proliferation 
- Inhibition of cell differentiation 
(Zheng et al., 
2012) 
miR-155 Flt3 wild type (WT)-
AML cells 
- Promotion of apoptosis and 
cell differentiation 
(Palma et al., 
2014) 
miR-511 lung cancer cells - Promotion of apoptosis 
- Inhibition of cell proliferation 
(Zhang et al., 
2014) 
(Zhang et al., 
2012a) 
miR-1297 lung cancer cells - Inhibition of cell proliferation (Zhang et al., 
2012a) 
 
1.4.3 E3 ubiquitin ligases 
TRIB2 protein level was found to be elevated in a subset of liver cancers and 
reported to be critical for liver cancer cell survival and transformation (Wang et al., 
2013a). Further study found that TRIB2 has increased protein stability in liver 
cancer cells compared with other cells and this was due to down regulation of 
SMAD ubiquitination regulatory factor 1 (SMURF1), an E3 ubiquitin ligase that 
ubquitinates TRIB2 and promotes its proteasomal dependent degradation (Wang et 
al., 2013b). SMURF1-mediated ubiquitination requires an intact TRIB2 N-terminus 
degradation domain and phosphorylation of TRIB2 by p70S6K (Figure 1.3) (Wang 
et al., 2013b). Like SMURF1, another E3 ubiquitin ligase -TRCP was shown to 
regulate stability of TRIB2 in liver cancer cells although TRIB2 phoshorylation was 
not shown to be a prerequisite (Qiao et al., 2013).    
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1.5 Steady state haematopoiesis 
 
1.5.1 Bone marrow haematopoiesis 
In adults, haematopoiesis takes place in the BM, and is sustained by 
haematopoietic stem cells (HSCs) which are located atop the haematopoietic 
hierarchy (Figure 1.4), to produce blood cells of all lineages throughout the life. 
HSCs are multipotent and reversibly switch from dormancy to self renewal while 
generating multipotent progenitors (MPPs) (Wilson et al., 2008). However, they 
cycle infrequently as Wilson and colleagues showed that HSCs are predominantly 
quiescent with 70% of them are in G0 phase of cell cycle (Wilson et al., 2008). 
Based on computational modelling, it is estimated that adult murine HSCs undergo 
5-20 divisions over the course of a 2 year life span (Wilson et al., 2008, Foudi et al., 
2009). Lineage determination and differentiation are initiated in MPPs which are 
also multipotent but with reduced self renewal capacity (Reya et al., 2001). 
Oligopotent common myeloid progenitors (CMPs) gives rise to all myeloid cell types 
(erythroid cells, megakaryocytes, granulocytes and monocytes) via the commitment 
to either megakaryocyte-erythroid (MEPs) or granulocyte-macrophage (GMPs) 
progenitors (Akashi et al., 2000). Likewise, oligopotent common lymphoid 
progenitors (CLPs) were identified to have the potential to generate cells of 
lymphoid lineages (T cells, B cells and natural killer cells) in vivo (Kondo et al., 
1997). Identification of CMP and CLP progenitors marked the branching of MPPs 
into myelo- and lymphopoiesis respectively. However, the model for haematopoietic 
blood lineage commitment was revised with the identification of lymphoid-primed 
multipotent progenitors (LMPPs) which have combined lympho-myeloid 
differentiation potential but have lost the ability to adopt megakaryocyte and 
erythroid lineage fates (Adolfsson et al., 2005). 
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Figure 1.4 │ Model for haematopoietic hierarchy used in this thesis research. 
MPPs lose their multipotent capacity in a stepwise fashion when they differentiate 
into oligopotent progenitors (CMPs, LMPPs, MEPs, GMPs and CLPs) which in turn 
undergo further lineage commitment to produce unipotent progenitors that 
eventually make all mature blood cells. This model is currently under review due to 
recent findings in haematopoietic lineage differentiation as described below in the 
text. HSC, haematopoietic stem cell; MPP, multipotent progenitor; CMP, common 
myeloid progenitors; LMPP, lymphoid-primed multipotent progenitor; MEP, 
megakaryocyte-erythroid progenitor; GMP, granulocyte-macrophage progenitor; 
CLP, common lymphoid progenitor.  
 
While the model described above served as the framework of the research 
reported in this thesis, findings from recent studies in the past two years, reviewed 
by Cabezas-Wallscheid and Trumpp (Cabezas-Wallscheid and Trumpp, 2016), 
suggest a simpler haematopoietic hierarchy. These studies employed single-cell 
assays to provide strong evidence that either CMPs represent a highly transient cell 
state, or that such oligopotent cells do not exist in mouse or human BM (Notta et al., 
2016, Paul et al., 2015). Rather, mature cells such as megakaryotes are generated 
from committed unipotent progenitors derived directly from multipotent cells such as 
HSCs and MPPs (Paul et al., 2015, Notta et al., 2016).  
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1.5.2 Intrathymic T-cell development 
Pre-thymic progenitors are BM-derived progenitors (primarily CLPs (Serwold et al., 
2009) and LMPPs (Luc et al., 2012)) that colonize the thymus continuously and 
sustain thymopoiesis to generate naïve CD4 or CD8 single positive (SP) T-cells. 
Immature thymocytes are CD4/CD8 double negative (DN) and divided into DN1-
DN4 subsets based on their surface expression of CD25 and CD44 markers 
(Godfrey et al., 1993). DN1 thymocytes are the most immature progenitors and 
require NOTCH-DLL4 signalling activated by interaction with thymic stromal cells for 
specification, commitment and development (Pui et al., 1999, Radtke et al., 1999). 
As such, specification of DN1 thymocytes to DN2 stage involves surface expression 
of CD25 which is a T-cell marker (Godfrey et al., 1993). DN2a thymocytes commit 
to T-lineage fate as they develop into DN2b stage with decreasing surface 
expression of c-Kit which is a BM haematopoietic progenitor marker (Yui et al., 
2010). Until the maturation to DN2b stage, the uncommitted cycling DN1 and DN2a 
progenitors retain the potential to generate dendritic cells, granulocytes, 
macrophage, natural killer cells and to a lesser extent, B cells (Figure 1.5) (Yui and 
Rothenberg, 2014). T-cell committed progenitors are then separated into the 
development of α and γδ lineages where the former is predominant in an adult 
thymus as it contains approximately 300-folds more CD4/CD8 double positive (DP) 
α cells than γδ cells (Prinz et al., 2006). γδ lineage development begins in the 
DN2b and DN3 cells where productive Tcrγδ rearrangements give rise to γδ cells 
(Carpenter and Bosselut, 2010). However, α lineage development begins at DN3 
stage. DN3a thymocytes are briefly arrested to undergo Tcr rearrangement, a 
checkpoint known as -selection where productive rearrangements lead to 
expression of pre-T-cell receptor (TCR) complex and initiation of pre-TCR signalling 
to turn off NOTCH signalling (Figure 1.5) (Hoffman et al., 1996, Taghon et al., 
2006). The pre-TCR signalling drives immature DN3b thymocytes to proliferate and 
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further differentiate into non-proliferating mature DP thymocytes where they 
undergo Tcrα rearrangements and positive/negative selections to become CD4 or 
CD8 SP naïve T cells (Figure 1.5) (Carpenter and Bosselut, 2010).  
 
 
Figure 1.5 │ Overview of murine α T-cell development. The main stages of 
thymocyte development along the α T-lineage are depicted. NOTCH signalling is 
essential for the commitment of thymic progenitors to the T-cell lineage fate. 
However, NOTCH signalling is switched off in DN3b thymocytes that have passed 
through the -selection checkpoint and instead become dependent on Pre-TCR 
signalling. DN, CD4/CD8 double negative; DP, CD4/CD8 double positive. 
 
It is noteworthy that α T-cell development described above is delineated based 
on mouse studies. Human T-cells undergo the same developmental checkpoints (-
selection and positive/negative selection) during development despite some of the 
developmental stages being characterized by different phenotypic markers (Taghon 
et al., 2012). For example, human thymic progenitors undergo T-cell lineage 
specification and commitment but they are not characterized by the markers CD44 
and CD25, and hence are not divided into DN1-4 stages as described in mouse. A 
detailed discussion of human T-cell development is reviewed here, by Taghon and 
colleagues (Taghon et al., 2012), and highlights important differences between both 
species.     
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1.5.3 TRIB2 in normal haematopoiesis 
Trib2 was identified as a direct target gene of FOG-1, a transcription factor that is 
required for megakaryocyte and erythorid-lineage commitment (Mancini et al., 
2012). Indeed, Mancini and colleagues showed that Trib2 is selectively expressed 
in murine pre-megakaryocyte/erythroid progenitor cells compared to pre-
granulocyte/macrophage and CLP progenitor cells (Mancini et al., 2012). Hence, 
TRIB2 appears to be an important effector of FOG-1 in suppression of myeloid 
progenitor specification. This could be attributed to the role of TRIB2 in promoting 
degradation of CEBPα and CEBP which are required for generation of GMPs 
(Keeshan et al., 2006, Naiki et al., 2007). In accordance with this, a separate study 
found that CEBPα binds to the promoter region of Trib2 in murine GMPs to inhibit 
E2F1-mediated upregulation of Trib2 expression in order to promote myelopoiesis 
(Rishi et al., 2014).  
 
Besides the potential role of TRIB2 in myelo-erythroid lineage specification, 
recent studies also suggest TRIB2 to be important in intrathymic T-cell 
development. Using whole-transcriptome sequencing, Casero and colleagues 
studied the transcriptional programs that initiate human lymphopoiesis, and regulate 
the subsequent B lymphoid and T lymphoid specification (Casero et al., 2015). 
Human TRIB2 expression was found to be upregulated more than 10 fold in the 
earliest BM-derived uncommitted thymic progenitors compared to BM progenitors 
(HSCs, LMPPs, CLPs and B cell-committed progenitors) (Casero et al., 2015). In 
murine fetal liver-derived DN1 thymic progenitors, Trib2 was bound by both GATA3-
binding protein 3 (GATA3) and PU.1, two transcription factors with complementary 
roles in early T-cell development (Zhang et al., 2012d). Hence, it is likely that TRIB2 
has a previously unrecognized role in thymopoiesis. 
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As mentioned earlier in this chapter, Tribbles inhibits String function in 
Drosophila (Seher and Leptin, 2000, Grosshans and Wieschaus, 2000, Mata et al., 
2000). The ortholog of String in mammalian is CDC25 phosphatases which are also 
known as cell cycle activators (Kristjansdottir and Rudolph, 2004) (Chapter Six). It 
remains unknown if TRIB2 is capable to interact with and regulate CDC25 
phosphatases in a similar way in the context of haematopoiesis. The role of CDC25 
phosphatases in normal haematopoiesis (BM haematopoiesis and intrathymic T-cell 
development) is unclear although one of the members (CDC25A) was shown to 
regulate cell cycle of early erythroid progenitors (Melkun et al., 2002).  
 
1.6 Stressed haematopoiesis 
 
1.6.1 Ageing 
Haematopoietic ageing is an evolutionarily conserved process in human and mice 
that affects the balanced generation of all blood cell lineages. As mice age, HSCs 
expands numerically due to increased self-renewal but they exhibit functional 
decline with diminished lymphoid differentiating potential and hence are myeloid-
biased (Sudo et al., 2000, Sun et al., 2014, Rossi et al., 2005). Pang and colleagues 
found the similar features of ageing murine HSCs in older human HSCs (above 65 
years) as they showed older human HSCs are increased in frequency and do not 
engraft or generate lymphoid progeny as efficiently as young human HSCs (20-35 
years) in a xenotransplant murine model (Pang et al., 2011). Flach and colleagues 
showed that the functional decline in murine old HSCs (24 months or greater) is 
driven by replication stress where the cells have extended S phase and acquisition 
of chromosomal gaps/break (Flach et al., 2014).     
 
Regression or involution of the thymus is also a feature of haematopoietic 
ageing. Thymic involution leads to the diminished production of naïve T-cells due to 
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the age-related changes in thymopoiesis (Palmer, 2013). The thymus is 
continuously seeded by BM-derived progenitors to sustain thymopoiesis (Serwold et 
al., 2009, Luc et al., 2012). Hence, any age-related alterations in HSC function 
would contribute toward thymic involution. As mentioned above, HSCs lose the 
lymphoid potential as they age (Sudo et al., 2000). In accordance with this, Zediak 
and colleagues showed that old donor MPPs (24 months) give rise to 2.4 folds 
fewer DP thymocytes compared to young donor MPPs (2 months) at three weeks 
after injection into the thymus of non-irradiated recipient mice (Zediak et al., 2007). 
Furthermore, old mice have fewer numbers of early thymic progenitors, a subset of 
DN1 progenitors that give rise to subsequent thymocyte subsets (Min et al., 2004, 
Heng et al., 2005). Min and colleagues showed that old early thymic progenitors (17 
months or greater) have reduced thymopoietic potential, reduced proliferation and 
increased apoptosis compared to young early thymic progenitors (1-2 months) (Min 
et al., 2004). These physiological age-related changes contribute to the gradual and 
progressive decline in the number of thymocytes.    
 
1.6.2 Infection 
At steady state, bone marrow haematopoiesis generates a balanced supply of 
granulocytes (granulopoiesis), monocytes/macrophages (myelopoiesis) and B-
lymphocytes (B-lymphopoiesis) which are essential for the maintenance of immune 
homeostasis. The pre-existing pool of granulocytes is usually sufficient to combat 
local bacteria infection. However, in the setting of systemic infection which is more 
severe, granulocytes which are short-lived are consumed in large quantities (Manz 
and Boettcher, 2014). The increase demand for granulocytes during systemically 
disseminated infection causes the haematopoietic system to switch from steady 
state to emergency granulopoiesis where HSPCs expand to increase de novo 
generation of granulocytes (Manz and Boettcher, 2014). However, the shift in BM 
haematopoietic activity towards granulopoiesis results in descreased production of 
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B-lymphocytes, erythroyctes and megakaryocytes (Glatman Zaretsky et al., 2014). 
Zhang and colleagues showed that E. coli-induced bacterimia in mice caused 10 
folds expansion of HSPCs and these cells are committed to 
granulocyte/macrophage lineage development as assessed by the Colony-Forming 
Unit assay (Zhang et al., 2008). Cytokines and growth factors play an important role 
in emergency granulopoiesis. For example, granulocyte-colony stimulating factor 
level is increased during severe infection to promote myeloid cell production in bone 
marrow and was shown recently to be secreted by non-haematopoietic cells that 
sense invading pathogens (Boettcher et al., 2012, Kawakami et al., 1990).        
 
Infection by viruses, bacteria, parasites and fungi is known to cause premature 
thymic involution (Nunes-Alves et al., 2013). In this context, thymopoiesis is 
disrupted due to induction of thymocyte (DP primarily) apoptosis by glucocorticoids 
and pro-inflammatory mediators released by the body in response to systemic 
infection (Borges et al., 2012, Ashwell et al., 2000). Besides that, thymocytes are 
also sensitive to toxin and virulence factors that are released by pathogens 
systemically (Ozeki et al., 1997, Islam et al., 1998). Apoptosis induction of human 
and murine thymocytes by direct viral infections (Human Immunodeficiency virus 
(Berkowitz et al., 1998), Murine Leukaemia virus (Yoshimura et al., 1999) and 
Highly Pathogenic Influenza virus (Vogel et al., 2010)) has also been 
demontstrated.   
 
1.6.3 Iatrogenic interventions (irradiation and chemotherapy) 
Clinically, irradiation and chemotherapy are conventional therapies for patients with 
cancer since both targets rapidly proliferating cells, one of the hallmarks of cancer 
(Hanahan and Weinberg, 2011). However, irradiation and chemotherapy induced 
cytotoxicity are not selective and are known to induce BM suppression which would 
be life threatening because cycling normal haematopoietic cells are also being 
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targeted during the course of treatment (Mauch et al., 1995). The resulting clinical 
symptoms include anaemia, thrombocytopenia, neutropenia and lymphocytopenia 
due to the disrupted production of RBCs, platelets, granulocytes and B-lymphocytes 
in the BM respectively. While this side effect is detrimental in the clinical setting, 
both have been used experimentally to study haematopoiesis during stress and 
recovery. Li and Slayton showed that although both irradiation and 5-fluorouracil (5-
FU, a standard chemotherapy agent which is reviewed further in section 4.1) 
treatments reduce murine BM cellularity and cause similar morphological changes 
in BM niche; B lymphocytes are more sensitive to iradiation whereas neutrophils 
and monocytes are more sensitive to 5-FU treatment (Li and Slayton, 2013). In 
addition to that, they found that murine haematopoietic system recovered faster 
following 5-FU treatment, as evidence by the earlier expansion of HSPC 
populations, compared to irradiation (Li and Slayton, 2013). Shao and colleagues 
found that sublethal dose of total body irradiation causes long term suppression of 
murine BM functions because HSCs are induced to senescence prematurely (Shao 
et al., 2014). 
 
Similar to 5-FU treatment (Aquino Esperanza et al., 2008, Eichhorst et al., 
2001), Randle-Barrett and Boyd (Randle-Barrett and Boyd, 1995) showed that 
sublethal dose of total body irradiation causes reduction of murine thymic cellularity 
and damages to the murine thymic microenvironment (Randle-Barrett and Boyd, 
1995, Aquino Esperanza et al., 2008, Eichhorst et al., 2001). Furthermore, they 
showed that DP thymocytes are the most sensitive thymic subset to irradiation-
induced injury (Randle-Barrett and Boyd, 1995). Thymus recovers at a similar rate 
in both irradiation and 5-FU murine models (Randle-Barrett and Boyd, 1995, Aquino 
Esperanza et al., 2008, Eichhorst et al., 2001). 
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1.7 TRIB2 and acute leukaemia 
 
1.7.1 Acute myeloid leukaemia 
AML is a heterogeneous haematological malignancy characterized by the clonal 
expansion of myeloid blasts due to a differentiation block in haematopoietic stem 
and progenitor cells (HSPCs). In children, AML is rare with an incidence of 8 cases 
per million children aged 1-18 years per year (Chaudhury et al., 2015). However, 
the incidence of AML increases as the population ages. AML occurs at an incidence 
of 20 cases per million younger adults aged 18-60 years per year and increases to 
170 cases per million older adults aged above 60 years per year (Chaudhury et al., 
2015). Hence, AML is mainly an adulthood leukaemia. A combination of cytarabine 
and an anthracycline remains as a standard induction chemotherapy in AML except 
acute promyelocytic leukaemia which is a distinct entity that can be treated 
successfully with differentiating therapy (all-trans retinoic acid and arsenic trioxide) 
(Freireich et al., 2014). The five-year overall survival rate for paediatric AML 
patients is 70-75% but decreases to 45-50% in younger adult AML patients 
(Chaudhury et al., 2015). Nevertheless, increased understanding of the molecular 
genetics and pathogenesis of AML has allowed clinical development of new 
therapeutic drugs (chemotherapies, hypomethylating agents, antibody-drug 
conjugates and molecularly targeted agents) and this was recently reviewed by 
Stein and Tallman (Stein and Tallman, 2016).  
 
AML was first classified morphologically based on the lineage-associated 
phenotype (undifferentiated, myeloid, monoblastic, erythroblastic or 
megakaryoblastic) and defined according to the French-American-British (FAB) 
classification (Bennett et al., 1991). In 2001, the World Health Organization (WHO) 
published a new classification based on not only morphologic but also biologic and 
genetic features that have proved to have clinical relevance (Vardiman et al., 2002). 
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In 2008 and 2016, the WHO classification was updated as cytogenetic and 
molecular genetic studies uncovered more genetic abnormalities in AML (Table 1.2) 
(Vardiman et al., 2009, Arber et al., 2016). For example, discovery of Npm1 
mutation in AML with normal cytogenetics which has prognostic impact led to the 
addition of this provisional entity to the current WHO classification (Table 1.2) (Falini 
et al., 2005). With advances in technologies such as development of whole genome 
sequencing, whole exome sequencing and RNA sequencing, AML subsets are now 
defined by cytogenetic and molecular genetic abnormalities which confer 
independent prognostic information (Table 1.2 and 1.3). 
 
As described above in section 1.3.7, the first cellular function of TRIB2 was 
demonstrated in myeloid leukaemogenesis where it induces potent murine AML 
through promotion of CEBPα degradation (Keeshan et al., 2006). TRIB2 was also 
shown to cooperate with HOXA9 and accelerate the onset of murine AML (Keeshan 
et al., 2008), and Trib2 is activated in MEIS1-HOX induced murine AML 
(Argiropoulos et al., 2008, Garcia-Cuellar et al., 2015) In human AML, TRIB2 
expression is upregulated in a biologically and epigenetically distinct subset of AML 
characterized with silenced Cebpα expression and a mixed myeloid/T-lymphoid 
phenotype (Wouters et al., 2007, Keeshan et al., 2006). TRIB2 expression is also 
higher in promyelocytic leukaemia-retinoic acid receptor alpha positive leukaemia 
that harbour FLT3 tyrosine kinase domain mutations compared with promyelocytic 
leukaemia-retinoic acid receptor alpha negative leukaemias or promyelocytic 
leukaemia-retinoic acid receptor alpha positive leukaemias with FLT3 internal 
tandem duplication mutations (Liang et al., 2013). This could be due to the fact that, 
unlike Fms-like tyrosine kinase 3 (FLT3) internal tandem duplication mutants, FLT3 
tyrosine kinase domain mutants could not repress CEBPα activity and hence 
necessitate the upregulation of TRIB2. 
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Table 1.2 │ Genetic abnormalities in paediatric and younger adult AML1. 
AML categories 
frequency 
Younger adult 
(18-60 years) 
Paediatric  
(below 18 years) 
WHO 2016 classification  
AML with recurrent genetic abnormalities 
t(8;21)(q22;q22)/RUNX1-RUNXTt1 8% 12-14% 
inv(16)(p13.1q22) or 
t(16;16)(p13.1;q22)/CBFB-MYH11 
5% 8% 
t(15;17)(q22;q21)/PML-RARA 5-10% 6-10% 
t(9;11)(p23;q34.1)/MLLT3-KMT2A 2% 7% 
t(10;11)(p12;q23)/Mllt10-Mll 1% 3%  
mainly infants 
t(6;9)(p23;q34)/DEK-NUP214 1% < 2% 
inv(3)(q21.3q26.2) or 
t(3;3)(q21.3;q26.2)/GATA2, 
MECOM 
1% < 1% 
t(1;22)(p13.3;q13.3)/RBM15-MKL1 < 1% AMKL only; 
infants 
mutated NPM1 35% 5-10% 
biallelic mutations of CEBPA 10% in CN 14% in CN 
Provisional entity: BCR-ABL1 - - 
Provisional entity: mutated RUNX1 - - 
Not included in WHO 2016 
Karyotypes/mutations 
t(7;12)(q36;p13)/t(7;12)(q32;p13) Not in adults Infants 
t(5;11)(q35;p15.5)/NUP98-NSD1 Not in adults Mostly in CN 
FLT3-ITD 20-40% 10% 
N-RAS 10% 20% 
MLL-PTD 3-5% 3% 
c-KIT 17% in CBF 
leukaemia2 
25% in t(8;21) 
WT1 10% in CN 13% in CN 
PTPN11 Not in adults 5-21%;  
infants only 
IDH1/2 16% Rare, 2-3% 
TET2 8-17% Very rare 
DNMT3A 20% Rare 
WHO 2016 classification continued 
AML with myelodysplasia-related 
changes 
48% low 
Therapy-related myeloid neoplasms 6% 3.5% 
AML, not otherwise specified 17% 15% 
Myeloid sarcoma 1% 2-4% 
Myeloid proliferations related to Down syndrome 
Transient abnormal myelopoiesis Not in adults In 5% of the 
newborns with 
Down syndrome 
Myeloid-leukaemia associated Not in adults 400-fold 
increased risk for 
AMKL 
Acute leukaemias of ambiguous 
lineage 
- - 
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1 AMKL, acute megakaryoblastic leukaemia; CBF, core binding factor; CN, 
cytogenetic normal.Modified from (Creutzig et al., 2012). 
2 AML with t(8;21) and inv(16) are also known as CBF leukaemia.  
 
Table 1.3 │ Risk stratification for younger adults with AML†. 
Risk group Cytogenetic/molecular  genetic abnormality 
Favourable t(15;17)(q22;q21)/PML-RARA 
t(8;21)(q22;q22)/RUNX1-RUNX1T1 
inv(16)(p13q22)/t(16;16)(p13;q22)/CBFB-MYH11 
NPM1 mutation (in absence of FLT3-ITD or DNMT3A mutation) 
Biallelic CEBPA mutation 
Intermediate Cytogenetic/molecular genetic abnormalities not classified as 
favourable or adverse 
Adverse In the absence of favourable risk cytogenetic/molecular genetic 
abnormalities 
abn(3q) [excluding t(3;5)(q21~25;q31~35)/NPM1-MLF1 
inv(3)(q21q26)/t(3;3)(q21;q26)/GATA2/EVI1 
add(5q)/del(5q), -5 
t(5;11)(q35;p15.5)/NUP98-NSD1 
t(6;9)(p23;q34)/DEK-NUP214 
add(7q)/del(7q), -7 
t(11q23) [excluding t(9;11)(p21~22;q23) and t(11;19)(q23;p13)] 
t(9;22)(q34;q11)/BCR-ABL 
-17/abn(17q)/TP53 mutation 
Complex karyotype (≥4 unrelated abnormalities) 
ASXL1 mutation 
DNMT3A mutation 
FLT3-ITD 
MLL-PTD 
RUNX1 mutation 
† Adapted from (Grimwade et al., 2016). 
 
1.7.2 T-cell acute lymphoblastic leukaemia 
In contrast to AML, T-ALL is a heterogenous haematological malignancy caused by 
the transformation of thymic progenitors. Please refer to the introduction of Chapter 
5 where we overviewed the incidence, therapy, oncogenes and molecular subtypes 
for T-ALL.  
 
In T-ALL, TRIB2 was identified in a knockdown screen as one of the critical 
targets of the core transcriptional regulatory circuit controlled by the TAL1 complex 
comprised of TAL1, GATA3 and Runt-related transcription factor 1 (RUNX1), and 
TRIB2 was shown to be essential for the growth and survival of human TAL1+ T-
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ALL cell lines (Sanda et al., 2012). A follow-up study showed that TRIB2 
upregulates X-linked inhibitor of apoptosis (XIAP), an anti-apoptotic protein to 
promote cell survival and regulates the balance between the oncogenic TAL1 
complex and the transcription factor E2-alpha (E2A) tumour suppressor (Tan et al., 
2015). Although TRIB2 has also been implicated in NOTCH1+ (Hannon et al., 2012) 
and PITX1+ (Nagel et al., 2011) T-ALL as mentioned in section 1.4.1, it remains 
unclear how TRIB2 contributes to the pathogenesis of T-ALL.  
 
Most of the studies discussed in this chapter examined the pathological roles of 
TRIB2 in different diseases to understand the contribution of TRIB2 dysregulation, 
at mRNA and protein levels, to the coordination of signalling networks present in 
diseased or transformed cells. However, the physiogical role of TRIB2 remains 
elusive.   
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1.8 Thesis aims 
(i) Investigate the physiological role of TRIB2 in haematopoiesis 
Current literature suggests TRIB2 to be important in the specification of 
megakaryocyte and erythroid lineage as well as in intrathymic T-cell development. 
To delineate the role of TRIB2 in haematopoiesis, we examined the haematopoietic 
system of a Trib2 knockout mouse model. 
 
(ii) Investigate the role of TRIB2 in modulation of haematopoietic stress response  
Haematopoiesis at steady state is often perturbed by physiological and external 
stress. TRIB2 has been implicated in the pathogenesis of both AML and T-ALL 
indicating a role for TRIB2 in regulating the response of normal haematopoietic cells 
to oncogenic stress. We aimed to determine if this is linked to the physiological role 
of TRIB2 in haematopoiesis and if TRIB2 also modulates haematopoietic response 
to other type of stress. 
 
(iii) Examine the relationship between TRIB2 and CDC25 phosphatases. 
Previous studies suggest the functional roles of Drosophila Tribbles are evolutionary 
conserved in mammalian Tribbles. This is illustrated in the relationship between 
Drosophila Tribbles and Slbo. In Drosophila, Tribbles also regulates String and 
hence cellular proliferation, but it is unclear if mammalian Tribbles also interact with 
CDC25 family. We aimed to examine the relationship between TRIB2 and different 
members of CDC25 family at the molecular level. 
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CHAPTER TWO: MATERIALS AND METHODS 
 
2.1 Materials 
 
2.1.1 Antibodies 
 
2.1.1.1 Flow cytometry application 
 
Table 2.1 │ List of antibodies used to stain cells for flow cytometry analysis. 
Antibody† Clone 
anti-BrdU BU20A 
anti-mouse CD3 17A2 
anti-mouse CD4 RM4-5 
GK1.5 
anti-mouse CD8 53-6.7 
anti-mouse CD11c N418 
anti-mouse CD16/CD32 93 
anti-mouse CD19 eBio1D3 (1D3) 
anti-mouse CD25 PC61.5 
anti-mouse CD34 RAM34 
anti-mouse CD45.1 A20 
anti-mouse CD45.2 104 
anti-mouse CD48 HM48-1 
anti-mouse CD71 R17217 
anti-mouse CD150 TC15-12F12.2 
anti-mouse c-Kit  2B8 
anti-mouse Gr-1  RB6-8C5 
anti-mouse IL-7R A7R34 
anti-mouse NK1.1 PK136 
anti-mouse Sca-1 D7 
anti-mouse Ter-119 TER-119 
anti-mouse/human B220 RA3-6B2 
anti-mouse/human CD11b M1/70 
anti-mouse/human CD44 IM7 
anti-mouse/human phosphor-p38 (T180/Y182) 4NIT4KK 
anti-mouse/rat Ki-67 SolA15 
† Antibodies were purchased from BioLegend (London, UK) and eBioscience 
(Hatfield, UK). Identical clones for all antibodies, as indicated above, were 
purchased from these two companies. Antibodies were conjugated either with 
fluorochrome or with biotin, depending on the design of individual multicolour 
fluorescent antibody panel, and these were specified in section 2.2.10. 
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2.1.1.2 Western blotting application 
 
Table 2.2 │ List of antibodies used to probe signals for Western blotting. 
Antibody Clone Company 
anti-α-tubulin B-5-1-2 Sigma-Aldrich (Dorset, UK) 
anti-β-actin AC-15 Sigma-Aldrich 
anti-CDC25A M-191 Santa Cruz Biotechnology 
(Heidelberg, Germany) 
anti-CDC25B C-20 Santa Cruz Biotechnology 
anti-CDC25C C-20 Santa Cruz Biotechnology 
anti-FLAG M2 Sigma-Aldrich 
anti-HA HA-7 Sigma-Aldrich 
anti-HDAC1 H-51 Santa Cruz Biotechnology 
anti-JNK1 2C6 Cell Signalling Technology 
(Leiden, Netherlands) 
anti-K48-Ub Apu2 Millipore (Cork, Ireland)  
anti-mouse IgG horseradish 
peroxidase (HRP)-linked1 
- GE Healthcare Life Sciences 
(Little Chalfont, UK) 
anti-MYC 9E10 Santa Cruz Biotechnology 
anti-p38 D13E1 Cell Signalling Technology 
anti-p44/42 137F5 Cell Signalling Technology 
anti-phospho-Histone H3 (S10) D2C8 Cell Signalling Technology 
anti-phospho-JNK (T183/Y185)2 - Cell Signalling Technology 
anti-phospho-p38 (T180/Y182) D3F9 Cell Signalling Technology 
anti-phospho-p44/42 (T202/Y204) D13.14.4E Cell Signalling Technology 
anti-rabbit IgG HRP-linked3 - GE Healthcare Life Sciences 
anti-TRIB2 B-06 Santa Cruz Biotechnology 
1 A polyclonal antibody which is identifiable by its catalogue number (NXA931). 
2 A polyclonal antibody which is identifiable by its catalogue number (#9251). 
3 A polyclonal antibody which is identifiable by its catalogue number (NA934). 
 
2.1.2 Bacterial strains 
E.coli DH5 strain from the Keeshan and McCarthy labs was used for 
transformation to replicate plasmids.  The bacteria were grown in Luria-Bertani (LB) 
broth and agar. 
 
2.1.3 Cell lines 
Human embryonic kidney (HEK) 293T, 3T3 and U937 cell lines were from the 
Keeshan lab whereas RPMI-8402 cell line was purchased from DSMZ 
(Braunschweig, Germany). HeLa cell line was a kind gift from Professor Mary 
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McCaffrey (UCC, Cork, Ireland). All cell lines were checked for mycoplasma 
contamination periodically. 
 
2.1.4 Chemicals, consumables and reagents 
 
Table 2.3 │ Essential chemicals, consumables and reagents used in the 
experiments described in this thesis. 
Product Brand/Company 
100 bp and 1 kb deoxyribonucleic acid (DNA) 
ladder 
New England Biolabs (Herts, 
UK) 
30% acrylamide mix Sigma-Aldrich 
384-well plate Applied Biosystems (Paisley, 
UK) 
4’, 6-diamidino-2-phenylindole (DAPI) Sigma-Aldrich 
5-FU solution Accord Healthcare  
(North Harrow, UK) 
6-well culture plates Greiner-Bio-One  
(Gloucestershire, UK) 
Agarose powder Sigma-Aldrich 
Ammonium persulfate Sigma-Aldrich 
Aprotinin Sigma-Aldrich 
AsiSI New England Biolabs 
β-mercaptoethanol Sigma-Aldrich 
BD Cytofix/CytopermTM Kit BD Biosciences (Oxford, UK) 
BD PharmingenTM Propidium Iodide 
(PI)/RNase Staining Buffer 
BD Biosciences 
Bio-Rad Protein Assay Dye Reagent 
Concentrate 
Bio-Rad (Dublin, Ireland) 
Boric acid Sigma-Aldrich 
Bovine serum albumin (BSA) Sigma-Aldrich 
BrdU Labeling Reagent Invitrogen (Paisley, UK) 
Calcium chloride (CaCl2) Sigma-Aldrich 
Carbobenzoxy-Leu-Leu-leucinal (MG132) Sigma-Aldrich 
Cell culture dishes/flasks Greiner-Bio-One 
Cell scrappers Greiner-Bio-One 
Cell strainers Fisher Scientific  
(Loughborough, UK) 
CL-XPosureTM radiography films Thermo Scientific (Paisley, UK) 
Cryotubes Greiner-Bio-One 
Cytokines (Interleukin (IL)-3, IL-6 and stem cell 
factor (SCF)) 
PeproTech (London, UK) 
Dimethysulfoxide (DMSO) Sigma-Aldrich 
Disodium phosphate (Na2HPO4) Sigma-Aldrich 
DNase I STEMCELL Technologies 
(Grenoble, France) 
dNTP Thermo Scientific 
DPX mountant Sigma-Aldrich 
Dulbecco’s Modified Eagle Medium (DMEM) Gibco (Paisley, UK) 
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Ethanol Sigma-Aldrich 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich 
FastStartTM High Fidelity PCR Kit Roche (Dorset, UK) 
Fast SYBR Green Master Mix Applied Biosystems 
Fetal bovine serum (FBS) Gibco 
Glass slides VWR (Graumanngasse, 
Vienna) 
Glucose Sigma-Aldrich 
Glycerol Sigma-Aldrich 
Glycine Sigma-Aldrich 
Hank’s balanced salt solution Gibco 
High Capacity cDNA Reverse Transcription 
(RT) Kit 
Applied Biosystems 
Hydroxyethyl piperazineethanesulfonic acid 
(HEPES) 
Gibco 
IGEPAL CA-630 Sigma-Aldrich 
Leupeptin Sigma-Aldrich 
LB broth (Lennox) Sigma-Aldrich 
LB broth with agar (Lennox) Sigma-Aldrich 
L-glutamine Gibco 
Magnesium chloride (MgCl2) Sigma-Aldrich 
MangoMixTM PCR kit Bioline (London, UK) 
Marvel dried skimmed milk powder Tesco (Ireland and UK) 
Methanol Sigma-Aldrich 
Microvette CB 300 K2E Sarstedt (Leicester, UK) 
MluI New England Biolabs 
Monopotassium phosphate (KH2PO4) Sigma-Aldrich 
MycoAlertTM mycoplasma detection Kit Lonza (Slough, UK) 
N-Ethylmaleimide (NEM) Sigma-Aldrich 
Nitrocellulose membrane Sigma-Aldrich 
Nuclear Extract Kit Active Motif (La Hulpe, 
Belgium) 
Nuclease free water Sigma-Aldrich 
Parafilm VWR 
Paraformaldehyde Sigma-Aldrich 
Penicillin-streptomycin Gibco 
Phenol:chloroform:isoamyl alcohol (25:24:1) Sigma-Aldrich 
Phenylmethylsulfonyl fluoride (PMSF) Sigma-Aldrich 
Polybrene Sigma-Aldrich 
Ponceau S Thermo Scientific 
Potassium chloride (KCl) Sigma-Aldrich 
Precision Plus ProteinTM Prestained Standards Bio-Rad (Hertfordshire, UK) 
Primers Sigma Aldrich 
IDT (Surrey, UK) 
PI Sigma-Aldrich 
Proteinase K Sigma-Aldrich 
Protein G Agarose beads Millipore (Cork, Ireland) 
PureYieldTM Plasmid Midiprep System Promega (Southampton, UK) 
Q5 Hot Start High-Fidelity DNA Polymerase New England Biolabs 
QIAquick Gel Extraction Kit QIAGEN (Manchester, UK) 
QIAquick PCR Purification Kit QIAGEN 
QIAshredder homogenizor QIAGEN 
RestoreTM stripping buffer Thermo Scientific 
RNeasy Mini Kit QIAGEN 
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Roswell Park Memorial Institute (RPMI) 
medium 
Gibco 
SafeView Nucleic Acid Stain NBS Biologicals  
(Cambridgeshire, UK) 
Saponin Sigma-Aldrich 
ShandonTM Kwik-DiffTM Kit Thermo Scientific 
Sodium acetate (C2H3NaO2) Sigma-Aldrich 
Sodium chloride (NaCl) Sigma-Aldrich 
Sodium deoxycholate Sigma-Aldrich 
Sodium dodecyl sulphate (SDS) Sigma-Aldrich 
Sodium fluoride (NaF) Sigma-Aldrich 
Sodium hydroxide Sigma-Aldrich 
Sodium orthovanadate (Na3VO4) Sigma-Aldrich 
Sticky-end Ligase Master Mix New England Biolabs 
Streptavidin-eFluor 450 eBioscience 
Streptavidin-PerCP-Cy5.5 eBioscience 
Streptavidin-phycoerythrin (PE) eBioscience 
SuperSignalTM West Pico and Femto 
Substrates 
Thermo Scientific 
Tetramethylethylenediamine (TEMED) Sigma-Aldrich 
Thymidine Sigma-Aldrich 
Trizma base Sigma-Aldrich 
Trizma HCl Sigma-Aldrich 
Trypan blue Sigma-Aldrich 
Trypsin-EDTA Sigma-Aldrich 
Tween 20 Sigma-Aldrich 
UltraComp eBeads® eBioscience 
Vybrant DyeCycle Violet Stain Invitrogen 
X-tremeGENETM HP DNA Roche 
 
2.1.5 Mice 
Trib2 knockout (Trib2-/-) mice (B6; 129S5-Trib2tm1Lex) were purchased from Lexicon 
Genetics (The Woodlands, TX, USA) and backcrossed onto C57BL/6 background 
for more than 7 generations. Mice were bred and housed in the biological service 
unit of the University of Glasgow. Homozygous Trib2 knockout female mice are 
infertile. Hence, homozygous Trib2 knockout male and heterozygous Trib2 
knockout female mice were used as a breeding pair to obtain Trib2-/- offspring which 
were identified by genotyping. Mice (B6.SJL-Ptprca Pepcb/ BoyJ) used in BM 
transplantation as recipients were bred and housed in the Beatson Biological 
Service and Research Units. Age-matched (6-14 weeks old) mice of both genders 
were used for comparison between wild type (WT) and Trib2-/- genotypes. All mouse 
experiments were approved by United Kingdom (UK) Animal Ethical Committees 
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and performed according to UK Home Office project license #60-4512 (Animal 
[Scientific Procedures] Act 1986) guidelines. 
 
2.1.6 Plasmids 
 
Table 2.4 │ Plasmids used in the experiments described in this thesis. 
Plasmid Source 
MigR1 Keeshan lab 
MigR1-ICN1 Keeshan lab 
pcDNA3 Keeshan lab 
pcDNA3-FLAG-TRIB2 Keeshan lab 
pcDNA3-HisA-CDC25C (human) Requested from Addgene repository (#10964) 
pcDNA3-Ub-HA Keeshan lab 
pCMV-Gag-Pol Keeshan lab 
pCMV-VSV-G Keeshan lab 
pCMV6-AC-FLAG McCarthy lab 
pCMV6-CDC25A-FLAG Sub-cloned from pCMV6-CDC25A-MYC-FLAG 
pCMV6-CDC25A-MYC-FLAG Purchased from OriGene (RC200496) 
pCMV6-CDC25B-FLAG Sub-cloned from pCMV6-CDC25B-MYC-FLAG 
pCMV6-CDC25B-MYC-FLAG Purchased from OriGene (RC207409) 
pCMV6-CDC25C (human)-FLAG Sub-cloned from pcDNA3-HisA-CDC25C  
pCMV6-CDC25C (mouse)-FLAG Sub-cloned from pCMV6-CDC25C 
pCMV6-CDC25C (mouse) Purchased from OriGene (MC200198) 
PHMA Keeshan lab 
PHMA-MYC-dC-TRIB2 Keeshan lab 
PHMA-MYC-dN-TRIB2 Keeshan lab 
PHMA-MYC-FL-TRIB2  Keeshan lab 
PHMA-MYC-KD-TRIB2 Keeshan lab 
 
2.2 Methods 
 
2.2.1 Agarose gel electrophoresis 
Agarose gel solution was made by dissolving agarose powder in Tris-borate-EDTA 
(TBE) buffer containing 90 mM Tris-borate and 2 mM EDTA, via microwave heating. 
2.5 µL of SafeView Nucleic Acid Stain was added per 50 mL of gel solution and 
mixed well by shaking before casting. 1x TBE buffer also served as the 
electrophoresis buffer.  Samples were mixed with 6x gel loading dye before loading 
on agarose gel. Electrophoresis was run at 100 volts and at room temperature. The 
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electrophoresis was stopped when tracking dye migrated at three quarters of the 
gel. 
 
2.2.2 Annexin V expression and apoptosis assay 
Single cell suspension from thymus was prepared as described in section 2.2.10.1. 
To enable identification of thymus subsets, cells were stained, as described in 
section 2.2.10.2, with 50 L of antibody panel A from Table 2.20. Following that, cell 
suspension was centrifuged at 350 x g and at 4°C for 5 minutes. 100 L of Annexin 
V-fluorescein isothiocyanate (FITC) and DAPI, diluted 1:100 in Hank’s balanced salt 
solution (HBSS), was then added to the cell pellet, mixed by pulsed vortex, and 
incubated at room temperature in the dark for 15 minutes. The stock concentration 
for DAPI was 1 mg/mL. After the incubation, 400 L of HBSS was added. The cell 
suspension was pulsed vortex before analyzed by flow cytometry. 
 
2.2.3 Bacterial transformation 
Competent E.coli bacterial cells from the lab stocks were thawed on ice for 5 
minutes. 50-100 ng of plasmid DNA was added into 50 µL of competent cells and 
incubated on ice for 20 minutes. The cells were heat shocked at 42°C for 90 
seconds and placed on ice for 90 seconds. 500 µL of SOC medium (LB broth 
containing 2.5 mM KCl, 10 mM MgCl2 and 20 mM glucose) was added and the cells 
were incubated in a shaker at 37°C for 45 minutes. For each transformation, 100 µL 
and 300 µL of cells were plated on two ampicillin-supplemented LB plates. The 
plates were checked the next morning for the presence of colony.  
 
2.2.4 Blood cell counts 
Mice were euthanized by carbon dioxide inhalation and blood was collected by 
cardiac puncture into EDTA-coated Microvette CB 300 K2E to prevent coagulation. 
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Blood was mixed thoroughly by gently flicking and inverting the microvette before 
analyzed by Hemavet HV950 (Drew Scientific, Miami Lakes, FL, USA) to generate 
complete blood counts and WBC differential counts (Table 2.5).  
 
Table 2.5 │ Normal haematology profile of a mouse. 
Parameter Units Normal Range† 
White blood cell (WBC) 103/L 1.8 - 10.7 
Neutrophil  103/L 0.1 - 2.4 
Lymphocyte  103/L 0.9 - 9.3 
Monocyte  103/L 0.0 - 0.4 
Eosinophil 103/L 0.0 - 0.2 
Basophil  103/L 0.0 - 0.2 
Red blood cell (RBC) 106/L 6.36 - 9.42 
Platelet 103/L 592 - 2972 
† Adapted from Hemavet HV950 Product Reference Manual. 
 
2.2.5 Bone marrow transduction and transplantation 
 
2.2.5.1 Production of retroviral supernatants 
15 x 106 of 293T cells were seeded in a cell culture dish (150 x 20 mm) the day 
before transfection. On the transfection day, 1.5 mL of fresh transfection buffer 
(Table 2.6) and 1.5 mL of DNA cocktail were made (Table 2.8). The existing culture 
medium was removed from the culture dish followed by addition of 9 mL of pre-
warmed fresh culture medium. The DNA cocktail was added drop by drop to the 
transfection buffer in a 15 mL centrifuge tube. Bubbles were then introduced into the 
mixture with a pipetting aid equipped with a 1 mL serological pipette for 30 seconds. 
The mixture was added to the culture dish drop by drop and the dish was tilted 
gently to distribute the mixture evenly. The next day, with no longer than 16 hours 
after the addition of transfection mixture, the existing culture medium in the dish was 
replaced with 13 mL of fresh pre-warmed medium. After 24 hours of culture, the 
supernatant of transfected cells was collected and another 13 mL of fresh pre-
warmed medium was added to the cells. The cells were cultured for another 24 
51 
 
hours before the supernatant was collected. These supernatants contained the 
retroviral particles. They were syringe-filtered (0.45 m pore size), aliquoted into 1.5 
mL microcentrifuge tubes, and stored at -80°C. 
 
Table 2.6 │ Transfection buffer for retroviral production. 
 
 
 
 
Table 2.7 │ 10x NaCl-Tris-EDTA (NTE) buffer. 
 
 
 
Table 2.8 │ DNA cocktail for retroviral production. 
Components Final concentration 
Sterile-filtered water quantity sufficient to 1.5 mL 
CaCl2 0.25 M 
10x NTE bufffer  1x 
MigR1 or MigR1-ICN1 45 g 
pCMV-Gag-Pol 30 g 
pCMV-VSV-G 18 g 
 
2.2.5.2 Determination of retrovirus titer 
0.2 x 106 of 3T3 cells in 3 mL of culture medium were seeded per cell culture dish 
(60 x 15 mm) the day before transduction. On the transduction day, the existing 
culture medium was replaced with 1 mL of fresh pre-warmed medium containing 4 
g of polybrene. To titre retrovirus supernatant per harvest, 10 L and 100 L of the 
supernatant were added gently to two tilted dishes. The dishes were returned to 
tissue incubator once the supernatant was added. After 24 hours of culture, 2 mL of 
fresh medium was added to each dish. Cells were cultured for another 24 hours 
before harvest. The existing culture medium was removed and cells were washed 
Components Final concentration 
HEPES (pH7.1) 0.05 M 
NaCl 0.18 M 
Na2HPO4 2 mM 
Sterile-filtered water quantity sufficient to 1.5 mL 
Components Final concentration 
NaCl 1.5 M 
Tris-HCl (pH7.4) 0.1 M 
EDTA (pH8.0) 10 mM 
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once in 1 mL of phosphate buffered saline (PBS) containing 137 mM NaCl, 2.7 mM 
KCl, 10 mM Na2HPO4 and 2 mM KH2PO4. 500 L of trypsin was then added to each 
dish followed by incubation for 5 minutes at room temperature to detach the cells. 1 
mL of 2% FBS-supplemented PBS was added to each dish. The detached cells 
were pipetted up and down few times to generate single cell suspensions, before 
being transferred to polystyrene tubes (12 x 75 mm) which were kept on ice. The 
cells were centrifuged at 350 x g and at 4°C for 5 minutes. The cell pellet was 
resuspended in 500 L of 2% FBS-supplemented PBS and was ready for flow 
cytometry analysis. The retroviral titre is the percentage of green fluorescent protein 
(GFP) positive 3T3 cells due to transduction by 100 L of the retroviral supernatant. 
 
2.2.5.3 Ex vivo culture and transduction of bone marrow 
BM was collected from 6-8 weeks old WT and Trib2-/- mice (donor) 4 days after 
administration of 5-FU (250 mg/kg, i.p.). One donor mouse was required to obtain 
sufficient cells for transplantation into two recipients. Single cell suspension from 
WT and Trib2-/- BM was generated as described in section 2.2.10.1, resuspended in 
pre-stimulation medium (Table 2.9) at a density of 4 x 106 cells/mL and was 
transferred to a 6-well culture plate (up to 4 mL per well) for overnight incubation. 
The next day, WT and Trib2-/- cells were transferred to 50 mL centrifuge tubes and 
kept on ice. The culture wells were washed thrice with 2 mL of ice-cold PBS and 
each wash was transferred to the corresponding centrifuge tubes to minimize cell 
loss. Cell counting was performed to determine the recovery. WT and Trib2-/- cell 
suspensions were divided into halves for transduction with MigR1 and MigR1-ICN1 
(total of four transduction conditions) and were centrifuged at 350 x g and at 4°C for 
10 minutes. Each cell pellet was resuspended in 3 mL of activation medium (Table 
2.10) and transferred to a 6-well culture plate (one well per transduction condition). 
MigR1 and MigR1-ICN1 retroviral supernatants were thawed on ice and up to 1 mL 
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of supernatant with a titre of 40% was added into each well. Equal titre was used for 
MigR1 and MigR1-ICN1 retroviral supernatants and across three independent 
transplant experiments to ensure similar transduction efficiency of cells. If less than 
1 mL of supernatant was added, DMEM was used for compensation. The cells were 
centrifuged at 1290 x g and at room temperature for 90 minutes (first spin-infection). 
Following that, the cells were returned to tissue incubator for overnight incubation. 
The next day, the cells were transferred to 50 mL centrifuge tubes and kept on ice. 
The culture wells were washed thrice with 2 mL of ice-cold PBS and each wash was 
transferred to the corresponding centrifuge tubes to minimize cell loss. The cell 
suspensions were centrifuged at 350 x g and at 4°C for 10 minutes. MigR1 and 
MigR1-ICN1 retroviral supernatants were thawed on ice and 4 mL of each 
supernatant, each mL with a titre of 40%, was added into each tube containing the 
cell pellet. Cytokines (IL-3, IL-6 and SCF from PeproTech, London, UK) and 
polybrene were added directly to the tube. Their final concentrations were listed in 
Table 2.10. Cells were resuspended gently and the suspension was transferred to a 
6-well culture plate (4 mL per transduction condition per well). The cells were 
centrifuged at 1290xg and at room temperature for 90 minutes (second spin-
infection). Following that, the cells were returned to tissue incubator and incubated 
for 3 hours. The cells were transferred from each well of the culture plate into 
individual centrifuge tubes and kept on ice. The culture wells were washed thrice 
with 2 mL of ice-cold PBS and each wash was transferred to the corresponding 
centrifuge tubes to minimize cell loss. Cell counting was performed to determine the 
recovery. Cells were centrifuged at 350 x g and at 4°C for 10 minutes. The cell 
pellets were washed twice in 20 mL of ice-cold PBS. After that, the cell pellets from 
all the four transduction conditions were resuspended in ice-cold PBS and adjusted 
so that all have the equal concentrations (1.25-2.5 x 106 cells/mL). The cells were 
kept on ice and were ready to be transplanted into recipients. 
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Table 2.9 │ Pre-stimulation medium for retroviral transduction. 
Components Final concentration 
DMEM  quantity sufficient to desired volume 
Penicillin/streptomycin 100 I.U.mL-1/100 gmL-1 
L-glutamine 2 mM 
FBS 15% 
IL-3 10 ng/mL 
IL-6 10 ng/mL 
SCF 100 ng/mL 
 
Table 2.10 │ Activation medium for retroviral transduction. 
Components Final concentration per transduction condition† 
DMEM  3 mL per transduction condition 
Penicillin/streptomycin 100 I.U.mL-1/100 gmL-1 
L-glutamine 2 mM 
FBS 15% 
IL-3 10 ng/mL 
IL-6 10 ng/mL 
Polybrene 4 g/mL 
SCF 100 ng/mL 
† The amount of penicillin/streptomycin, L-glutamine, FBS, polybrene and cytokines 
added to 3 mL of DMEM was based on the calculation for the final volume (4 mL) of 
one transduction condition. 
 
2.2.5.4 Transplantation and monitoring for leukaemia development 
On the day where donor cells had second spin-infection, recipients were lethally 
irradiated with two fractionated doses, each 4.25 grays, given three hours apart. 
200 L of donor cells (0.25-0.5 x 106 cells) were then injected intravenously into 
each recipient. The recipients were kept in individually ventilated cages and treated 
with Baytril antibiotic, administered in the drinking water at a concentration of 80 
mg/L, daily for 10 days post transplantation. The recipients were monitored by 
periodic tail vein bleedings three weeks post transplantation. To count WBC, 97 L 
of 3% acetic acid solution was added to 3 L of blood followed by pipetting up and 
down for a few times before it was loaded onto a haemocytometer (Hawksley, 
Lancing, Sussex, UK). To monitor the level of donor engraftment and leukaemia 
development, the remaining collected blood was used for flow cytometry analysis 
(Section 2.2.10.2 and Table 2.22). Mice were euthanized when they showed any of 
55 
 
the following symptoms of disease: severe cachexia, lethargy, WBC count more 
than 20 x 106 cells/mL and hunching. Healthy controls were euthanized at the end 
of experiment when all mice in the test groups succumbed to disease. 
 
2.2.5.5 Analysis for moribund mice 
The body weight for each euthanized mouse was measured. Blood, liver, BM and 
spleen were collected and processed as described in section 2.2.10.1 for flow 
cytometry analysis using antibody panel C from Table 2.19. Blood cell counts were 
determined as described in section 2.2.4. Blood smears were made and stained as 
described in section 2.2.14. BM cells were also lysed in radio immunoprecipitation 
assay (RIPA) buffer to derive cell lysates for Western blotting analysis (section 
2.2.28.1). Spleen was photographed and weighed before being processed for flow 
cytometry analysis. Genomic DNA was also extracted from spleen cells to verify 
transplant experimental group based on Trib2 genotyping (section 2.2.26).   
 
2.2.6 Cell counting by trypan blue exclusion 
20 L of 0.4% trypan blue solution was added to 20 L of cell suspension and was 
mixed by pipetting up and down. The mixture was loaded onto a haemocytometer 
and examined immediately under an inverted microscope at low magnification. Only 
unstained live cells were counted in two of the large nine squares. The 
concentration of cells in the original suspension was calculated as below: 
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2.2.7 Co-immunoprecipitation 
After 24 hours of transfection, the cells were washed once with ice-cold PBS and 
harvested by using a cell scraper. The cells were transferred to a microcentrifuge 
tube and centrifuged at 11,000 x g and at 4°C for 45 seconds. 300 µL of protease 
inhibitors-supplemented Tris lysis buffer (Table 2.11) were added to the cell pellet. 
The crude cell lysate was incubated on ice for 30 minutes with vortexing every 5 
minutes. After the incubation, the lysate was centrifuged at 21,912 x g and at 4°C 
for 10 minutes. The supernatant which was the cleared protein lysate was 
transferred to a new microcentrifuge tube and kept on ice. Protein concentration 
was determined by using Bio-Rad Protein Assay Dye Reagent Concentrate. 50 µg 
of the lysate was aliqouted as input. For immunoprecipitation, equal amount of 
protein lysate for all the conditions were quantified sufficient to 1 mL with protease 
inhibitors-supplemented Tris lysis buffer (Table 2.11). Prior to immunoprecipitation, 
the lysate was pre-cleared with addition of 20 µL of Protein G Agarose beads 
followed by incubation on a rotary tube mixer in a cold room for 30 minutes. The 
lysate was centrifuged at 21,912 x g and at 4°C for 2 minutes. The supernatant 
which was the pre-cleared lysate was transferred to a new microcentrifuge tube. 
1.5-5 µg of anti-FLAG antibody and 20 µL of Protein G Agarose beads were added 
to the pre-cleared lysate followed by incubation on a rotary tube mixer in a cold 
room for overnight. The beads were washed in 1 mL of ice-cold Tris lysis buffer by 
inverting the tube repeatedly, and centrifugation at maximum speed and at 4°C for 
30 seconds. The washing was repeated for three times. In the final wash, residual 
supernatant was removed by 26 G needle. 25 µL of 2x Laemmli buffer containing 
1.5% of fresh β-mercaptoethanol was added to the beads followed by boiling at 
95°C for 5 minutes to elute immunoprecipitated proteins. The mixture was vortexed, 
and centrifuged at maximum speed and at 4°C for 2 minutes. 2x Laemmli buffer 
containing 1.5% of fresh β-mercaptoethanol was also added to the input followed by 
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boiling at 95°C for 5 minutes The supernatant and input were analyzed as described 
in section 2.2.28.2. 
 
Table 2.11 │ Protease inhibitors-supplemented Tris lysis buffer. 
Components  Final concentration 
Tris buffer [pH 7.4] 50 mM 
NaCl 150 mM 
IGEPAL CA-630 0.5 % 
Glycerol 5 % 
EDTA 1 mM 
PMSF† 1 mM 
Aprotinin† 2 g/mL 
Leupeptin† 5 g/mL 
Pepstastin† 1 g/mL 
Na3VO4
†
 1 mM 
NaF† 5 mM 
† Fresh protease inhibitors were added to Tris lysis buffer prior cell lysis. 
 
2.2.8 Cytospin preparation and staining 
100 µL of single cell suspension containing 50-100 x 103 cells was deposited onto a 
glass slide using ShandonTM CytospinTM 4 Cytocentrifuge. The cells were 
centrifuged at 450 rpm and at room temperature for 4 minutes with medium 
acceleration rate. The cells deposited onto slide were fixed and stained as 
described in section 2.2.14 using ShandonTM Kwik-DiffTM Kit. 
 
2.2.9 Detection of endogenous Tcrb rearrangements 
 
2.2.9.1 Extraction and clean up of thymic DNA 
Unfractionated thymocytes were digested overnight in 500 L of lysis buffer (Table 
2.12) (Wang et al., 2008) at 56°C. The following day, sample was heated at 95°C 
for 30 minutes to inactivate proteinase K. 500 L of Phenol:Chloroform:Isoamyl 
Alcohol (25:24:1) reagent was added to the sample. The mixture was inverted 
repeatedly to mix homogenously, and centrifuged at maximum speed and at 4°C for 
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5 minutes. The separated aqueous phase was transferred to a new microcentrifuge 
tube. 45 L of 3M sodium acetate (pH 5.2) and 1125 L of ice-cold absolute ethanol 
were then added. The mixture was inverted repeatedly to mix homogenously and 
kept at -20°C for overnight. The following day, it was centrifuged at maximum speed 
and at 4°C for 10 minutes. The supernatant was removed carefully to leave the 
DNA pellet undisturbed. 500 L of 70% ice-cold ethanol was added carefully to 
leave the DNA pellet undisturbed, and it was centrifuged at maximum speed and at 
4°C for 5 minutes. The supernatant was again removed carefully to leave the DNA 
pellet undisturbed. The DNA pellet was left to air-dry at room temperature for at 
least 30 minutes. Finally, the DNA pellet was resuspended in 50 L of nuclease free 
water and the concentration was determined using NanoDrop ND-1000 
Spectrophotometer. All extracted DNA were stored indefinitely at -20°C. 
 
Table 2.12 │ Lysis buffer to extract thymic DNA. 
 
† Fresh lysis buffer was made on the experiment day. 
 
2.2.9.2 Polymerase chain reaction (PCR) amplification of Tcrb rearrangements  
V(D)J rearrangements of the Tcrb locus were amplified by FastStartTM High Fidelity 
PCR Kit using published primers (Cobaleda et al., 2007). Primer sequences and the 
annealing temperatures for all amplifications were listed in Table 2.13. All the 
reagents and DNA were thawed and kept on ice. After thawing, all DNA samples 
were pre-diluted to 25 ng/L in nuclease free water and kept on ice. All 
components, listed in Table 2.14, were added in an order to make a PCR master 
mix. 22 L of master mix was aliquoted into individual PCR tubes. 1 L of pre-
Components† Final concentration 
KCl 50 mM 
Tris-HCl (pH8.3) 10 mM 
MgCl2 2 mM 
IGE 0.45% (vol/vol) 
Tween 20 0.4 % (vol/vol) 
Proteinase K 60 g/mL 
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diluted sample (25 ng of DNA input) was then added to the tube. Importantly, 2 L 
of primer mix (Table 2.15) was added to the tube in the final step to complete the 
setup of a PCR reaction. All tubes were pulsed vortexed and spunbriefly with a mini 
centrifuge before loaded onto a PCR machine. The thermal cycling conditions were 
listed in Table 2.16. PCR products and 1 kb DNA ladder were separated on a 1.5% 
agarose gel, detected by SafeView Nucleic Acid Stain, and imaged using Bio-Rad 
ChemiDoc XRS system. 
 
Table 2.13 │ PCR primers used to detect Tcrb rearrangements. 
Primer Tcrb 
locus 
5’>3’ sequence Annealing 
temperature (°C) 
Forward 
Dβ2 GTAGGCACCTGTGGGGAAGAAACT  58 
Vβ2 GGGTCACTGATACGGAGCTG  58 
Vβ4 GGACAATCAGACTGCCTCAAGT  58 
Vβ5.1 GTCCAACAGTTTGATGACTATCAC 56 
Vβ8 GATGACATCATCAGGTTTTGTC  56 
Vβ14 CTTCTACCTCTGTGCCTGGAGT  58 
Reverse Jβ2 TGAGAGCTGTCTCCTACTATCGATT  According to 
forward primer 
 
Table 2.14 │ PCR master mix for detection of Tcrb rearrangements. 
† Provided in the FastStart High Fidelity PCR kit. 
 
Table 2.15 │ PCR Primer mix for detection of Tcrb rearrangements. 
 
 
 
 
Components volume per reaction (L) Final concentration 
Nuclear free water 18.5   - 
10x buffer† 2.5 1.8 mM MgCl2 
dNTP 0.5 200 M 
Enzyme† 0.5 2.5 U 
Primer volume per reaction (L) Final concentration 
Forward 1  0.4 M 
Reverse 1 0.4 M 
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Table 2.16 │ PCR thermal cycling conditions for detection of Tcrb rearrangements. 
 
2.2.10 Flow cytometry 
 
2.2.10.1 Preparation for primary cells 
Pelvises, femurs and tibias collected from euthanized mice were dissected free of 
muscle tissues and tendons. The bones were crushed in 2% (vol/vol) FBS-
supplemented PBS using a mortar and pestle. The resulting BM cell suspension 
was filtered through a cell strainer. Whole spleen and thymus were isolated and 
grinded directly onto a pre-wet cell strainer and washed with 2% FBS-supplemented 
PBS to generate single cell suspensions. Cell suspension from liver was derived in 
a similar way except that a cut piece instead of whole organ was used. All the cell 
suspensions were centrifuged at 350 x g and at 4°C for 5 minutes. The cell pellets 
were resuspended in 1 mL homemade ammonium-chloride-potassium lysing buffer 
containing 10 mM KHCO3, 150 mM NH4Cl and 0.1 mM EDTA, and incubated on ice 
for 5 minutes to lyse RBCs. This was followed by washing and resuspension in 2% 
FBS-supplemented PBS. The RBC lysing procedure was repeated once when the 
cell pellet remained to be visibly red. Live cell count was then determined by trypan 
blue exclusion. 
 
2.2.10.2 Surface staining 
Cell suspensions were centrifuged at 350 x g and at 4°C for 5 minutes. 50-100 L of 
antibody cocktails, diluted in 2% FBS-supplemented FBS, were added to the cell 
Steps Number of 
cycles 
Duration Temperature (°C) 
Initial 
denaturation 
1 2 minutes 95 
Denaturation 
35 
30 seconds 95 
Annealing 30 seconds refer to Table 2.4 
Elongation 3 minutes 72 
Final elongation 1 7 minutes 72 
Cooling unlimited indefinite 4 
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pellets, mixed by pulsed vortex and incubated on ice for 30 minutes. Following that, 
the cells were washed once and resuspended in 2% FBS-supplemented PBS. The 
surface-stained cells were kept on ice and were ready for (i) secondary staining with 
fluorochrome-conjugated streptavidin, (ii) intracellular staining or (iii) flow cytometry 
analysis.  
 
Table 2.17 │ Multicolour fluorescent antibody panel to detect HSCs. 
Antibody Fluorochrome Dilution 
anti-mouse CD3 
Biotin2 1:200 
anti-mouse CD4 
anti-mouse CD8 
anti-mouse CD45.11 
anti-mouse Gr-1  
anti-mouse Ter-119 
anti-mouse/human B220 
anti-mouse/human CD11b 
anti-mouse CD48 PE 1:600 
anti-mouse CD16/CD32 APC 1:100 
anti-mouse c-Kit  APC-Cy7 1:200 
   
anti-mouse Sca-1 PE-Cy7 1:200 
1 Included only for whole BM transplant experiment to exclude CD45.1+ donor cells 
from analysis. 
2 Biotinylated primary antibodies were revealed by streptavidin-eFluor 450. 
 
Table 2.18 │ Multicolour fluorescent antibody panel to detect haematopoietic 
progenitor cells. 
Antibody Fluorochrome Dilution 
anti-mouse CD3 
Biotin2 1:200 
anti-mouse CD4 
anti-mouse CD8 
anti-mouse CD45.11 
anti-mouse Gr-1  
anti-mouse Ter-119 
anti-mouse/human B220 
anti-mouse/human CD11b 
anti-mouse c-Kit  APC-Cy7 1:200 
anti-mouse CD16/CD32 APC 1:100 
anti-mouse CD34 FITC 1:100 
anti-mouse IL-7R PE 1:100 
anti-mouse Sca-1 PE-Cy7 1:200 
1 Included only for whole BM transplant experiment to exclude CD45.1+ donor cells 
from analysis. 
2 Biotinylated primary antibodies were revealed by streptavidin-eFluor 450. 
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Table 2.19 │ Multicolour fluorescent antibody panels to detect cells of myeloid, B- 
and T-lineages. 
Antibody 
Fluorochrome1 
Dilution 
Panel A Panel B Panel C2 
anti-mouse CD4 Brilliant 
Violet 510TM 
Brilliant Violet 
510TM 
Brilliant 
Violet 510TM 
1:250 
anti-mouse CD8 PE PE PE 1:250 
anti-mouse CD19 APC eFluor 780 eFluor 780 1:150 
anti-mouse CD45.2 - PE-Cy7 PE-Cy7 1:250 
anti-mouse Gr-1  PE-Cy7 PerCP-Cy5.5 PerCP-Cy5.5 1:250 
anti-mouse/human B220 PerCP-
Cy5.5 
APC APC 1:250 
anti-mouse/human CD11b FITC FITC eFluor 450 1:250 
1 Panel A was designed for non-transplant experiments. Panel B and C were 
designed for transplant experiments involved whole and transduced BM 
respectively. 
2 GFP expression was also measured as a marker for transduced donor cells. 
 
Table 2.20 │ Multicolour fluorescent antibody panels to detect thymic subsets. 
Antibody 
Fluorochrome1 
Dilution 
Panel A Panel B Panel C Panel D 
anti-mouse CD11c 
eFluor 
450 
eFluor 
450 
Biotin2 Biotin2 1:250 
anti-mouse Gr-1  
anti-mouse NK1.1 
anti-mouse Ter-119 
anti-mouse/human 
B220 
anti-mouse CD4 Brilliant 
Violet 
510TM 
Brilliant 
Violet 
510TM 
Biotin2 FITC 1:1503 
1:2504 
anti-mouse CD8 PE APC Biotin
2 APC 1:250 
anti-mouse CD25 PE-Cy7 PE-Cy7 PE-Cy7 PE-Cy7 1:250 
anti-mouse CD44 PerCP-
Cy5.5 
PerCP-
Cy5.5 
PerCP-
Cy5.5 
PerCP-
Cy5.5 
1:250 
anti-mouse CD71 - PE - - 1:250 
anti-mouse c-Kit APC-
Cy7 
APC-
Cy7 
APC-
Cy7 
APC-
Cy7 
1:1505 
1:2506 
1 Panel A was designed for Annexin V (section 2.2.2), Ki-67 and phospho-p38 
(section 2.2.10.3.3) staining. Panel B was designed to measure expression of CD71 
for different thymic subsets. Panel C was designed for staining of cells in resting 
and cycling state (section 2.2.10.3.4), and for detection of incorporated 
bromodeoxyuridine (BrdU) (section 2.2.13). Panel D was designed for DNA staining 
of different thymic subsets (section 2.2.10.3.1). 
2 Biotinylated primary antibodies were revealed by streptavidin-PE. 
3 Antibody dilution used for panel A and B. 
4 Antibody dilution used for panel C and D. 
5 Antibody dilution used for panel C. 
6 Antibody dilution used for panel A, B and D.  
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Table 2.21 │ Multicolour fluorescent antibody panel to detect non-T-lineage cells 
present in the thymus. 
Antibody Fluorochrome Dilution 
anti-mouse CD11c Biotin† 1:250 
anti-mouse CD19 eFluor 780 1:150 
anti-mouse Gr-1  PE-Cy7 1:250 
anti-mouse NK1.1 eFluor 450 1:250 
anti-mouse/human B220 APC 1:250 
anti-mouse/human CD11b FITC 1:250 
† Biotinylated primary antibody was revealed by streptavidin-PerCP-Cy5.5. 
 
Table 2.22 │ Multicolour fluorescent antibody panel used to monitor leukaemia 
development†. 
Antibody Fluorochrome Dilution 
anti-mouse CD45.2 PE-Cy7 1:250 
anti-mouse CD4 APC 1:250 
anti-mouse Gr8  eFluor 450 1:250 
† GFP expression was also measured as a marker for transduced donor cells. 
 
2.2.10.3 Intracellular staining 
 
2.2.10.3.1 DNA staining for thymocytes 
To enable identification of thymus subsets, cells were stained in 50 L of antibody 
panel D from Table 2.20. Following that, cell suspension was centrifuged at 350 x g 
and at 4°C for 5 minutes. To fix and permeabilize the cells, BD Cytofix/CytopermTM 
Kit was used. 500 L of BD Cytofix/Cytoperm solution was added to the cell pellet 
followed by pulse vortex and incubation on ice in the dark for 20 minutes. The fixed 
and permeabilized cells were washed twice in 500 L of BD 1x Perm/Wash buffer 
followed by centrifugation at 350 x g and at 4°C for 5 minutes. To stain DNA, the 
cells were incubated with DNA selective Vybrant DyeCycle Violet Stain (1:100 
dilution), diluted in 100 L of BD 1x Perm/Wash buffer, for 30 minutes on ice in the 
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dark. Finally, the cells were washed and resuspended in 500 L of 2% FBS-
supplemented PBS for flow cytometry analysis.  
 
2.2.10.3.2 DNA staining for cell cycle synchronization 
Cells were transferred to polystyrene tube (12 x 75 mm) and washed once in ice-
cold PBS. The cells were centrifuged at 350 x g and at 4°C for 5 minutes. The cell 
pellet was resuspended in 300 µL of ice-cold PBS. 700 µL of ice-cold absolute 
ethanol was added to the cell suspension drop by drop while vortexing. The tube 
was sealed with parafilm and the sample was stored at -20°C. To prepare for DNA 
staining, the cells were centrifuged at 200 x g and at 4°C for 10 minutes. The cells 
were washed twice in ice cold PBS. Each wash involved centrifugation at 200 x g 
and at 4°C for 10 minutes. After the last wash, the cells were resuspended in 350 
µL of BD PharmingenTM PI/RNase Staining Buffer and incubated at room 
temperature in the dark for 15 minutes. The cells were ready for flow cytometry 
analysis. 
 
2.2.10.3.3 Ki-67 and phospho-p38 staining 
To enable identification of thymus subsets, cells were stained, as described in 
section 2.2.10.2, with antibody panel A from Table 2.20. Following that, cell 
suspension was centrifuged at 350 x g and at 4°C for 5 minutes. To fix the cells, 
400 L of 4% (wt/vol) paraformaldehyde solution was added to the cell pellet 
followed by pulse vortex and incubation at room temperature in the dark for 20 
minutes. The fixed cells were centrifuged at 350 x g and at 4°C for 5 minutes. To 
permeabilize the cells, 400 L of 0.1% (wt/vol) saponin solution was added to the 
cell pellet followed by pulse vortex and incubation at room temperature in the dark 
for 15 minutes. The fixed and permeabilized cells were centrifuged at 350 x g and at 
4°C for 5 minutes. To stain the cells for Ki-67 and phospho-p38, 100 L of antibody 
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cocktail (Table 2.23), diluted in 0.1% (wt/vol) saponin solution, was added to the cell 
pellet. This was followed by pulsed vortex and incubation on ice in the dark for 30 
minutes. Finally, the cells were washed and resuspended in 500 L of 2% FBS-
supplemented PBS for flow cytometry analysis. 
 
Table 2.23 │ Fluorescent antibody panel to stain Ki-67 and phospho-p38. 
Antibody Fluorochrome Dilution 
anti-mouse/human 
phosphor-p38 (T180/Y182) 
APC 1:250 
anti-mouse/rat Ki-67 FITC 1:250 
 
2.2.10.3.4 Staining for cells in resting and cycling state 
To enable identification of immature DN thymus subsets, cells were stained in 100 
L of antibody panel C from Table 2.20. Following that, cell suspension was 
centrifuged at 350 x g and at 4°C for 5 minutes. To fix and permeabilize the cells, 
500 L of BD Cytofix/Cytoperm Buffer was added to the cell pellet followed by pulse 
vortex and incubation on ice in the dark for 20 minutes. The fixed and permeabilized 
cells were washed twice in 500 L of BD 1x Perm/Wash Buffer followed by 
centrifugation at 350 x g and at 4°C for 5 minutes. To distinguish resting (G0) from 
cycling (G1-S/G2/M) cell cycle state, the cells were incubated with anti-Ki-67 FITC 
antibody (1:250 dilution) and Vybrant DyeCycle Violet Stain (1:100 dilution), 
diluted in 100 L of BD 1x Perm/Wash Buffer, for 30 minutes on ice in the dark. 
Finally, the cells were washed and resuspended in 500 L of 2% FBS-
supplemented PBS for flow cytometry analysis.  
 
2.2.10.4 Data collection and analysis 
UltraComp eBeads® was used to prepare single-color compensation controls in 
multicolor flow cytometry experiments. Flow cytometry was performed using BD 
FACSCanto II system (BD Biosciences), equipped with blue, red and violet lasers. 
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Aggregates were excluded by forward scatter (FSC) height versus area signals. The 
singlet population was then gated by FSC area versus side scatter area signals to 
exclude dead cells and debris. Whenever possible, dead cells were also excluded 
by DAPI (1:1000 dilution of 1 mg/mL stock solution) or PI (1:2000 dilution of 10 
mg/mL stock solution) staining. In this case, the dye was added into cell suspension 
and mixed by pulsed vortex prior flow cytometry analysis. FlowJo (Tree Star, 
Ashland, OR, USA) was used to analyze flow cytometry data. Fluorescence Minus 
One (FMO) controls were used to facilitate gating as appropriate. 
 
2.2.11 Gene set enrichment analysis (GSEA) 
Gene expression profiles of T-ALL and healthy BM samples from GSE13159 data 
set (Haferlach et al., 2010) were downloaded from the Leukaemia Gene Atlas 
platform (Hebestreit et al., 2012). Based on 202478_at feature, TRIB2 expression of 
low TRIB2 T-ALL group ranged from 3.602 to 5.370 whereas high TRIB2 T-ALL 
group ranged from 8.811 to 11.103. The mean value of TRIB2 for healthy BM 
samples (n = 73) was 6.172. GSEA (Subramanian et al., 2005) was performed 
using the default settings. Gene sets from the Molecular Signatures Database v5.0 
of GSEA (Broad Institute of MIT and Harvard, Cambridge, MA, USA) were used. 
These included the 1330 gene sets in C2: CP collection for canonical pathways and 
the 3 gene sets in C2: CGP collection (M4175, M2059 and M1007) for T-ALL 
molecular subtypes. 
 
2.2.12 In vivo 5-FU treatment 
On the drug administration day, mice were weighed to calculate the weight-adjusted 
dosage (150 or 250 mg/kg), as indicated in the related figure legends. 5-FU 50 
mg/mL solution was diluted in PBS on the same day and was administered by 
intraperitoneal (i.p.) injection. For 150 mg/kg dosage, the diluted concentration of 5-
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FU was 15 mg/mL whereas for 250 mg/kg dosage, it was 25 mg/mL. In this case, a 
mouse of 20 g received 0.2 mL of the diluted 5-FU. 
 
2.2.13 In vivo BrdU pulsing and detection of incorporated BrdU 
On day 14 post 5-FU treatment, mice were pulsed with 1 mg of BrdU Labelling 
Reagent, by i.p. injection, for one or four hours. Thymus was collected from 
euthanized mice and single cell suspension was prepared as described in section 
2.2.10.1. To enable identification of immature DN thymus subsets, cells were 
stained in 100 L of antibody panel C from Table 2.20. Following that, cell 
suspension was centrifuged at 350 x g and at 4°C for 5 minutes. To fix and 
permeabilize the cells, 250 L of BD Cytofix/Cytoperm Buffer was added to the cell 
pellet followed by pulse vortex and incubation on ice in the dark for 30 minutes. The 
fixed and permeabilized cells were washed in 3% FBS-supplemented PBS, and 
were centrifuged at 350 x g and at 4°C for 5 minutes. To permeabilize the nuclear 
membrane further, 1 mL of 10% DMSO-supplemented FBS was added to the cell 
pellet followed by pulse vortex and incubation for overnight at -80°C. The cells were 
then thawed at 37°C, washed in 3% FBS-supplemented PBS, and incubated with 
250 L of BD Cytofix/Cytoperm Buffer for an additional 10 minutes on ice in the 
dark. Following incubation, the cells were washed in 3% FBS-supplemented PBS 
and treated in 100 L of DNase I solution (30 g per 1x106 cells diluted in PBS) for 
one hour at 37°C in the dark. The cells were washed once in BD 1x Perm/Wash 
Buffer before intracellular staining. The cells were incubated with anti-BrdU FITC 
antibody (1:50 dilution) and Vybrant DyeCycle Violet Stain (1:100 dilution), diluted 
in BD Perm/Wash Buffer, for 30 minutes at room temperature in the dark. Finally, 
the cells were washed and resuspended in 500 L of 3% FBS-supplemented PBS 
for flow cytometry analysis.  
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2.2.14 Making and staining a blood smear 
Blood collected in EDTA-coated microvette was pulsed-vortexed. 3 L of blood was 
transferred to one end of a clean glass slide. The blood was spread into a thin 
smear by using another clean slide to touch the blood drop and push carefully along 
the length of the first slide. The smear was allowed to air dry at room temperature 
before it was stained using ShandonTM Kwik-DiffTM Kit. The blood smear slide was 
dipped into Kwik-Diff Reagent 1 (Fixative) for 10 times, Reagent 2 (Eosin) for 10 
times and into Reagent 3 (Methylene Blue) for 10 times. Each dip was about a 
second. After that, the slide was dipped into clean water for a few times to wash off 
the excess staining reagent. The stained blood smear was allowed to air dry at 
room temperature and DPX mountant was applied to preserve the stain.  
 
2.2.15 Mycoplasma detection assay 
Mycoplasma contamination in cultured cell lines was monitored using MycoAlertTM 
Mycoplasma Detection Kit (Lonza, Slough, UK). Aliquots of MycoAlertTM reagent 
and substrate (50 L each), stored at -20°C, were thawed and allowed to equilibrate 
to room temperature. 50 L of fresh supernatant of cultured cells was added to the 
reagent and incubated for 5 minutes before luminescence (reading A) was 
measured by GloMax 20/20 Single Tube Luminometer (Promega, Southampton, 
UK). The substrate was subsequently added to the sample and incubated for 10 
minutes before luminescence (reading B) was measured again. The results (ratio of 
reading B to reading A) were interpreted according to the manufacturer guidelines. 
 
2.2.16 Plasmid construction 
 
2.2.16.1 Sub-cloning to derive pCMV6-CDC25A/B-FLAG 
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pCMV6-CDC25A/CDC25B-MYC-FLAG and pCMV6-AC-FLAG (empty vector) 
plasmids were double-digested using MluI and AsiSI restriction enzymes. CDC25A 
and CDC25B inserts were extracted using QIAquick Gel Extraction Kit whereas the 
digested pCMV6-AC-FLAG was cleaned up using QIAquick PCR Purification Kit. 
CDC25A and CDC25B inserts were ligated individually with digested pCMV6-AC-
FLAG using Sticky-end Ligase Master Mix with 1:3 molar ratio of vector to insert. 
Bacterial transformation was performed as described in section 2.2.3. Colonies 
were picked and screened by double digestion using MluI and AsiSI restriction 
enzymes.  
 
2.2.16.2 Sub-cloning to derive pCMV6-CDC25C-FLAG 
CDC25C (human/mouse) inserts were derived from pcDNA3-HisA-CDC25C 
(human) and pCMV6-CDC25C (mouse) plasmids. AsiSI and MluI cloning sites were 
appended to the 5’ and 3’ ends of the inserts respectively by PCR (Table 2.24) 
using Q5 Hot Start High-Fidelity DNA Polymerase. PCR products were cleaned up 
using QIAquick PCR Purification Kit. CDC25C inserts and pCMV6-AC-FLAG (empty 
vector) plasmids were double-digested using MluI and AsiSI restriction enzymes. 
The digested inserts and vector were cleaned up using QIAquick PCR Purification 
Kit. CDC25C (human/mouse) inserts were ligated individually with digested pCMV6-
AC-FLAG using Sticky-end Ligase Master Mix. Bacterial transformation was 
performed as described in section 2.2.3. Colonies were picked and screened by 
double digestion using MluI and AsiSI restriction enzymes. Positive clones were 
verified further by DNA sequencing to ensure no mutation presents in the PCR-
cloned inserts. 
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Table 2.24 │ PCR primers used to clone CDC25C inserts. 
CDC25C Forward primer (5’>3’)† Reverse primer (5’>3’)† 
mouse 
gaggcgatcgccATGTCTACAGGACC 
TATCCCACC 
gcgacgcgtTTGTGGGCTCGCA 
CCCTTCA 
human 
gaggcgatcgccATGTCTACGGAACT 
CTTCTCATC 
gcgacgcgtTGGGCTCATGTCC 
TTCACC 
† Letters in lower case contain the AsiSI and MluI cloning sites. 
 
2.2.17 Plasmid purification 
A sterile pipette tip was used to stab the frozen glycerol stock of transformed 
bacteria and placed in 5 mL of ampicillin-supplemented LB broth. The LB broth was 
incubated in a shaker at 37°C for approximate 8 hours. After that, the bacteria 
culture was transferred to a bigger flask containing 150 mL of fresh ampicillin-
supplemented LB broth for overnight incubation in a shaker at 37°C. Plasmid DNA 
was purified from the overnight culture using PureYieldTM Plasmid Midiprep System. 
The cells were centrifuged at 5,000 x g for 10 minutes. 6 mL of Cell Resuspension 
Solution was added to resuspend the cell pellet. 6 mL of Cell Lysis Solution was 
added and mixed by gently inverting the tube 3 times. The mixture was incubated 
for 3 minutes at room temperature. 10 mL of Neutralization Solution was added to 
the lysed cells and mixed by gently inverting the tube 3 times. The lysate was 
centrifuged at room temperature and at 15,000 x g for 15 minutes. The cleared 
lysate was transferred into the PureYieldTM Clearing Column. Vacuum was applied 
so that the lysate passed through the Clearing and Binding Columns. 5 mL of 
Endotoxin Removal Wash and 20 mL of Column Wash Solution were added to the 
Binding Column sequentially and removed by the vacuum. The membrane was 
dried by applying a vacuum for 1 minute and the the tip of the column was tapped 
on a paper towel to remove excess ethanol. 400 µL of nuclease free water was 
added to elute the plasmid DNA by vacuum.               
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2.2.18 Protein BLAST 
Basic Local Alignment Search Tool (BLAST) (Altschul et al., 1990) was used to 
align the amino acid sequence of human and mouse orthologs for CDC25B and 
CDC25C. The reference sequences for CDC25B were NP_075606.1 (mouse 
ortholog) and NP_068659.1 (human ortholog). The reference sequences for 
CDC25C were NP_033990.2 (mouse ortholog) and NP_001781.2 (human ortholog). 
Blastp (protein-protein BLAST) algorithm was executed with default parameters.  
 
2.2.19 Quantitative RT-PCR 
 
2.2.19.1 Analysis for TRIB2 knockdown in U937 cells 
High throughput quantitative RT-PCR analysis was performed on the Fluidigm 
48.48 Dynamic Array Integrated Fluidic Circuits system (Biomark HD). Primer 
sequences are listed in Table 2.25. Specific target pre-amplification was carried out. 
Each target was measured in triplicate reactions. Expression levels of the target 
genes (TRIB1 and TRIB2) were normalized relative to the mean of the reference 
genes (ABL, B2M, ENOX2 and RNF20). Relative messenger ribonucleic acid 
(mRNA) levels were calculated using the 2-ΔΔCT method. 
 
Table 2.25 │ Primers used for quantitative RT-PCR. 
Gene Forward primer (5’>3’) Reverse primer (5’>3’) 
TRIB1 CTTCAAGCAGATTGTCTCCGC  CTAAGCTGGGTTCTCTCCTCC  
TRIB2 AGCCAGACTGTTCTACCAGA  GGCGTCTTCCAGGCTTTCCA  
ABL TGGAGATAACACTCTAAGCATA 
ACTAAAGGT 
GATGTAGTTGCTTGGGACCCA 
β2M TTGTCTTTCAGCAAGGACTGG ATGCGGCATCTTCTAACCTCC 
ENOX2 GAGCTGGAGGGAACCTGATTT CACTGGCACTACCAAACTGCA  
RNF20 GGTGTCTCTTCAACGGAGGAA TAGTGAGGCATCATCAGTGGC 
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2.2.19.2 Analysis for cell cycle synchronization 
Trib2 and 2m expressions were measured using Fast SYBR Green Master Mix. 
Primer sequences are listed in Table 2.25. Each target was measured in triplicate 
reactions. Master mix (Table 2.26) was prepared on ice and 9 µL of the mix was 
aliquoted per well of a 384-well plate. 1 µL of cDNA was added into each well. The 
volume of a complete reaction was 10 µL. The plate was sealed and centrifuged 
briefly before loaded onto the Applied Biosystems 7900HT Fast Real-Time PCR 
system (Table 2.27). Expression of Trib2 was normalized relative to B2m. Relative 
mRNA levels were calculated using the 2-ΔΔCT method. 
 
Table 2.26 │ Master mix for quantitative RT-PCR. 
Components Volume per reaction (µL) 
Fast SYBR Green Master Mix 5 
Forward primer (10 µM) 0.25 
Reverse primer (10 µM) 0.25 
Nuclease free water 3.5 
 
Table 2.27 │ Thermal cycling conditons for quantitative RT-PCR. 
 
2.2.20 RNA extraction and complementary DNA (cDNA) synthesis 
Total ribonucleic acid (RNA) was extracted from cells using RNeasy Mini Kit. Cells 
were washed once in ice-cold PBS and centrifuged at 350 x g and at 4°C for 5 
minutes. Filtered tips were used during the whole procedure. 350 µL of Buffer RLT 
was added to the cell pellet. Cell lysis was aided by repeated pipetting. The lysate 
was transferred into a QIAshredder spin column placed in a 2 mL collection tube 
and centrifuged for 2 minutes at full speed and at room temperature. 350 µL of 70% 
ethanol was added to the homogenized lysate and mixed well by pipetting. The 
Steps Number of cycles Temperature (°C) Duration (seconds) 
Activation 1 95 20 
Melting 
40 
95 1 
Annealing 60 20 
Extending 50 120 
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sample was transferred to an RNeasy spin column placed in a 2 mL collection tube. 
The lid was closed gently and centrifuged for 15 seconds at 10,000 x g and at room 
temperature. The flow through was discarded. 700 µL of Buffer RW1 was added to 
the RNeasy spin column. The lid was closed gently and centrifuged for 15 seconds 
at 10,000 x g and at room temperature. The flow through was discarded. 500 µL of 
Buffer RPE was added to the RNeasy spin column. The lid was closed gently and 
centrifuged for 15 seconds at 10,000 x g and at room temperature. The flow through 
was discarded. Another 500 µL of Buffer RPE was added to the RNeasy spin 
column. The lid was closed gently and centrifuged for 2 minutes at 10,000 x g and 
at room temperature. The RNeasy spin column was placed in a new 2 mL collection 
tube, and centrifuged at full speed for 1 minute and at room temperature. The 
RNeasy spin column was placed in a new 1.5 mL microcentrifuge tube. 30 µL of 
nuclease free water was added directly to the spin column membrane. The lid was 
closed gently and centrifuged for 1 minute at 10,000 x g and at room temperature to 
elute the RNA. The RNA concentration was determined using NanoDrop ND-1000 
Spectrophotometer. All RNA samples were stored at -80°C. 
 
cDNA was synthesized using High Capacity cDNA Reverse Transcription Kit. 
Master mix (Table 2.28) were prepared on ice and 6.8 µL of the master mix was 
aliquoted into individual PCR tube. 13.2 µL of sample containing up to 0.5 µg of 
RNA was added into each tube. The volume of a complete reaction was 20 µL. 
Tube was pulsed vortex and centrifuged briefly before loaded onto a PCR machine. 
The thermal cycling conditions were listed in Table 2.29. All cDNA samples were 
stored at -20°C. 
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Table 2.28 │ Master mix for cDNA synthesis. 
Components Volume per reaction (µL) 
10x RT buffer 2 
25x dNTP mix (100 mM) 0.8 
10x RT Random Primers 2 
MultiScribe Reverse Transcriptase (50 U/µL) 1 
RNase inhibitor† (20 U/µL) 1 
† RNase inhibitor was not included in the kit. 
 
Table 2.29 │ PCR thermal cycling conditons for cDNA synthesis. 
 
 
 
 
2.2.21 Single thymidine block 
RPMI-8402 cells were synchronized by single thymidine block. Cells were sub-
cultured at 0.5 x 106 cells/mL the day before treatment with thymidine. The following 
day, the cells were plated at 0.5 x 106 cells/mL. Asynchronous samples (AS) were 
collected at this time point. The remaining cells were treated with 0.75 mM 
thymidine and cultured for 21 hours. At 21 hours post treatment, synchronous 
samples (S0) were collected. The remaining synchronous cells were released from 
thymidine block by washing for twice in PBS. Each wash involved centrifugation of 
cells at 350 x g and at room temperature for 5 minutes.  After the final wash, the 
cells were resuspended in fresh complete culture medium and returned to tissue 
incubator. Samples were then collected at different time points (S12, S15, S17, 
S20, S22 and S24). At each time point, cells were collected for flow cytometry 
(Section 2.2.10.3.2), Western blotting (Section 2.2.28.4) and quantitative RT-PCR 
analyses (Section 2.2.19.2). Each analysis required 250 x 103 cells.  
 
 
Steps Temperature (°C) Duration (minutes) 
1 25 10 
2 37 120 
3 85 5 
4 4 indefinite 
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2.2.22 Statistics 
GraphPad Prism (version 5.03; LA Jolla, CA, USA) was used for statistical analysis 
and graphing. An unpaired, two-tailed, Student’s t-test was applied for comparison 
of two groups. For analysis of multiple groups between WT and Trib2-/- genotypes, 
two-way analysis of variance (ANOVA) with Bonferroni post-tests was applied. Log-
rank test was applied for survival curve comparison. Pearson correlation test was 
applied to examine association between TRIB2 and LYL1 expressions of T-ALL 
samples from GSE33315 data set (Zhang et al., 2012c). This data set was 
downloaded from Gene Expression Omnibus and Robust Multichip Average method 
was used for data normalization. D’Agostino-Pearson omnibus test confirmed these 
samples had Normal distributions of TRIB2 and LYL1 values. Statistical significance 
of differences was attained when P value <0.05 and was indicated in the related 
graphs. Statistical analyses where P value ≥ 0.05 were not indicated in the graphs 
and deemed not significant. 
 
2.2.23 Subcellular fractionation 
Transfected cells were treated with DMSO (vehicle) or 10 µM of MG132 for 4 hours 
before being subcellular fractionated. Active Motif Nuclear Extract Kit was used to 
derive nuclear and cytoplasmic lysates. Cells were washed with 4 mL of ice-cold 
phosphatase inhibitors-supplemented PBS. Following that, the cells were harvested 
in 1 mL of ice-cold phosphatase-inhibitors supplemented PBS by using cell 
scrapper and the cell suspension was transferred to a pre-chilled microcentrifuge 
tube. The suspension was centrifuged for 4 minutes at 200 x g and at 4°C. The cell 
pellet was resuspended gently in 300 µL of 1x hypotonic solution and incubated on 
ice for 15 minutes. 25 µL of detergent was then added and the suspension was 
vortexed at the highest speed for exactly 10 seconds. The suspension was 
centrifuged for 30 seconds at 14,000 x g and at 4°C. The supernatant was the 
cytoplasmic lysate and transferred to a new microcentrifuge tube. The nuclear pellet 
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was resuspended in 25 µL of complete lysis buffer and vortexed at the highest 
speed for 1 minute. The nuclear suspension was incubated on a laboratory rocking 
mixer in a cold room for 30 minutes. The suspension was vortexed again at the 
highest speed for 30 seconds before being centrifuged for 10 minutes at 14,000 x g 
and at 4°C. The supernatant was the nuclear lysate and transferred to a new 
microcentrifuge tube. The concentration of nuclear and cytoplasmic lysates was 
determined by using Bio-Rad Protein Assay Dye Reagent Concentrate. All lysates 
were kept at -80°C until being analyzed as described in section 2.2.28.3.  
 
2.2.24 Tissue culture 
293T and 3T3 cell lines were cultured in DMEM complete medium whereas RPMI-
8402 and HeLa cell lines were cultured in RPMI complete medium (Table 2.30). To 
maintain 293T, 3T3 and HeLa cell lines, cells were sub-cultured at 1:5 ratio in fresh 
medium every 2-3 days. Trypsin-EDTA solution was used to detach the cells from 
growth surface. To maintain RPMI-8402 cell line, cells were sub-cultured at 0.5 x106 
cells/mL in fresh medium every 2-3 days. To cryopreserve cells, cells were 
centrifuged at 350 x g and at room temperature for 5 minutes. Ice-cold 
cyopreservation medium (10% DMSO-supplemented FBS) was added to the cell 
pellet and cells were resuspended by gentle pipetting. 1 mL of cell suspension was 
aliquoted into each cryotube, and stored at -80°C for short term and in liquid 
nitrogen tank for long term. To resuscitate frozen cells, cryopreserved cells were 
thawed at 37°C and transferred to a 50 mL centrifuge tube. 10 mL of pre-warmed 
complete culture medium was added drop by drop to the cells and mixed by gentle 
shaking. The cells were centrifuged at 350 x g and at room temperature for 5 
minutes. The cell pellet was resuspended in complete culture medium. The cell 
suspension was transferred to a culture flask and cultured at 37°C.  
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Table 2.30 │ Culture medium used to maintain cell lines. 
Components Final concentration 
DMEM/RPMI - 
Penicillin/streptomycin 100 I.U.mL-1/100 gmL-1 
L-glutamine 2 mM 
FBS 10% 
 
2.2.25 Transient transfection 
 
2.2.25.1 Examination of TRIB2 and CDC25A-C interactions 
HeLa cells were transiently transfected with plasmid vectors using X-tremeGENETM 
HP DNA transfection reagent to express exogenous TRIB2, all human isoforms of 
CDC25 family and orthologs (human and mouse) for CDC25C. Cells were plated 
the day before transfection so that cells were at 90% confluency. Transfection 
reagent, plasmid DNA and serum free RPMI medium were allowed to equilibrate to 
room temperature and vortexed gently. 1:1 ratio of DNA (µg) to transfection reagent 
(µL) was used and was diluted in serum free medium followed by incubation at 
room temperature for 25 minutes. To transfect cells seeded in a culture dish of 150 
x 20 mm, a total of 20 µg DNA was diluted in 2 mL of medium whereas for a culture 
dish of 100 x 20 mm, a total of 8 µg DNA was diluted in 1 mL of medium. For co-
transfection, equal amount of plasmids were used. The transfection complex was 
added to the cells in a dropwise manner and the dish was swirled gently before 
being returned to tissue incubator. The cells were processed as described in section 
2.2.7 after 24 hours of transfection. 
 
2.2.25.2 Examination of CDC25C degradation 
HeLa cells were plated in a culture dish of 100 x 20 mm the day before transfection 
so that cells were at 90% confluency for transfection. X-tremeGENETM HP DNA 
Transfection reagent, plasmid DNA and serum free RPMI medium were allowed to 
equilibrate to room temperature and vortexed gently. 1:1 ratio of DNA (µg) to 
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transfection reagent (µL) was used and was diluted in 1 mL of serum free medium 
followed by incubation at room temperature for 20 minutes. 6-8 µg of empty vector 
or pcDNA-FLAG-TRIB2 was used per transfection condition. The transfection 
complex was added to the cells in a dropwise manner and the dish was swirled 
gently before being returned to tissue incubator. The cells were processed as 
described in section 2.2.23 after 24 hours of transfection. 
 
2.2.25.3 Examination of CDC25C ubiquitination. 
HeLa cells were plated in a culture dish of 100 x 20 mm the day before transfection 
so that cells were at 90% confluency for transfection. X-tremeGENETM HP DNA 
Transfection reagent, plasmid DNA and serum free RPMI medium were allowed to 
equilibrate to room temperature and vortexed gently. 1:1 ratio of DNA (µg) to 
transfection reagent (µL) was used and was diluted in 1 mL of serum free medium 
followed by incubation at room temperature for 25 minutes. Regardless of the 
transfection conditions, 3 µg of pcDNA3-Ub-HA, 3 µg of PHMA-MYC-(FL, dN, KD 
and dC)-TRIB2, 2 µg of pCMV6-human CDC25C-FLAG and 2 µg of pCMV6-mouse 
CDC25C-FLAG were used. The transfection complex was added to the cells in a 
dropwise manner and the dish was swirled gently before being returned to tissue 
incubator. The cells were processed as described in section 2.2.27 after 24 hours of 
transfection. 
 
2.2.26 Trib2 genotyping 
 
2.2.26.1 DNA extraction 
DNA was extracted from ear clips of weaned mice. 250 µL of Digestion Buffer 1 
(Table 2.31) was added to a sample and boiled at 95°C for 15 minutes. During 
boiling, the sample was vortexed at an interval of 3 minutes. After boiling, 25 µL of 
79 
 
Digestion Buffer 2 (Table 2.31) was added and the sample was vortexed. All 
samples were stored at -20°C. 
 
Table 2.31 │ DNA digestion buffers. 
Buffer Components  Final concentration 
1 NaOH  50 mM 
2 
Tris buffer 1 M 
EDTA 10 mM 
 
2.2.26.2 PCR amplification of Trib2 WT and mutant alleles 
Trib2 WT and mutant alleles were amplified by MangoMixTM PCR system using the 
primers listed in Table 2.32. All the reagents and DNA were thawed and kept on ice. 
23 L of master mix (Table 2.33) was aliquoted into individual PCR tubes. 2 L of 
DNA was then added to the tubes. All tubes were pulsed vortexed and centrifuged 
briefly before loaded onto a PCR machine. The thermal cycling conditions were 
listed in Table 2.34. PCR products and 100 bp DNA ladder were separated on a 2% 
agarose gel, detected by SafeView Nucleic Acid Stain, and imaged using Bio-Rad 
ChemiDocTM XRS system. 
 
Table 2.32 │ PCR primers used for Trib2 genotyping. 
Primer 5’>3’ sequence 
1† CACAATAGCGAGATATGGGAG  
2 GCAATGCGACAAGTTCGGAG  
Neo3A GCAGCGCATCGCCTTCTATC  
† Primer 1 anneals to genome sequence deleted in the disrupted region of Trib2 
exon1. 
 
Table 2.33 │ PCR master mix for Trib2 genotyping. 
Components volume per reaction (L) Final concentration 
MangoMixTM 12.5  - 
Primer 1 0.5 2 µM 
Primer 2 1.0 4 µM 
Primer Neo3A 0.5 2 µM 
Nuclease free water 8.5 - 
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Table 2.34 │ PCR thermal cycling conditions for Trib2 genotyping. 
 
2.2.27 Ubiquitination assay 
Transfected cells were treated with 10 µM of MG132 or DMSO (vehicle control) and 
cultured at 37°C for 7 hours. After that, the cells were treated with 10 mM of NEM at 
room temperature for 30 seconds. The culture medium was removed and the cells 
were washed in 4 mL of ice-cold PBS containing 10 mM of NEM. The cells were 
harvested in 1 mL of ice-cold PBS containing 10 mM of NEM using cell scrapper 
and transferred to a microcentrifuge tube. The cell suspension was centrifuged at 
11,000 x g at 4°C for 45 seconds. 100 µL of 1% (wt/vol) SDS was added to the cell 
pellet followed immediately by vortexing for 10 seconds and boiling at 95°C for 5 
minutes. The crude cell lysate was sonicated using Soniprep 150 equipped with an 
exponential probe (MSE, London, UK), with 6 micron amplitude for 10 seconds to 
break down remaining DNA. The lysate was sonicated further if it was very viscous. 
The lysate was centrifuge at full speed and at 4°C for 10 minutes. The supernatant 
(cleared protein lysate) was transferred to a new microcentrifuge tube. 5 µL of the 
lysate was aliquoted as input and stored at -20°C. 900 µL of ice-cold protease 
inhibitors-supplemented Tris lysis buffer (Table 2.11) was added to the remaining 
lysate. Prior immunoprecipitation, the lysate was pre-cleared with addition of 20 µL 
of Protein G Agarose beads followed by incubation on a rotary tube mixer in a cold 
room for 30 minutes. The lysate was centrifuged at maximum speed and at 4°C for 
2 minutes. The supernatant which was the pre-cleared lysate was transferred to a 
new microcentrifuge tube. 1 µg of antibody and 20 µL of Protein G Agarose beads 
Steps Number of 
cycles 
Duration Temperature (°C) 
Initial 
denaturation 
1 5 minutes 94 
Denaturation 
30 
30 seconds 94 
Annealing 30 seconds 60 
Elongation 1 minute 72 
Final elongation 1 5 minutes 72 
Cooling unlimited indefinite 4 
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were added to the pre-cleared lysate followed by incubation on a rotary tube mixer 
in a cold room for overnight. The beads were washed in 1 mL of ice-cold Tris lysis 
buffer by inverting the tube repeatedly, and centrifugation at maximum speed and at 
4°C for 30 seconds. The washing was repeated for three times. In the final wash, 
residual of supernatant was removed by 26 G needle. 25 µL of 2x Laemmli buffer 
containing 1.5% of fresh β-mercaptoethanol was added to the beads followed by 
boiling at 95°C for 5 minutes to elute immunoprecipitated proteins. The mixture was 
vortexed, and centrifuged at maximum speed and at 4°C for 2 minutes. 5 µL of 2x 
Laemmli buffer containing 1.5% of fresh β-mercaptoethanol was added to the inputs 
followed by boiling at 95°C for 5 minutes. The supernatant and input were analyzed 
as described in section 2.2.28.4. 
 
2.2.28 Western blotting 
 
Table 2.35 │ Solutions for preparing 5% stacking gel for SDS-PAGE. 
Components Volume required to cast a gel (5 mL) 
Water 3.4 
30% acrylamide mix 0.83 
1.0 M Tris (pH 6.8) 0.63 
10% SDS 0.05 
10% ammonium persulfate 0.05 
TEMED 0.005 
 
Table 2.36 │ Solutions for preparing resolving gel for SDS-PAGE. 
Components 
Volume required to cast a gel (10 mL) 
8% 12% 
Water 4.6 3.3 
30% acrylamide mix 2.7 4.0 
1.5 M Tris (pH 8.8) 2.5 2.5 
10% SDS 0.1 0.1 
10% ammonium persulfate 0.1 0.1 
TEMED 0.006 0.004 
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Table 2.37 │ Tris-glycine buffer for SDS-PAGE. 
Components Final concentration  
Tris-Cl 25 mM 
Glycine 192 mM 
SDS 0.1% (wt/vol) 
 
Table 2.38 │ Transfer buffer. 
Components Final concentration  
Tris-Cl 25 mM 
Glycine 192 mM 
Methanol 20% (vol/vol) 
 
2.2.28.1 Detection of MAPK signalling 
Total BM cells collected from mice succumbed to leukaemia were lysed in protease 
inhibitors-supplemented RIPA buffer (Table 2.39). Crude cell lysates were 
centrifuged at maximum spend and at 4°C for 10 minutes after incubation for 30 
minutes on ice with periodic pulse vortex. The supernatants which were cleared 
protein lysates were stored at -80°C. To prepare for gel electrophoresis, protein 
lysates were mixed with 4x Laemmli buffer (Table 2.40) containing 3% (vol/vol) 
fresh β-mercaptoethanol and boiled at 95°C for 5 minutes. Protein lysates and 
Precision Plus ProteinTM Prestained Standards were resolved by SDS-
polyacrylamide gel electrophoresis (PAGE) using 5% stacking (Table 2.35) and 
12% resolving gels (Table 2.36). Electrophoresis was run at 100 volts using Tris-
glycine buffer (Table 2.37) until the tracking dye diffused into the buffer. After 
electrophoresis, the separated proteins were wet-transferred (Table 2.38) from the 
gel to nitrocellulose membranes, with pore size of 0.45 m, at 100 volts for 1 hour. 
The transfer efficiency was checked by Ponceau S staining. The membranes were 
blocked with PBS supplemented with 5% (wt/vol) milk and 0.01% (vol/vol) Tween 
20, at room temperature for 1 hour. Triplicate membranes were incubated with 
primary antibodies (Table 2.41), to detect activation of p38, p44/42 and JNK 
separately, on a roller mixer in a cold room for overnight. The following day, the 
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membranes were washed thrice in PBS supplemented with 5% (wt/vol) milk and 
0.01% (vol/vol) Tween 20. Each time the incubation was 5 minutes. The 
membranes were incubated with horseradish peroxidise-conjugated secondary 
antibodies (Table 2.41) on a roller mixer at room temperature for 1 hour. The 
membranes were washed thrice and each time the incubation was 10 minutes. The 
signals were detected by chemiluminescence method using SuperSignalTM West 
Pico and Femto Substrates, and were developed onto CL-XPosureTM radiography 
films. For each membrane, RestoreTM stripping buffer was used for secondary 
probing to detect total level of MAPK and for tertiary probing to detect -actin. 
 
Table 2.39 │ Protease inhibitors-supplemented RIPA buffer. 
Components  Final concentration 
Tris buffer [pH 7.4] 50 mM 
NaCl 150 mM 
IGEPAL CA-630 0.5% 
Sodium 
deoxycholate 
0.25% 
EDTA 1 mM 
PMSF† 1 mM 
Aprotinin† 2 g/mL 
Leupeptin† 5 g/mL 
Pepstastin† 1 g/mL 
Na3VO4
†
 1 mM 
NaF† 5 mM 
† Fresh protease inhibitors were added to RIPA buffer prior cell lysis. 
 
Table 2.40 │ 4x Laemmli buffer. 
Components Final concentration  
Tris buffer [pH6.8] 250 mM 
SDS 8% (wt/vol) 
Glycerol 40% (vol/vol) 
Bromophenol blue 0.005% (wt/vol) 
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Table 2.41 │ Antibodies used to detect MAPK signalling. 
Primary antibody† Dilution Dilution for 
secondary antibody†  
anti-β-actin 1:5000 1:5000 
anti-JNK1 1:1000 1:1000 
anti-p38 1:2000 1:4000 
anti-p44/42 1:2000 1:2000 
anti-phospho-JNK (T183/Y185) 1:1000 1:1000 
anti-phospho-p38 (T180/Y182) 1:3000 1:3000 
anti-phospho-p44/42 (T202/Y204) 1:2000 1:2000 
† Anti--actin and secondary antibodies were diluted in PBS supplemented with 5% 
(wt/vol) milk and 0.01% (vol/vol) Tween 20. The rest were diluted in Tris-buffered 
saline (TBS) containing 20 mM Tris and 150 mM NaCl, and supplemented with 5% 
(wt/vol) BSA and 0.01% (vol/vol) Tween 20. 
 
2.2.28.2 Detection of co-immunoprecipitated proteins 
Inputs, eluates and Precision Plus ProteinTM Prestained Standards were resolved by 
SDS-PAGE using 5% stacking (Table 2.35) and 12% resolving (Table 2.36) gels. 
Electrophoresis, wet transfer, membrane blocking, antibody incubation (Table 2.42), 
membrane washing and signal detection were performed as described in section 
2.2.28.1. RestoreTM stripping buffer was used for repeated probing as appropriate. 
 
Table 2.42 │ Antibodies used to analyze co-immunoprecipitation assay. 
Primary antibody† Dilution Dilution for 
secondary antibody†  
anti-β-actin 1:5000 1:5000 
anti-CDC25C 1:500 1:1000 
anti-FLAG 1:1000 1:1000 
anti-MYC 1:1000 1:1000 
† All antibodies were diluted in PBS supplemented with 5% (wt/vol) milk and 0.01% 
(vol/vol) Tween 20.  
 
2.2.28.3 Detection of nuclear and cytoplasmic proteins 
2x Laemmli buffer containing 1.5 % of fresh β-mercaptoethanol was added to the 
nuclear and cytoplasmic lysates and were boiled at 95°C for 5 minutes. The lysates 
were resolved by SDS-PAGE using 5% stacking (Table 2.35) and 12% resolving 
(Table 2.36) gels. Unless stated otherwise, electrophoresis, wet transfer, membrane 
blocking, antibody incubation (Table 2.43), membrane washing and signal detection 
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were performed as described in section 2.2.28.1. RestoreTM stripping buffer was 
used for repeated probing as appropriate. 
 
Table 2.43 │ Antibodies used to analyze subcellular fractions. 
Primary antibody† Dilution Dilution for 
secondary antibody†  
anti-α-tubulin 1:2000 1:1000 
anti-CDC25C 1:500 1:1000 
anti-FLAG 1:1000 1:1000 
anti-HDAC1 1:1000 1:1000 
† All antibodies were diluted in PBS supplemented with 5% (wt/vol) milk and 0.01% 
(vol/vol) Tween 20.  
 
2.2.28.4 Detection of ubiquitination 
Inputs and eluates were resolved by SDS-PAGE using 12% and 8% resolving gels 
respectively (Table 2.36). Unless stated otherwise, electrophoresis, wet transfer, 
membrane blocking, antibody incubation (Table 2.44), membrane washing and 
signal detection were performed as described in section 2.2.28.1. For eluates, the 
electrophoresis was run till the 50 kDa marker of Precision Plus ProteinTM 
Prestained Standards reached the bottom of the gel. RestoreTM stripping buffer was 
used for repeated probing as appropriate. 
 
Table 2.44 │ Antibodies used to analyze ubiquitination assay. 
Primary antibody† Dilution Dilution for 
secondary antibody†  
anti-β-actin 1:5000 1:5000 
anti-CDC25C 1:500 1:1000 
anti-FLAG 1:1000 1:1000 
anti-MYC 1:1000 1:1000 
anti-HA 1:1000 1:1000 
anti-K48-Ub 1:1000 1:1000 
† All antibodies were diluted in PBS supplemented with 5% (wt/vol) milk and 0.01% 
(vol/vol) Tween 20.  
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2.2.28.5 Detection of TRIB2 during cell cycle progression 
Cells were washed once in ice-cold PBS and centrifuged at 350 x g and at 4°C for 5 
minutes. 25 µL of 2x Laemmli buffer containing 1.5 % of fresh β-mercaptoethanol 
was added directly to the cell pellet followed by vortexing and boiling at 95°C for 5 
minutes. The lysate was stored at -80°C. Sample was thawed at room temperature 
and boiled again at 95°C for 5 minutes prior SDS-PAGE. Lysate and Precision Plus 
ProteinTM Prestained Standards were resolved by SDS-PAGE using 5% stacking 
(Table 2.35) and 12% resolving (Table 2.36) gels. Electrophoresis, wet transfer, 
membrane blocking, antibody incubation (Table 2.45), membrane washing and 
signal detection were performed as described in section 2.2.28.1. RestoreTM 
stripping buffer was used for repeated probing as appropriate. 
 
Table 2.45 │ Antibodies used to analyze cell cycle synchronization. 
Primary antibody† Dilution Dilution for 
secondary antibody†  
anti-β-actin 1:5000 1:5000 
anti-CDC25C 1:500 1:1000 
anti-phospho-Histone H3 (Ser10) 1:1000 1:1000 
anti-TRIB2 1:200 1:1000 
† All antibodies were diluted in PBS supplemented with 5% (wt/vol) milk and 0.01% 
(vol/vol) Tween 20 except anti-phospho-Histone H3 which was diluted in TBS 
supplemented with 5% (wt/vol) BSA and 0.01 (vol/vol) Tween 20. 
 
2.2.29 Whole bone marrow transplantation 
BM cells were harvested from WT and Trib2-/- mice. After lysis of red blood cells, 
cell counting (Section 2.2.6) was performed. 8 x 106 unfractionated cells were 
injected intravenously into lethally irradiated (2 x 4.25 grays fractionated doses were 
given with three hours apart) recipients. The recipients were kept in individually 
ventilated cages and treated with Baytril antibiotic, administered in the drinking 
water at a concentration of 80 mg/L, daily for 10 days post transplantation. The 
recipients were monitored by periodic tail vein bleedings 4 weeks post 
transplantation. The collected blood was used for flow cytometry analysis with 
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antibody panel B from Table 2.19. All the recipients were euthanized at 17 weeks 
post transplantation where blood and BM were collected. Blood cell counts were 
determined as described in section 2.2.4. The blood was also analyzed by flow 
cytometry using antibody panel B from Table 2.19. Cell counting (Section 2.2.6) was 
performed to determine the cellularity of the BM. To immunophenotype HSPCs, the 
BM was also analyzed by flow cytometry using antibody panels listed in Table 2.17 
and 2.18. 
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CHAPTER 3: EXAMINATION OF THE ROLE OF TRIB2 IN  
STEADY STATE HAMATOPOIESIS 
 
3.1 Introduction 
Studies focused on the pathological role of TRIB2 in various disease states 
including haematological malignancy, solid tumours, autoimmune and inflammatory 
diseases have identified TRIB2 as a critical signalling modulator and mediator 
(Yokoyama and Nakamura, 2011). However, it is unclear if this is true in a 
physiological context where regulation of diverse signalling pathways is cell type 
and developmental stage dependent. Studies of Tribbles orthologues in Xenopus 
(Saka and Smith, 2004) and Drosophila (Grosshans and Wieschaus, 2000, Mata et 
al., 2000, Seher and Leptin, 2000) highlight an evolutionary conserved role for 
Tribbles in the regulation of normal cellular proliferation. In these organisms, 
Tribbles coordinates cell division and morphogenesis to ensure proper organ 
development. In Drosophila, Tribbles ensures mitosis occurs in a timely manner by 
regulating String turnover at the protein level (Grosshans and Wieschaus, 2000, 
Mata et al., 2000, Seher and Leptin, 2000). Takasato and colleagues generated a 
Trib2 knockout mouse model (Trib2tm1Ryn) where the exon 1 of Trib2 is disrupted 
with the insertion of a LacZ-Neo cassette, to investigate the role of TRIB2 in kidney 
development (Takasato et al., 2008). However, microscopic examinations of WT 
and Trib2tm1Ryn mutant embryos at 14.5 days post coitum showed no phenotypic 
defects in organs (heart, eye, testis, thymus and kidney) where Trib2 is abundantly 
expressed (Takasato et al., 2008). These data suggest TRIB2 function is required 
for proper cellular behaviour rather than tissue organization. 
 
In Chapter One, literature review of previous TRIB2 studies allowed us to 
speculate the possible roles of TRIB2 in normal haematopoiesis. TRIB2 could be 
important in the development and differentiation of erythroid/megakaryocyte 
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lineages, and intrathymic T-cell development. Elucidation of the role of TRIB2 in 
normal haematopoiesis is crucial because TRIB2 has been implicated in both AML 
and T-ALL which are malignant haematopoiesis (Section 1.7). This could improve 
our understanding of how dysregulation of Trib2 in normal haematopoiesis 
contributes to leukaemogensis. Hence, we aimed to investigate the impact of Trib2 
ablation in adult BM haematopoiesis and intrathymic T-cell development using a 
commercially available Trib2 knockout mouse model (129S5-Trib2tm1Lex, referred as 
Trib2-/- hereafter). Similar to Trib2tm1Ryn (Takasato et al., 2008), exon 1 of Trib2 in 
Trib2tm1Lex is disrupted (Lexicon Phenotypic Analysis Database: LEXKO-1136). A 
third Trib2 knockout mouse model (Trib2tm1Myam) was generated by Satoh and 
colleagues, where exon 2 of Trib2 is replaced with neomycin-resistance gene, to 
study tissue-resident macrophages in the spleen (Satoh et al., 2013). In all the three 
Trib2 knockout mouse models, characterization of BM haematopoiesis and 
intrathymic T-cell development has not been reported. 
 
3.2 Results 
   
3.2.1 TRIB2 is dispensable for murine bone marrow haematopoiesis.  
The coding and non-coding regions of exon 1 of Trib2 in Trib2-/- mice were 
disrupted and thus enabled Trib2 genotyping by PCR analysis (Figure 3.1). 
Compared to WT mice, Trib2-/- mice had similar RBC and WBC differential 
(neutrophil, lymphocyte, monocyte, eosinophil and basophil) counts, except for the 
platelet count which was significantly higher but within the normal physiological 
range (Figure 3.2A and 3.2B). In addition, no difference was found between WT and 
Trib2-/- mice in the distribution of mature myeloid, B and T cells in the blood (Figure 
3.2C). These data indicate loss of TRIB2 does not affect terminal differentiation and 
production of mature blood cells of different lineages. We next studied the BM, the 
primary site of adult haematopoiesis, to determine if TRIB2 influences 
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hematopoietic cell fate choice at an earlier stage of differentiation. Trib2-/- mice had 
similar BM cellularity compared to WT mice (Figure 3.2D) as determined by cell 
counting. No difference was found in the peripheral blood for the frequency of 
circulating CD4+ and CD8+ T cells, lineage committed Gr-1+/CD11b+ myeloid cells 
and CD19+/B220+ B-lymphoid cells (Figure 3.2E). Moving up the hematopoietic 
hierarchy, Trib2-/- mice had similar frequencies of HSPCs, including HSCs, MPPs, 
CMPs, GMPs, MEPs and CLPs compared to WT mice (Figure 3.2F and 3.2G). 
Hence, TRIB2 is not essential for hematopoietic cell fate choice since loss of TRIB2 
did not lead to skewing of hematopoietic cell differentiation. Thus, at steady state, 
Trib2 ablation does not affect the hierarchical organization of the murine 
haematopoietic system.  
 
 
Figure 3.1 │ Genotyping of Trib2 by genomic DNA PCR. (A) Exon 1 of Trib2 in 
Trib2tm1Lex is disrupted by insertion of LacZ/Neo selection cassette. Modified from 
Lexicon Phenotypic Analysis Database: LEXKO-1136. (B) A representative gel 
electrophoresis image showing resolution of PCR products amplified from WT, 
Trib2+/- and Trib2-/- mice using primers listed in Appendix D:  Table 1. M, marker; 
Neg ctrl, no template negative control; mut, mutant.  
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Figure 3.2 │ TRIB2 loss does not affect murine haematopoiesis in BM. 
Complete blood counts (A) and WBC differential counts (B) of WT (n = 13) and 
Trib2-/- (n = 22) mice were determined by haematology analyzer. NE, neutrophils; 
LY, lymphocytes; MO, monocytes; EO, eosinophils; BA, basophils. (C) The 
distribution of mature myeloid, B and T cells in the blood of WT (n = 3) and Trib2-/- 
(n = 10) mice were measured by flow cytometry using the indicated lineage specific 
cell surface markers. (D) BM cellularity (n=5-7 per genotype) was counted by trypan 
blue exclusion after RBC lysis of the cell suspension harvested from two pelvises, 
femurs and tibias. (E) The distribution of myeloid, B and circulating T cells in the BM 
of WT (n = 3) and Trib2-/- (n = 9) mice. (F) Immunophenotyping of HSPCs 
populations (HSC, MPP, CMP, GMP, MEP and CLP) in BM. Each sub-population is 
indicated in the outlined areas (top row). The corresponding values in the 
representative staining profile of WT (middle row) and Trib2-/- (bottom row) mice (n = 
3 per genotype) are frequency of BM and graphed in (G). Lin, lineage; LK, Lin-c-Kit+ 
cells; LSK, Lin-Sca-1+c-Kit+ cells; HSC: LSK CD150+CD48-; MPP: LSK CD150-
CD48-; CMP: LK CD34+CD16/32lo; GMP: LK CD34+CD16/32hi; MEP: LK CD34-
CD16/32-; CLP: Lin-IL-7Rα+; SSC-H, side scatter-height. For A, unpaired Student’s 
t-test was used for statistical analysis. *P<0.05, all quantified data are presented as 
mean and SEM. 
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We next assessed the repopulating capability and multi lineage differentiation 
potential of Trib2-/- HSPCs by transplantation of CD45.2+ whole BM nucleated cells 
(WT or Trib2-/- donor) into lethally irradiated CD45.1+ mice (recipients). At 17 weeks 
post transplantation, recipients transplanted with cells from both genotypes had 
similar expression of donor marker, CD45.2 (Figure 3.3A). This indicates TRIB2 
loss did not affect long-term engraftment of donor cells. In the absence of TRIB2, 
HSPCs retain  their capability to fully reconstitute the blood system of recipients as 
the recipients had no measurable difference of  RBC, platetet and WBC (total and 
differential) counts compared to the control group (Figure 3.3B and 3.3C). Analysis 
of blood collected periodically at 6, 10, 14 and 17 weeks post transplantation from 
recipients showed no skewing of differentiation into myeloid and lymphoid lineages 
in the absence of TRIB2 during hematopoietic reconstitution (Figure 3.3D). No 
significant difference was found in the HSPCs in recipients transplanted with either 
genotype (Figure 3.3E and 3.3F). We conclude that TRIB2 is dispensable for the 
maintenance of the hematopoietic system through differentiating HSPCs that reside 
in the BM.  
 
93 
 
 
Figure 3.3 │ TRIB2 loss does not affect the repopulation capability of BM 
HSPCs. Lethally irradiated CD45.1+ mice were transplanted with CD45.2+ WT (n = 
5) or Trib2-/- (n = 5) whole BM cells, and sacrificed after 17 weeks of transplantation. 
(A) Engraftment of donor cells was determined by measurement of CD45.2 
expression in the blood of transplanted mice. Complete blood counts (B) and WBC 
differential counts (C) of these two groups of mice were determined by hematology 
analyzer. NE, neutrophils; LY, lymphocytes; MO, monocytes; EO, eosinophils; BA, 
basophils. (D) The distribution of donor derived mature myeloid, B and T cells in the 
blood of these mice was measured by flow cytometry. (E) BM cellularity was 
counted by trypan blue exclusion. (F) Immunophenotyping and quantification of 
donor derived HSPCs in BM. All quantified data are presented as mean and SEM. 
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3.2.2 TRIB2 regulates the proliferation of developing thymocytes. 
At steady state, we found that Trib2-/- mice had statistically significant higher thymic 
cellularity compared to WT mice (Figure 3.4A). This suggests dysregulation of 
thymopoiesis in the absence of TRIB2. We further examined thymic subsets along 
the T lineage developmental pathway by immunophenotyping. Non-T lineage 
markers (CD11c, Gr-1, B220, Ter119 and NK1.1) were included in all the 
experimental analysis to exclude cells of other lineages present in thymus. Gating 
for lineage markers, including CD4 and CD8, were adjusted so as not to exclude c-
Kit+ thymic progenitors that express low cell surface levels of lineage markers when 
defining immature DN thymocytes (Bhandoola and Sambandam, 2006) (Figure 
3.4B). For gating of thymic subsets, DN3 thymocytes (LinloCD44-CD25+) were 
divided further into DN3E (expected: FSC
lo) and DN3L (larger: FSC
hi) subsets, based 
on cell size (Hoffman et al., 1996). This is equivalent to characterization of DN3 into 
DN3a and DN3b subsets, based on CD27 marker, that are corresponded to pre- 
and post  selection (Taghon et al., 2006). Similarly, DP thymocytes were divided 
further into DPsm (small resting: FSC
lo) and DPbl (blasts: FSC
hi) subsets 
(Mingueneau et al., 2013). To validate the thymic subsets identified by our gating 
strategy, we assessed their cell cycle profile and proliferation status by DNA 
staining and measurement of CD71 expression respectively. In accordance with 
previous studies (Hoffman et al., 1996, Seitan et al., 2011, Brekelmans et al., 1994), 
we found that WT DN3E and DPsm subsets were not proliferative as >99% were in 
G0/G1 phase and only 10-20% were CD71
+ (Figure 3.5A-C). In contrast, WT DN3L 
and DPbl subsets were actively cycling as 60-70% were in S-G2/M phases and 90% 
were CD71+ (Figure 3.5A-C). In comparison of WT and Trib2-/- thymic subsets, no 
measurable difference was found in their cell cycle profile and expression of CD71 
(Figure 3.5A-C).  
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Figure 3.4 │ TRIB2 loss causes increased thymic cellularity. (A) Thymic 
cellularity of WT (n = 31) and Trib2-/- (n = 21) mice was counted by trypan blue 
exclusion after RBC lysis. (B) Gating strategy to identify thymic subsets. FSC-A, 
forward scatter-area; SSC-A, side scatter-area; DN1: LinloCD44+CD25-; DN2: 
LinloCD44+CD25+; DN3E: Lin
loCD44-CD25+FSClo; DN3L: Lin
loCD44-CD25+FSChi; 
DN4: LinloCD44-CD25-; DPbl: CD4
+CD8+FSChi; DPsm: CD4
+CD8+FSClo; CD4 SP: 
CD4+CD8-; CD8 SP: CD4-CD8+. For statistical analyses, unpaired Student’s t-test 
was used for A. **P<0.01, all quantified data are presented as mean and SEM. 
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Figure 3.5 │ TRIB2 loss does not affect cell cycle phase progression and 
CD71 expression of thymocytes. Overlay of a representative cell cycle profile (A) 
of WT and Trib2-/- thymic subsets and the fractions of cell cycle phases were 
graphed in (B). Norm, normalized. (C) Quantification of CD71 expression of each 
thymic subset. For A-C, n = 3 per genotype. All quantified data are presented as 
mean and SEM. 
 
We next analysed the impact of TRIB2 loss on the frequency and cellularity of 
each thymic subset despite no change in cell cycle progression with TRIB2 loss. At 
steady state, our analysis of the thymic subsets showed that, in general, Trib2-/- 
mice had a lower frequency of immature DN1-4 subsets, but the mature DP and SP 
subsets were unaffected compared to WT mice (Figure 3.6A and 3.6B). The higher 
cellularity of Trib2-/- thymus was due to the significant increase of mature 
subsets (DPsm and CD4 SP) but not the immature DN1-4 subsets (Figure 3.6C). The 
DN1 (LinloCD44+CD25-) subset is heterogeneous and divided into DN1a-e subsets 
based on CD24 and c-Kit surface expression (Porritt et al., 2004). Here, the DN1 
subset was divided broadly into c-Kithi (DN1a/b), c-Kitlo (DN1c) and c-Kit- (DN1d/e) 
subsets (Figure 3.6D). At steady state, Trib2-/- c-Kit- DN1 progenitors were present 
at a significantly lower frequency but had similar cell numbers compared to WT 
mice (Figure 3.6E and 3.6F). To rule out the possibility that lower frequency of 
Trib2-/- of DN1-4 subsets were due to increased apoptosis, we measured Annexin V 
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expression and showed no difference between the two genotypes (Figure 3.6G). 
Since Trib2-/- mice had higher numbers of mature subsets which must be derived 
from immature subsets, we hypothesized that immature thymocytes were cycling 
faster and gave rise to more mature differentiated thymocytes in the absence of 
TRIB2. Ki-67 is a proliferation marker, expressed by cells in active cell cycle (G1-S-
G2/M) but not by resting cells in G0 (Byeon et al., 2005). Indeed, intracellular staining 
of Ki-67 showed Trib2-/- DN1, DN2 and DN3E subsets had significantly higher levels 
of Ki-67 compared to WT thymic subsets (Figure 3.6H), indicating more Trib2-/- 
developing thymocytes are in cycling state. This does not result in T cell 
accumulation outside the thymus however because there was no difference in the 
distribution of WT and Trib2-/- T-cells in the spleen (Figure 3.7). This is possible as 
TRIB2 loss could affect the later stages of T-cell development which we explain in 
the discussion. Satoh and colleagues also found that TRIB2 loss does not alter the 
populations of CD4+ and CD8+ splenic T-cells in a different Trib2 knockout mouse 
model (Trib2tm1Myam) although they did not studied the thymus (Satoh et al., 2013).  
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Figure 3.6 │ TRIB2 regulates the homeostasis of intrathymic T-cell 
development. (A) Flow cytometry of thymic subsets. The complete gating strategy 
is provided in Fig. 4. Each subset is indicated in the outlined areas (top row). The 
corresponded values in the representative staining profile of WT (middle row) and 
Trib2-/- (bottom row) mice are frequency of thymus and graphed in (B). FSC-A, 
forward scatter-area; SSC-A, side scatter-area; DN1: LinloCD44+CD25-; DN2: 
LinloCD44+CD25+; DN3E: Lin
loCD44-CD25+FSClo; DN3L: Lin
loCD44-CD25+FSChi; 
DN4: LinloCD44-CD25-; DPbl: CD4
+CD8+FSChi; DPsm: CD4
+CD8+FSClo; CD4 SP: 
CD4+CD8-; CD8 SP: CD4-CD8+. (C) Number of cells for each subset. (D) Further 
characterization of DN1 cells based on c-Kit surface expression. Neg, negative; lo, 
low; hi, high. DN1 subsets were graphed in frequency of thymus (E) and cell 
number (F). For B, C, E and F, n = 7-8 per genotype. (G) Basal level of apoptosis of 
each thymic subset (n = 3 per genotype) was determined by the surface expression 
of Annexin V after exclusion of DAPI-stained dead cells. (H) Intracellular level of Ki-
67 across thymic subsets (n = 4-5 per genotype) was measured by flow cytometry 
(left). An overlap of histogram (right) showed Trib2-/- DN1 cells had higher level of 
Ki-67 compared to that of WT. Norm, normalized; FMO, Fluorescence Minus One. 
For statistical analyses, unpaired Student’s t-test was used for H, and two-way 
ANOVA was used for B, C and E. **P<0.01; ***P<0.001, all quantified data are 
presented as mean and SEM. 
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Figure 3.7 │ TRIB2 loss does not affect the distribution of splenic T cells. 
Distribution of CD4+ and CD8+ T cells in the spleen of WT (n = 4) and Trib2-/- (n = 5) 
mice at steady state. All quantified data are presented as mean and SEM. 
 
Cell cycle regulation is crucial for proper T cell development. DN3 thymocytes 
must be briefly arrested (DN3E) at the G0/G1 cell cycle phases to allow V(D)J 
recombination to take place at the Tcrb locus, initiated by the RAG proteins (Li et 
al., 1996, Lin and Desiderio, 1994). Functional Tcrb rearrangements lead to 
formation of pre-TCR where the signals drive the subsequent development of 
thymocytes to early DP stage. Given that Trib2-/- developing thymocytes proliferate 
faster, we determined if loss of TRIB2 affects the cell cycle status of these subsets 
and Tcrb rearrangements. DNA staining showed Trib2-/- thymocytes at each stage 
of the T-cell development had a similar cell cycle profile compared to WT mice 
(Figure 3.5A and 3.5B). This suggests TRIB2 does not regulate the cell cycle 
phase progression and that the increased cycling of Trib2-/- developing thymocytes 
is likely due to changes in cell division kinetics at the steady state. Importantly, 
Trib2-/- DN3E thymocytes were arrested at G0/G1 phases like WT DN3E thymocytes. 
As such, analysis of Tcrb rearrangement involving the J2.1 to J2.7 gene 
segments demonstrated that Trib2-/- thymocytes contain polyclonal Tcrb 
rearrangements similar to WT thymocytes (Figure 3.8). This indicates that proper 
Tcrb rearrangements take place and TRIB2 loss doesn’t affect -selection, a key 
checkpoint of early T-cell development.  
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Figure 3.8 │ Polyclonal Tcrb rearrangements in Trib2-/- thymocytes. 
Endogenous Tcrb rearrangements of WT and Trib2-/- total thymocytes were 
analyzed by genomic DNA PCR. GL denotes the position of the germline PCR 
product and number indicates the different rearrangements involving the Jβ2.1 to 
Jβ2.7 gene segments. 1 kb M, 1 kb DNA marker; neg ctrl, no template negative 
control. 
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3.3 Discussion 
 
Here, we show TRIB2 as the first member of the mammalian Tribbles family to play 
an anti-proliferative role in the context of developing thymocytes during T cell 
development. TRIB1 was reported previously to negatively regulate proliferation of 
human aortic smooth muscle cells in vitro via interaction with MAPK kinase 4 
(MKK4) (Sung et al., 2007). TRIB2 regulates cell division kinetics of developing 
thymocytes. We found that the dysregulated proliferation of Trib2-/- developing 
thymocytes does not affect Tcrb rearrangement, a key event in early T cell 
differentiation. Furthermore, loss of TRIB2 did not affect terminal maturation of 
developing thymocytes. Intriguingly, the increased proliferation of developing 
thymocytes, in the absence of TRIB2, does not affect the percentage of peripheral T 
cells. Previous literature has showed that mice overexpressing CD69 have 
increased thymic SP subsets but a reduction in the number of T cells in the 
peripheral lymphoid organs (Nakayama et al., 2002). Our data suggests that TRIB2 
may impact on thymic selection (DPsm to CD69+ DP transition) or thymic T cell 
export. It is also likely that TRIB2 has a distinct role in mature T cell biology and 
function because Trib2 expression distinguishes CD4+ from CD8+ peripheral T cells 
(Mingueneau et al., 2013). This could be further explored using appropriate infection 
and immunization models. 
 
Previous literature suggests a role of TRIB2 in the development of 
megakaryocyte/erythroid lineage (Mancini et al., 2012). We did not detect any 
difference in the frequency of MEP populations in the BM but we found a significant 
increase of platelets (but not RBC counts) in the blood in the absence of TRIB2. 
Hence, the increase of platelets could have arisen from another source. Recent 
studies showed that platelets could be derived directly from stem cell-like 
megakaryocyte progenitors within the HSC compartment (Yamamoto et al., 2013, 
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Haas et al., 2015). Hence, our study did not rule of the role of TRIB2 in the 
development of platelets and characterization should be focused on the upper 
primitive populations that commit to megakaryocyte lineage. 
 
Analysis of haematopoietic system at steady state allowed us to establish a role 
for TRIB2 in negatively regulating the proliferation of developing thymocytes. In the 
absence of TRIB2, more immature thymocytes are in the active cycling state. 
However, the thymic phenotype we found in Trib2-/- mouse at steady state appears 
to be modest and have little impact on the development of peripheral T-cells in the 
blood as well as in the spleen. We speculate that TRIB2 function is more critical in 
perturbed T-cell development where the cellular proliferation is a key determinant of 
developing thymocyte response to stress inflicted on the thymopoietic system.  
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CHAPTER FOUR: EXAMINATION OF THE ROLE OF TRIB2 IN 
5-FU INDUCED STRESSED HAEMATOPOIESIS 
 
4.1 Introduction 
 
5-FU is a standard chemotherapeutic drug widely used to treat cancers since it 
targets rapidly cycling cells. Misincorporation of 5-FU metabolite into DNA during 
DNA replication initiates futile cycles of DNA excision, repair, and further 
misincorporation that eventually lead to DNA strand breaks and cell death (Longley 
et al., 2003). Due to its mechanism of action, 5-FU has been widely used 
experimentally as a BM haematopoietic stress inducer. In this context, 5-FU targets 
cycling haematopoietic cells and this depletes the supply of mature blood cells. 
Hence, 5-FU treatment creates a proliferative stress to HSCs which are relatively 
quiescent at steady state to enter cell cycle, undergo extensive self renewal and 
differentiation to meet increased haematopoietic demands (Randall and Weissman, 
1997, Wilson et al., 2008, Harrison and Lerner, 1991). Hence, application of 5-FU in 
research not only allows study of the acute response of haematopoietic system to a 
genotoxic agent but also the dynamic cellular changes that occur from steady state 
to stressed BM haematopoiesis during recovery. Importantly, proliferative stress 
inflicted on HSCs by 5-FU is a universal feature in stressed haematopoiesis which 
can be caused by other conditions such ageing and irradiation (Section 1.6). 
Beerman and colleagues showed that induced proliferation of HSCs by repeated 
exposure to 5-FU leads to functional decline and DNA methylation changes that 
closely mimic physiological HSC aging observed in old (25 months old) mice 
(Beerman et al., 2013). Hence, 5-FU appears to be a useful experimental tool to 
model stressed BM haematopoiesis and to study haematopoietic regeneration.     
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Clinically, 5-FU chemotherapy affects BM haematopoiesis and also disrupts T 
cell development in the thymus, depletes T cell repertoire, and impairs T cell 
immunity of patients. At steady state, human T cell repertoire is established during 
early childhood (Spits, 2002). Hence, thymopoietic recovery is critical to replenish 
the T cell repertoire in order to reconstitute cellular immunity of patients. However, 
unlike stressed BM haematopoiesis which has been studied and characterized in 
depth (Brenet et al., 2013), thymopoietic restoration following experimental 5-FU 
mediated thymic injury is poorly understood. Previous studies focused on the acute 
response of thymus to 5-FU treatment and were limited to morphological and 
biochemical descriptions (Eichhorst et al., 2001, Aquino Esperanza et al., 2008). 
Treatments are available to counteract the clinical 5-FU induced myelosuppresion 
such as blood and platelet transfusions, and injection of granulocyte colony-
stimulating growth factors to promote granulocytic regeneration. However, no 
clinical therapy is available yet to improve thymopoietic recovery in order to restore 
cellular immunity of patients (Awong et al., 2010).   
 
In the previous chapter, we showed that ablation of Trib2 does not affect steady 
state haematopoiesis in the BM. However, TRIB2 appears to regulate the 
proliferation of developing thymocytes and hence thymopoietic homeostasis. On 
account of the mechanism of 5-FU action, it was of primary interest in this chapter 
to use 5-FU as an experimental tool to test our hypothesis that Trib2-/- developing 
thymocytes which are highly proliferative would be more sensitive to 5-FU 
compared to WT thymocytes.  As 5-FU is a haematopoietic stress inducer in the BM 
and thymopoiesis in the thymus, we also aimed to examine if TRIB2 plays a role in 
the regeneration of these two biologic systems following genotoxic insult mediated 
by 5-FU.  
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4.2 Results 
 
4.2.1 Trib2-/- thymocytes are hypersensitive to 5-FU induced cell death. 
To address our hypothesis, we performed a time course study of in vivo 5-FU 
treatment. Trib2-/- mice had significantly higher total thymic cellularity at steady state 
(Figure 3.6), however this significant difference was lost at 16 and 24 hours post 
treatment (Figure 4.1A). Significant increase of cell death (late apoptotic) was found 
in Trib2-/- thymic cells at 24 hours post treatment (Figure 4.1B and 4.1C). Notably, 
we demonstrated that DN3L and DPbl subsets, which are known to be proliferative 
(Figure 3.5), were significantly reduced in Trib2-/- mice 16 hours post treatment. 
DN3E and DPsm subsets which are in resting state were unaffected in treated WT 
and Trib2-/- mice. Unexpectedly, Trib2-/- c-Kithi DN1 thymic progenitors were also 
significantly reduced after 16 hours of exposure to 5-FU whereas Trib2-/- c-Kit- and 
c-Kitlo DN1 progenitors were unaffected like WT mice (Figure 4.1D and 4.1E). c-
Kithi DN1 progenitors were shown previously to exclusively exhibit a proliferative 
burst capacity by OP9-DL1 co-culture system compared to c-Kit- and c-Kitlo DN1 
progenitors (Porritt et al., 2004). Interestingly, 5-FU was shown recently to 
preferentially induce apoptosis in c-Kithi HSCs that have rapid cell division kinetics 
compared to c-Kitlo HSCs in vitro (Shin et al., 2014). Overall, these data showed 
that the thymic subsets that are most sensitive to apoptosis following 5-FU 
treatment are the subsets with increased cycling kinetics due to loss of TRIB2. This 
confirmed a role for TRIB2 in controlling the cell division kinetics of thymocytes and 
hence their enhanced sensitivity to 5-FU genotoxic drug.  
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Figure 4.1 │ Trib2-/- thymocytes are more susceptible to 5-FU induced cell 
death. (A) Mice were treated with 5-FU (250 mg/kg, i.p.) and sacrificed after 16 and 
24 hours to determine the thymic cellularity. (B) Apoptosis assays were performed 
to determine the fraction of living, early and late apoptotic cells in thymus at 16 and 
24 hours post treatment. (C) A representative staining profile (B) of 5-FU treated 
WT and Trib2-/- thymus. Living: DAPI-AV-; early apoptotic: DAPI-AV+; late apoptotic: 
DAPI+AV+. The values indicated in the outlined areas are frequency of thymus. (D) 
The cellularity of thymic subsets at 16 hours post treatment. (E) Overlay of the 
histograms of DN1 and DN3 cells for c-Kit expression and FSC-A signals 
respectively showed loss of Trib2-/- DN1 c-Kit+ and DN3L cells at 16 hours post 
treatment. For A,B and D, n = 5 per genotype per studied time point. For statistical 
analyses, unpaired Student’s t-test was used for A, and two-way ANOVA was used 
for B and D. *P<0.05; **P<0.01, all quantified data are presented as mean and SEM. 
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4.2.2 Acceleration of thymopoietic recovery in the absence of TRIB2 after 
genotoxic insult. 
Previous studies on the response of thymus organ and thymocytes to 5-FU 
mediated genotoxic insult have showed that 5-FU induces apoptosis of thymocytes, 
thymic weight loss and damages to thymic architecture which are crucial for T-cell 
development (Aquino Esperanza et al., 2008, Anderson and Takahama, 2012). 
Thymic inner architecture exhibited morphological recovery on day 7 and was back 
to normal on day 10 post 5-FU injury in previously published data (Aquino 
Esperanza et al., 2008). We compared thymopoietic recovery of WT and Trib2-/- 
mice 4 and 14 days after a single dose of 5-FU administration. Trib2-/- mice had 
higher thymic cellularity compared to WT mice at 4 and 14 days post treatment and 
the thymus was relatively bigger 14 days post treatment (Figure 4.2A and 4.2B), 
despite the observed earlier increase in apoptosis (Figure 4.1B and 4.1C). 
Importantly, the higher cell count was due to increase of T cells, natural killer cells 
and dendritic cells but not myeloid and B cells which do not normally develop in 
thymus (Figure 4.2C and 4.2D). Although WT and Trib2-/- mice both had the 
hierarchy of thymic subsets restored to normal at day 14 compared to day 4 post 5-
FU treatment (Figure 4.3), Trib2-/- mice had significantly higher numbers of DN1 
progenitors and the subsequent mature subsets at day 14 post 5-FU treatment 
(Figure 4.2D). This indicates that Trib2-/- mice had accelerated thymopoietic 
recovery. At steady state, thymopoiesis is sustained mainly by c-Kithi DN1 
progenitors (Benz et al., 2008). However, these progenitors were absent in WT and 
Trib2-/- thymus from day 1 to day 14 post 5-FU treatment (Figure 4.2F). Instead, 
we found a significant increase of c-Kit- DN1 progenitors in Trib2-/- thymus 
suggesting expansion of these progenitors drives the accelerated recovery (Figure 
4.2E).   
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Figure 4.2 │ Expansion of c-Kit- DN1 progenitors, in the absence of TRIB2, 
drives the accelerated thymopoietic recovery after genotoxic stress. (A) 
Thymic cellularity of mice after 4 and 14 days of 5-FU treatment. (B) The white 
arrow indicates representative thymus of the dissected WT and Trib2-/-mice. (C) The 
cellularity of non-T lineage cells (DC: CD11c+; NK cells: Nk1.1+; B: CD19+B220+; 
Myeloid: Gr-1+CD11b+) in thymus (n = 3 per genotype) were determined by flow 
cytometry. Cellularity for thymic subsets (D) and DN1 subsets (E). (F) c-Kit 
expression of WT and Trib2-/- DN1 thymocytes at steady state (n = 7-8 per 
genotype) and after 5-FU treatment (n = 4-6 per genotype per studied time point) 
were shown in overlaid histograms. For A,D and E, n = 9 per genotype per studied 
time point. 5-FU dosage for A-F was 250 mg/kg. For statistical analyses, unpaired 
Student’s t-test was used for A, and two-way ANOVA was used for C, D and E. 
*P<0.05; **P<0.01; ***P<0.001, all quantified data are presented as mean and SEM. 
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Figure 4.3 │ Hierarchical organization of thymopoietic system restored to 
normal at 14 days after genotoxic insult. (A) A representative staining profile of 
WT and Trib2-/- thymus (n = 9 per genotype per studied time point) after 4 and 14 
days of 5-FU treatment (250 mg/kg, i.p.) were shown here. The values indicated in 
the outlined areas are frequency of each thymic subset, and graphed in (B) and (C). 
All quantified data are presented as mean and SEM. 
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We postulated that the acceleration of thymopoietic recovery in the absence of 
TRIB2 is due to the intrinsic highly proliferative nature of Trib2-/- thymocytes. In 
developing thymocytes, proliferation and differentiation are tightly linked. Analysis of  
Tcrb rearrangements for the joining of D2 to J2 gene segments showed less 
immature thymocytes that haven’t undergo Tcrb rearrangements (Germline (GL)  
band) present in Trib2-/- thymus compared to WT thymus 14 days post 5-FU 
treatment (Figure 4.4A). Importantly, we showed in the previous chapter that, at 
steady state, there is no difference in the GL band for the Tcrb rearrangement 
analysis between WT and Trib2-/- total thymoctes (Figure 3.8). Hence, the 5-FU 
induced stress exacerbated the impact of loss of TRIB2 function in regulation of  
thymocyte proliferation. This supports our finding that thymopoiesis was more active 
in treated Trib2-/- mice. We further assessed the quiescent state of DN thymocytes 
through dual staining of DNA and Ki-67. Compared to WT DN thymocytes, 
significantly less Trib2-/- thymocytes in DN1 and DN4 subsets were resting (G0) and 
correspondingly more Trib2-/- thymocytes in these subsets were in cycling state (G1-
S/G2-M) following 5-FU treatment at day 14 (Figure 4.4B and 4.4C). This indicates 
TRIB2 regulates the cell cycle entry of thymocytes. To expand beyond a static 
assessment of proliferation, we did time course experiments of in vivo BrdU pulsing 
in WT and Trib2-/- mice. DN3 thymocytes of both genotypes had similar uptake of 
BrdU after 1 hour of pulsing, however BrdU+ Trib2-/- DN3 thymocytes were 
significantly increased after 4 hours of pulsing (Figure 4.4D and 4.4E). This 
demonstrated that Trib2-/- developing thymocytes had higher cell division kinetics 
and more DN3 thymocytes were available to uptake BrdU while replicating their 
DNA. 
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Figure 4.4 │ Higher cell division kinetics of Trib2-/- developing thymocytes 
accelerates the thymopoietic recovery after genotoxic stress. (A) PCR analysis 
(n = 3 per genotype) of Tcrb rearrangement involving the Dβ2 to Jβ2 gene segments. 
GL denotes the position of the germline PCR product and number indicates the 
different rearrangements. 1 kb M, 1 kb DNA marker; neg ctrl, no template negative 
control. (B) Flow cytometry to determine the fraction of developing thymocytes in 
resting (G0) and active (G1-S/G2/M) cell cycle. Each phase is indicated in the 
outlined areas (top row). The corresponding values in the representative staining 
profile of WT (middle row) and Trib2-/- (bottom row) mice (n = 2-3 per genotype) are 
frequency of each phase and graphed in (C). (D) The frequency of BrdU uptake by 
DN3 thymocytes after 1 and 4 hours of pulsing. A representative staining profile of 
WT and Trib2-/- mice (n = 3 per genotype per studied time point) is shown here. The 
values indicated in the outlined areas are the frequencies of BrdU+ DN3 thymocytes 
and graphed in (E).  5-FU dosage for A-E was 200 mg/kg. For statistical analyses, 
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two-way ANOVA was used for C and E. *P<0.05; **P<0.01; ***P<0.001, all quantified 
data are presented as mean and SEM. 
 
It is noteworthy that TRIB2 loss only affected thymopoietic recovery but not 
hematopoietic regeneration in BM following 5-FU induced genotoxic stress. On day 
14 post 5-FU treatment, blood cell counts of WT and Trib2-/- mice were restored to 
normal with no measurable differences detected (Figure 4.5A and 4.5B). However, 
more CD4+ and CD8+ T cells were present in the blood of Trib2-/- mice though these 
were not statistically significant (Figure 4.5C). Both genotypes had similar BM 
cellularity and HSPC populations including CLPs that are lymphoid restricted 
progenitors (Kondo et al., 1997) (Figure 4D-F). Hence, our immunophenotyping 
analyses showed that haematopoietic regeneration in BM is not impeded in the 
absence of TRIB2. Nevertheless, we did not investigate if TRIB2 loss affects the 
functionality of the reconstituted HSPC populations. Our finding was confirmed in 
another experiment where we examined the long-term (9 weeks) restoration of 
haematopoietic homeostasis following 5-FU treatment (Figure 4.6). Similar to what 
we found at 14 days post treatment, no measurable differences detected in blood 
cell counts (Figure 4.6A), BM cellularity (Figure 4.6C) and HSPC populations 
(Figure 4.6D) of the treated WT and Trib2-/- mice. However, the Trib2-/- mice had 
significantly higher number of CD4 SP subset (Figure 4.6F). This was in accordance 
with Trib2-/- mice have increased number of mature thymocyte subsets at steady 
state (Figure 3.6). 
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Figure 4.5 │ TRIB2 loss does not affect the recovery of haematopoietic 
system after 5-FU genotoxic insult. Mice were sacrificed for analysis after 14 
days of 5-FU treatment (250 mg/kg, i.p.). Complete blood counts (A) and WBC 
differential counts (B) of treated WT and Trib2-/- mice (n = 8-9 per genotype) were 
determined by haematology analyzer. (C) The distribution of mature myeloid, B and 
T cells in the blood of treated WT and Trib2-/- mice (n = 4-5 per genotype) were 
measured by flow cytometry. (D) BM cellularity was counted by trypan blue 
exclusion after RBC lysis of the cell suspension harvested from two pelvises, 
femurs and tibias. (E) Distribution of HSPC populations in BM of treated WT and 
Trib2-/- mice. (F) A representative staining profile of the HSPC populations 
measured in WT and Trib2-/- mice is shown here.  For D-F, n = 3 per genotype. All 
quantified data are presented as mean and SEM. 
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Figure 4.6 │ TRIB2 loss does not affect the restoration of haematopoietic 
homeostasis after 5-FU genotoxic insult. WT and Trib2-/- mice (n = 4-5 per 
genotype) were sacrificed at 9 weeks post 5-FU treatment (150 mg/kg, i.p.). 
Complete blood counts (A) and lineage distribution of blood cells (B) were 
measured by haematology analyzer and flow cytometry respectively. Cellularity of 
BM (C) and thymus (E) was determined by trypan blue exclusion after RBC lysis of 
the cell suspension. Immunophenotyping and quantification of HSPCs residing in 
the BM (D) and thymus subsets (F). For statistical analyses, two-way ANOVA was 
used for A. *P<0.05, all quantified data are presented as mean and SEM. 
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4.2.3 A single case of partial block in T-cell developmental in the absence of 
TRIB2 during thymopoietic recovery. 
While studying the impact of TRIB2 loss on thymopoietic recovery following 5-FU 
treatment at day 14, a Trib2-/- mouse (#381) treated with 5-FU showed abnormal 
thymic cellular phenotypes. Hence, analysis of this mouse was interpreted and 
presented separately. #381 had more than 2 fold increase of thymic cellularity 
compared to the other 5-FU treated Trib2-/- mice (Figure 4.7A) indicating an 
exaggerated rate of thympoietic recovery in the absence of TRIB2. However, 
unlike the treated WT and the other Trib2-/- mice, #381 had a partial block in T-cell 
developmental at the DP stage because subsequent mature CD4 and CD8 SP 
subsets were detected but their frequency in the thymus was  much lower (Figure 
4.7B bottom row). The DP population of #381 had varying expression levels of CD4 
and CD8 compared to the other treated WT and Trib2-/- mice (Figure 4.7B bottom 
row). Hence, direct comparison of the frequency of DP subset with the same gating 
was not possible.  The absolute number of CD4 and CD8 SP subsets did not 
increased proportionally although #381 had a much higher thymic cellularity 
compared to the other treated Trib2-/- mice (Figure 4.7C). Cytospin of #381 thymic 
cells followed by Romanosky staining also revealed that some of these cells were 
relatively bigger compared to the treated WT and the other Trib2-/- which had similar 
even cellular size (Figure 4.7B top row). We did not investigate further the 
reason underlying the partial block in T-cell developmental in this context as it 
was a single case observed. However, it suggests that TRIB2 is required to limit 
excessive proliferation of developing thymocytes during stress to ensure proper 
recovery of thymopoiesis.  
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Figure 4.7 │ A 5-FU treated Trib2-/- mouse (#381) had partial block of T-cell 
development during recovery. (A) Thymic cellularity after 14 days of 5-FU 
treatment (250 mg/kg, i.p.). (B) Romanowsky stained cytospin (top row) and flow 
cytometry (bottom row) profiles of #381 thymocytes. Representative profiles from 
treated WT (n = 9) and Trib2-/- mice (n = 9) were included for comparison. The 
values in the indicated areas (bottom row) are frequency of CD4 and CD8 SP 
subsets in the thymus and their absolute numbers were graphed in (C). For A and 
C, the data for WT and Trib2-/- mice was derived from Figure 4.2A and 4.2D 
respectively, and presented as mean and SEM.  
 
4.3 Discussion 
 
We examined the thymic response to 5-FU through a series of in vivo experiments 
with different study end points, and showed that TRIB2 loss has an impact on the 
susceptibility of thymocytes to genotoxic insult and on the thymopoietic restoration. 
In the absence of TRIB2, DN1, DN2 and DN3 thymocytes have increased cell 
division kinetics, and c-kithi DN1, DN3L and DPbl had  heightened sensitivity to 5-FU 
induced cell death. Following 5-FU mediated thymic injury, c-Kit- DN1 progenitors 
expanded in the absence of TRIB2 and the intrinsic highly proliferative nature of 
Trib2-/- developing thymocytes (DN1, DN3 and DN4 subsets) accelerate the 
recovery of thymopoiesis. Hence, our study showed TRIB2 limits the thymopoietic 
recovery after 5-FU injury.  
 
In the past, BM haematopoietic and thymopoietic recoveries following 5-FU 
injury have been generally studied separately. It has not been clearly established 
when the import of BM progenitors into thymus and thymopoietic homeostasis is re-
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established after 5-FU injury. Our study suggest this occurs after the restoration of 
haematopoiesis in BM since CLPs were detected in the WT and Trib2-/- BM 14 days 
post 5-FU treatment but c-Kit+ DN1 progenitors, which are derived from BM 
progenitors including CLP (Benz and Bleul, 2005, Gounari et al., 2002, Schlenner et 
al., 2010), were barely detected throughout the studied end points. Importantly, c-
Kit- DN1 progenitors were detected and remained resident in the thymus throughout 
this period. The origin of c-Kit- DN1 progenitors is currently unknown. Using the 
OP9-DL1 co-culture system, Poritt and colleagues showed that this subset of DN1 
has lower proliferative capacity but faster kinetics of T cell differentiation compared 
to c-Kit+ DN1 subset (Porritt et al., 2004). However, using a lineage tracing 
approach, Benz and colleagues showed that thymopoiesis at steady state is 
sustained by c-Kit+ instead of c-Kit- progenitors (Benz et al., 2008). Hence, the 
contribution of c-Kit- DN1 progenitors to in vivo T cell development is unclear. Our 
study demonstrated, in the absence of c-Kit+ DN1 progenitors, c-Kit- DN1 
progenitors remaining resident in Trib2-/- thymus expand and drive the thymopoietic 
recovery. Although a recent study showed c-Kit- DN1 progenitors are 
transcriptionally primed for dendritic cell development (Moore et al., 2012), we found 
expansion of c-Kit- DN1 progenitors led to an increase of T cells, dendritic cells as 
well as natural killer cells in the thymus of the treated Trib2-/- mice. Our findings 
suggest that TRIB2 regulates c-Kit- DN1 progenitor proliferative capacity as we have 
shown these cells have an important role in the initiation of the first wave of 
thymopoiesis during recovery which is modulated by the loss of TRIB2.  
 
 T cell development in the thymus is maintained by continual input from BM 
progenitors. It is generally accepted that all thymocyte subpopulations have short 
life spans and cannot self renew. The notion is based on evidence from thymus 
transplants where the grafted thymic pool of donor cells is replaced completely 
within 4 weeks by cells originated from the host BM (Berzins et al., 1998). Other 
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studies also showed that when WT thymus are transplanted into severe combined 
immunodeficiency or Rag2-/- hosts, the competent WT thymocyte populations from 
the graft are rapidly replaced by the incompetent BM-derived precursors (arrested 
at DN3 stage) from the host and additional T cell production stops (Frey et al., 1992, 
Takeda et al., 1996). However, the long standing dogma that the thymus lacks self 
renewing progenitors is overturned by recent studies that showed autonomous T 
cell development in WT thymus engrafted in hosts that are devoid of (Rag2-/-γc
-/-
KitW/Wv (Martins et al., 2012)) or have incompetent BM-derived precursors (Rag2-/-
Il7r-/- (Peaudecerf et al., 2012): arrested at DN2 stage). The capability of resident 
progenitors to self renew was not recognised previously because, under normal 
conditions, they are continuously replaced by the import of fresh BM progenitors. A 
later study showed that natural cell competition between ‘young’ BM-derived and 
‘old’ thymus-resident progenitors is crucial to suppress T cell leukaemic 
transformation and development of T-ALL (Martins et al., 2014). 
 
 In our study, 5-FU mediated genotoxic insult stressed the haematopoietic 
system and led to deprivation of the thymus from BM progenitors as c-Kit+ DN1 
progenitors were barely detected during recovery. We observed that c-Kit- DN1 
progenitors remain residing in the thymus after 5-FU injury and expand in the 
absence of TRIB2. Hence, the accelerated thymopoiesis found in Trib2-/- mice could 
be autonomous. Further studies are warranted to examine thymic autonomous T 
cell development under stress conditions.  
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CHAPTER FIVE: EXAMINATION OF THE ROLE OF TRIB2 IN 
T-CELL LEUKAEMOGENESIS 
 
5.1 Introduction  
 
T-ALL is an aggressive haematological malignancy arising from the transformation 
of thymic progenitors. In paediatric leukaemia 80-85% of cases are ALL, of which 
10-15% are T-ALL (Sallan, 2006). In adults, ALL incidence is only 15% of leukaemia 
cases, of which 20-25% are T-ALL (Sallan, 2006). Hence, T-ALL is mainly a 
childhood leukaemia. Currently, high dose multi-agent chemotherapeutic regimen is 
the standard frontline therapy for paediatric T-ALL patients. Despite its high efficacy 
with patients achieving a five-year event-free survival (EFS) rate of 75-80%, the 
regimen is aggressive and often associated with severe acute toxicities and long 
term adverse effects. Compared to the superior outcomes of paediatric T-ALL 
patients, only 45-55% of adults achieve long term EFS after being diagnosed 
(Sallan, 2006). Although salvage chemotherapy such as Nelarabine and allogeneic 
stem cell transplantation treatments are available for relapsed or refractory patients, 
their clinical outcomes remain very poor (Litzow and Ferrando, 2015, Durinck et al., 
2015). Unlike other types of leukaemia, there is no clinically approved targeted 
therapy for T-ALL yet (Durinck et al., 2015, Freireich et al., 2014). Thus, further 
understanding of the biology of T-ALL disease is crucial to improve patient risk 
stratification to current therapy, and to enable development of effective targeted 
therapies. 
 
The understanding of the biology of T-ALL disease begun in the early 1990s 
where cytogenetic studies of T-ALL cases revealed genomic alterations (Table 5.1) 
that include rearrangements involving TCR genes, translocations resulting in 
formation of fusion genes, and cryptic deletions. These genomic alterations lead to 
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the constitutive activation of developmentally important transcription factor genes 
(Table 5.1), including TLX1, TLX3, HOXA cluster, TAL1, TAL2, LYL1, MYC, LMO1 
and LMO2 and their aberrant expression in thymic progenitors has been associated 
with leukaemic transformation. However, genomic abnormalities in T-ALL are rare 
as 80% of paediatric T-ALLs do not have TCR translocations which are the most 
common alterations (Grabher et al., 2006). Nevertheless, the discovery of these 
genomic abnormalities has far more impact in human T-ALL pathogenesis than their 
incidence suggests. Later studies showed that overexpression of the oncogenic 
transcription factors, identified by previous cytogenetic studies, can be detected in 
up to 80% of T-ALLs. This can occur in the absence of chromosomal locus specific 
abnormalities due to loss of upstream transcriptional regulations (Ferrando et al., 
2004, Bash et al., 1995). Another classic example is NOTCH1, a T-cell oncogene, 
which was discovered in 1991 in three cases of T-ALL (less than 1%) where a 
truncated, activated form of NOTCH1 is translocated to the TCRB locus (Table 5.1) 
(Ellisen et al., 1991). A role of NOTCH1 in human T-ALL was not recognized widely 
until 1996 when enforced expression of the truncated NOTCH1 was shown to 
induce T-ALL in a BM transplant murine model (Pear et al., 1996). The significance 
of activated NOTCH1 in T-ALL was solidified in 2004 when Weng and colleagues 
showed somatic activating mutations of NOTCH1 occur in more than 50% of all T-
ALL cases (Weng et al., 2004). 
 
With the advance of microarray technology in gene expression profiling, 
oncogenic pathways involved in T-ALL pathogenesis begun to be unravelled in the 
2000s. In 2002, a landmark study defined three distinct gene expression signatures 
of T-ALL that represent leukaemic arrest at different stages of T-cell development: 
LYL1+ signature (pro-T), TLX1+ signature (early cortical thymocyte) and TAL1+ 
signature (late cortical thymocte) (Ferrando et al., 2002). This formed the basis for 
classification of T-ALL into different molecular subtypes (Figure 5.1). Both TLX1+ 
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and TAL1+ mature T-ALLs are associated with favourable outcome whereas 
the prognosis of LYL1+ immature T-ALLs is currently unknown (Van Vlierberghe 
and Ferrando, 2012). 
 
 
Figure 5.1 │ Correlation between different molecular subtypes of T-ALL and 
stage of thymocyte differentiation along the α T-cell lineage. LYL1+ T-ALL 
shows an expression profile indicating maturation arrest at the immature stage. 
Leukaemic cells from TLX1+ T-ALL are arrested at the early cortical DP stage, 
whereas TAL1+ T-ALL cases are arrested at the late cortical DP stage. Each 
molecular subtype has distinct gene expression profile except the upregulation of 
NOTCH1, which is the unifying feature. MLL+ T-ALL which is of γδ lineage is not 
included.  Modified from (Grabher et al., 2006). 
 
Regardless of the molecular subtypes of human T-ALL, abbrerant activation of 
NOTCH1 signalling is the unifying feature (Grabher et al., 2006). Indeed, as 
mentioned above, overexpression of a constitutively activated intracellular NOTCH1 
(ICN1) in BM cells is capable to induce T-ALL in mice where they are transplanted 
into (Pear et al., 1996). However, this orginal model only results T-ALL in 30-50% of 
BM-reconstituted mice (Pear et al., 1996). The BM transplant model was refined by 
Aster and colleagues to enable induction of NOTCH1-dependent T-ALL in 100% of 
mice (Aster et al., 2000). Since then, the refined BM transplant model has been 
widely used to study the molecular pathogenesis of T-ALL (Aster et al., 2011, 
Chiang et al., 2006, Li et al., 2008). BM cells that overexpress ICN1 undergo DN 
stages but are blocked at DP stage of extrathymic T-cell development. Li and 
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colleagues showed that ICN1-transduced BM cells generate polyclonal non-
tumourigenic DP cells at 2 weeks post transplantation and leukaemic transformation 
occur later in immature intermediate CD8+ single positive cells (Li et al., 2008).  
 
In normal human (Casero et al., 2015) and murine (Mingueneau et al., 2013) T-
cell development, TRIB2 expression is higher in the early uncommitted thymic 
progenitors compared to other DN thymic subsets but increases as cells develop 
into DP and SP stages. In T-ALL, TRIB2 was identified as a target gene of 
oncogenic NOTCH1 (Wouters et al., 2007), PITX1 (Nagel et al., 2011) and TAL1 
(Sanda et al., 2012). However, TRIB2 mRNA and TRIB2 protein levels have not 
been examined in cell lines or primary samples representing different molecular 
subtypes of T-ALL. Although TRIB2 was shown to be essential for the maintenance 
of TAL1+ T-ALL (Sanda et al., 2012), it remains unclear the role of TRIB2 in the 
initiation of T-ALL. Yokoyama and colleagues showed that activation of ERK 
signalling is essential for TRIB1–induced leukaemogenesis as well as cooperation 
with HOXA9 and MEIS1 to initiate murine AML (Yokoyama et al., 2010). A separate 
study showed that TRIB1 mutant accelerates the initiation of murine AML through 
enhanced ERK signalling (Yokoyama et al., 2012). In contrast to AML, activation of 
p38 and ERK signalling were found in dormant instead of aggressive T-ALL 
xenografts (Masiero et al., 2011). Although TRIB2 is known to modulate MAPK 
signalling, as explained in Section 1.3.5, its implications in T-ALL has not been 
studied. 
 
In the previous chapter, we showed that TRIB2 negatively regulates the 
proliferation of developing thymocytes and limits thymopoietic recovery following 
genotoxic insult. Tight regulation of thymopoietic restoration has been proposed to 
prevent adverse consequences such as leukaemic transformation of T cells and 
autoimmunity (Boehm and Swann, 2013). The observation of a Trib2-/- mouse that 
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developed a block in T cell development at DP stage following 5-FU treatment 
suggests TRIB2 could be important in T cell leukemogenesis. Hence, in this 
chapter, we aimed to investigate the role of TRIB2 in the initiation of T-ALL. 
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Table 5.1 │ Genomic alterations in T-ALL†. 
T-ALL 
oncogene 
Type of protein Chromosomal 
alterations 
Normal developmental 
role 
Frequency of T-ALL 
(%) 
References 
Children Adults 
Rearrangements involving TCR genes (TCRA/D on  14q11 and TCRB on 7q34) 
TLX1 Homeodomain t(7;10)(q34;q24) 
t(10;14)(q24;q11) 
Spleen development 4-7 14 (Dube et al., 
1991, 
Hatano et 
al., 1991, 
Kennedy et 
al., 1991, Lu 
et al., 1991, 
Bergeron et 
al., 2007) 
TLX3 Homeodomain t(5;14)(q35;q32) 
t(5;14)(q35;q11) 
Central nervous system 
(CNS) development 
22 13 (Hansen-
Hagge et 
al., 2002, 
Berger et 
al., 2003) 
HOXA 
cluster 
Homeodomain  Inv(7)(p15q34) 
t(7;7)(p15;q34) 
Axial patterning 3.3 (Speleman 
et al., 2005, 
Soulier et 
al., 2005, 
Cauwelier 
et al., 2007) 
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TAL1 bHLH t(1;14)(p32;q11) 
t(1;7)(p32;q34) 
Embryonic HSC 
development 
3 (Begley et 
al., 1989, 
Chen et al., 
1990, 
Carroll et 
al., 1990) 
TAL2 bHLH t(7;9)(q34;q32) CNS development Two cases (Xia et al., 
1991, Smith 
et al., 1988) 
LYL1 bHLH t(7;19)(q34;p13) Haematopoiesis Two cases (Mellentin et 
al., 1989, 
Cleary et 
al., 1988, 
Homminga 
et al., 2012) 
BHLHB1 bHLH t(14;21)(q11.2;q22) CNS development Single case (Wang et 
al., 2000) 
MYC bHLH/Lzip t(8;14)(q24;q11) Cell growth and apoptosis 2 (Finger et 
al., 1986, 
McKeithan 
et al., 1986, 
Shima et 
al., 1986, 
Erikson et 
al., 1986) 
LMO1 LIM domain t(11;14)(p15;q11) Hindbrain patterning 2 (Greenberg 
et al., 1990, 
McGuire et 
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al., 1989) 
LMO2 LIM domain t(11;14)(p13;q11) 
t(7;11)(q35;p13) 
Embryonic HSC 
development 
7 (Van 
Vlierberghe 
et al., 2006) 
LCK Tyrosine kinase t(1;7)(p34;q34) TCR signalling Two cases (Tycko et 
al., 1991) 
NOTCH1 Notch receptor t(7;9)(q34;q34.3) T-cell fate specification                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Three cases (Ellisen et 
al., 1991) 
CCND2 D-type cyclin t(7;12)(q34;p13) 
t(12;14)(p13;q11) 
Cell cycle 3 (Clappier et 
al., 2006) 
Formation of fusion genes 
NUP214- 
ABL1 
Nucleoporin/ 
Tyrosine kinase 
t(9;9)(q34;q34) 
(episomal) 
Nuclear transport- 
nuclear signalling 
6 (Graux et 
al., 2004, 
Cimino et 
al., 2001) 
NUP98- 
RAP1GDS1 
Nucleoporin/ 
GEF 
t(4;11)(q21;p15) Nuclear transport- 
Ras activation 
5 (Hussey et 
al., 1999) 
EML1- 
ABL1 
CC domain/ 
Tyrosine kinase 
t(9;14)(q34;q32) 
(cryptic) 
Cytoskeleton- 
nuclear signalling 
Single case (De 
Keersmaec
ker et al., 
2005, 
Hagemeijer 
and Graux, 
2010) 
ETV6- 
JAK2 
ETS domain/ 
Tyrosine kinase 
t(9;12)(p24;p13) Haematopoiesis- 
immune response 
3 
 
(Zhou et al., 
2012, 
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Lacronique 
et al., 1997) 
ETV6- 
ABL1 
ETS domain/ 
Tyrosine kinase 
t(9;12)(q34;p13) Haematopoiesis- 
nuclear signalling 
Single case (Zuna et al., 
2010, Van 
Limbergen 
et al., 2001) 
CALM- 
AF10 
ENTH domain 
AT-hook 
t(10;11)(p13;q21) Clathrin assembly- 
transcriptional factor 
10 (Carlson et 
al., 2000, 
Asnafi et al., 
2003) 
MLL- 
ENL 
Methyltransferase 
Nuclear targeting 
sequence 
containing 
t(11;19)(q23;p13)  Transcriptional regulator- 
super elongation complex 
8  
(all MLL) 
(Graux et 
al., 2006) 
MLL- 
AF6 
Methyltransferase 
GLGF motif 
containing 
t(6;11)(q27;q23) Transcriptional regulator- 
organization of cell 
junctions 
8  
(all MLL) 
(Graux et 
al., 2006) 
MLL- 
AF10 
Methyltransferase 
AT-hook 
t(10;11)(p13;q23) Transcriptional regulator- 
transcriptional factor 
8  
(all MLL) 
(Graux et 
al., 2006) 
MLL- 
AFX1 
Methyltransferase 
Forkhead family 
t(X;11)(q13;q23) Transcriptional regulator- 
cell cycle regulation 
8  
(all MLL) 
(Graux et 
al., 2006) 
MLL- 
AF4 
Methyltransferase 
Nuclear targeting 
sequence 
containing 
t(4;11)(q21;q23) Transcriptional regulator- 
transcriptional activator 
8  
(all MLL) 
(Graux et 
al., 2006) 
Others 
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  † Modified from REF. (Grabher et al., 2006, Graux et al., 2006).CALM-AF10 and MLL fusion genes are restricted to γδ lineage T-ALL subtype. 
 
LMO2 LIM domain del(11)(p12p13) Embryonic HSC 
development 
4 unknown (Van 
Vlierberghe 
et al., 2006) 
SIL- 
TAL1 
Proline rich 
extension/ 
bHLH 
del(1p) (cryptic) Mitotic spindle checkpoint 
Embryonic HSC 
development 
16 11 (Brown et 
al., 1990, 
Asnafi et al., 
2005, 
D'Angio et 
al., 2015) 
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5.2 Results 
 
5.2.1 TRIB2 loss accelerates murine T-ALL via defective MAPK signalling. 
We examined the role of TRIB2 in T-cell leukaemogenesis using a NOTCH1 
induced T-ALL BMT mouse model (Aster et al., 2000). WT and Trib2-/- total BM cells 
were transduced with an empty vector control (MigR1) or a retroviral vector 
encoding an intracellular Notch1 transgene (ICN1). This transgene is known to 
induce T-ALL with a CD4+/CD8+ phenotype with a latency of 7-12 weeks in the BM 
transplantation model (Aster et al., 2000, Pui et al., 1999, Aster et al., 2011, Chiang 
et al., 2006, Allman et al., 2001). The cells, which were CD45.2+, were then 
transplanted into lethally irradiated CD45.1+ recipient mice to monitor the 
development of T-ALL. All experimental groups were verified by Trib2 genotyping 
analysis of the transplanted moribund mice (Figure 5.2).  
 
 
Figure 5.2 │ Transplant experimental groups were verified by Trib2 
genotyping analysis. Splenic total genomic DNA was extracted from the moribund 
mice. PCR analysis of representative samples from different groups is shown here. 
M, marker; neg ctrl, no template negative control; ctrl, control; mut, mutant; ns, non 
specific.  
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Mice transplanted with ICN1-transduced Trib2-/- donor cells succumbed to T-ALL 
disease with a shorter latency (median survival of 43.5 days) whereas mice  
transplanted with ICN1-transduced WT donor cells had a median survival of 63.5 
days. Kaplan Meier survival analysis for these two groups was significantly different 
(Figure 5.3A) indicating T-ALL onset driven by NOTCH1 overexpression was 
accelerated in the absence of TRIB2. GFP expression was used as a marker for 
transduced donor cells and analysis showed similar engraftment levels of 
transduced WT and Trib2-/- donor cells in the recipients from all groups across 
different organs post mortem (Figure 5.3B). Importantly, the difference in disease 
latencies in mice from WT and Trib2-/- expressing ICN1 was not due to differences 
in engraftment levels of transduced donor cells post-transplant. Similar engraftment 
levels of transduced cells were present upon sequential analysis post transplant 
until the mice succumbed to disease (Figure 5.3C). Analysis of BM showed 
engrafted MigR1-transduced donor cells developed normally into lineage committed 
Gr-1+/CD11b+ myeloid cells and CD19+/B220+ B-lymphoid cells whereas ICN1-
transduced donor cells displayed CD4+/CD8+ T-ALL leukaemic cell profile (Figure 
5.3D). TRIB2 loss did not alter the immunophenotype (Figure 5.3D) and histological 
morphology (Figure 5.3E) of NOTCH1-induced T-ALL. Compared to mice from 
control groups (WT+MigR1 and Trib2-/-+MigR1), mice that succumbed to T-ALL 
disease had leukocytosis, anaemia and thrombocytopenia (Figure 5.4A). Despite a 
difference of 20 days for disease onset, mice that succumbed earlier to Trib2-/- T-
ALL had a similar degree of leukaemic burden (Figure 5.4B and 5.4C) but exhibited 
a trend of higher organ infiltration of leukaemic cells (Figure 5.4D) compared to 
mice that succumbed to WT T-ALL. We have ruled out that the accelerated T-ALL 
phenotype is not due to an increase in TRIB1 expression, as TRIB1 expression 
levels do not change upon knockdown of TRIB2 in T-ALL or AML cell lines (Figure 
5.5).  To understand how TRIB2 loss accelerated the initiation of T-ALL, we 
compared MAPK signalling between WT and Trib2-/- T-ALL as Tribbles family 
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(TRIB1-3) is known to be associated with MAPK signalling and required for the 
activation of ERK, JNK and p38 (Yokoyama et al., 2010, Wang et al., 2013c, Wei et 
al., 2012, Izrailit et al., 2013). Western blotting for MAPK signals in leukaemic 
infiltrated BM samples showed impaired activation of ERK, JNK and p38 in Trib2-/- 
T-ALL compared to WT T-ALL (Figure 5.4E). We also confirmed reduced activation 
of p38 signalling in normal developing DN2 and DN3L thymic subsets (Diehl et al., 
2000) in the absence of TRIB2 (Figure 5.6). These imply that modulation of MAPK 
signalling by TRIB2 may influence the phenotype of T-ALL. 
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Figure 5.3 │ Loss of TRIB2 accelerates the onset of NOTCH1-induced T-ALL. 
(A) Kaplan-Meier survival analysis of the lethally irradiated recipient (CD45.1+) mice 
transplanted with 5-FU enriched WT or Trib2-/- BM cells (donor: CD45.2+) 
transduced with either MigR1 control or ICN1 transgene. The number (n) of mice 
analysed was from three independent experiments. T-ALL, T-cell acute 
lymphoblastic leukaemia. (B) Engraftment of donor cells in all experimental groups 
across different organs were determined based on GFP expression post mortem. 
(C) Evolvement of transduced donor cells in test groups (WT and Trib2-/-+ICN1) 
after transplantation and till morbidity. Five mice from each group were shown here. 
(D) Development of T-ALL leukaemia was verified by immunophenotyping analysis 
of transduced donor cells for surface expression of different lineage markers. The 
values in the outlined areas are frequency of leukaemic cells (top row: CD4+/CD8+), 
lineage committed myeloid cells (middle row: Gr-1+/CD11b+) or B-lymphoid cells 
(bottom row: CD19+/B220+) in the BM of moribund mice. (E) Romanowsky staining 
of representative blood smears of moribund mice from test groups. Filled arrow 
head indicates a lymphoblast (WT and Trib2-/- T-ALL) and unfilled arrow head 
indicates a normal neutrophil. For A, Log-rank test was used to compare the 
survival curves. **P = 0.0053, all quantified data are presented as mean and SEM. 
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Figure 5.4 │ Trib2-/- T-ALL is more aggressive and has defective MAPK 
signalling compared to WT T-ALL. (A)  Health of the moribund mice was 
assessed by WBC, RBC and platelet counts. (B) Leukaemic burden was 
determined by spleen to body weight ratio. (C) Representatives of a spleen from 
each experimental group. (D) Leukaemic infiltration was assessed by measurement 
of the frequency of leukaemic cells in various organs of moribund mice. (E) 
Activation of MAPK signalling in T-ALL was determined by western blotting for p-
Erk, total Erk, p-p38, total p38, p-JNK, JNK1 and β-actin signals in the leukaemic 
BM (n = 4 per group). Signals shown were developed from triplicate immunoblots. 
For A, B and D, the number (n) of mice analysed was stated in Figure 5.3A. All 
quantified data are presented as mean and SEM. 
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Figure 5.5 │ TRIB1 expression remained unchanged following TRIB2 
knockdown. (A) Expression of TRIB1 and TRIB2 in GFP-sorted U937 cells was 
measured by quantitative RT-PCR after 48 hours of transduction with pLKO empty 
vector or pLKO-shTRIB2. (B) Normalized expression values of TRIB1 (average of 
202241_at, 235641_at and 239818_x_at) in Jurkat cells following TRIB2 
knockdown were derived from GSE66013 dataset (Tan et al., 2015). For statistical 
analyses, unpaired Student’s t-test was used for A and B. **P<0.01, all quantified 
data are presented as mean and SEM. 
 
 
Figure 5.6 │ Reduced activation of p38 in Trib2-/- DN2 and DN3L thymic 
subsets. Intracellular level of p-p38 across thymic subsets (n = 4 for Trib2-/- and n = 
5 for WT), indicated by the mean fluorescence intensity (MFI), was measured by 
flow cytometry (left). MFI of each subset was presented after deduction of the MFI 
of the corresponded FMO control. An overlap of histogram (right) showed Trib2-/- 
DN2 cells had lower level of p-p38 compared to that of WT. Norm, normalized; 
FMO, Fluorescence Minus One. For statistical analyses, unpaired Student’s t-test 
was used. *P<0.05; **P<0.01, all quantified data are presented as mean and SEM. 
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5.2.2 TRIB2 expression levels distinguish molecular subtypes of human T-ALL 
and correlate with MAPK signalling.  
Since TRIB2 loss accelerated T-ALL onset in our experimental model, we 
performed GSEA analysis to compare gene expression profiles of low and high 
TRIB2 expression (Table 5.2) from a database (GSE13159) derived from 174 T-ALL 
patient samples (Haferlach et al., 2010) (Figure 5.7A). GSEA analysis showed 
these two groups, defined by TRIB2 expression, were of distinct molecular subtypes 
of T-ALL (Figure 5.7B). Low TRIB2 expressing T-ALL group was enriched with gene 
set associated with TLX1+ T-ALL (early cortical mature T-ALL) whereas high TRIB2 
expressing T-ALL group had upregulation of LYL1+ T-ALL (immature T-ALL) gene 
set (Table 5.3) (Ferrando et al., 2002). TAL1+ T-ALL (late cortical mature T-ALL) 
gene set was not enriched in either group. A significant positive correlation 
between TRIB2 and LYL1 expression was confirmed in an independent T-ALL 
dataset (GSE33315) (Zhang et al., 2012c) (Figure 5.7C). As shown in Fgure 5.4E in 
our experimental model, Trib2-/- T-ALL leukaemic cells exhibited deficiencies in 
MAPK signalling. In accordance with this, using GSEA analysis of low and high 
Trib2 expressed human T-ALL groups, MAPK signalling was found to be 
upregulated in the high Trib2 expressing T-ALL group (Figure 5.7D). Hence, 
impaired activation of MAPK signalling in the absence of TRIB2 contributed to the 
increased aggressiveness of NOTCH1 induced murine T-ALL disease which 
recapitulated the immunophenotypes of human cortical mature T-ALL. Our analysis 
suggests TRIB2 possesses tumour suppressive functions important for T-ALL. 
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Table 5.2 │ Low and high TRIB2 expressed human T-ALLs (GSE13159 dataset). 
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Figure 5.7 │ TRIB2 levels distinguish molecular subtypes of human T-ALL and 
associate with MAPK signalling. (A) GSEA was performed to compare human T-
ALL samples from GSE13159 dataset (Haferlach et al., 2010) that expressed low 
and high TRIB2 (n = 26 per group) for enrichment of human T-ALL molecular 
subtypes (B) and canonical pathways (D). NES, normalized enrichment score; 
Nom, nominal; FDR, false discovery rate. (C) Correlation between TRIB2 (average 
of 202478_at and 202479_s_at) and LYL1 (210044_s_at) expressions were 
examined in 84 human T-ALL samples from GSE33315 dataset (Zhang et al., 
2012c). For C, Pearson correlation test was used to examination association 
between TRIB2 and LYL1 expressions. 
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Table 5.3 │ Core enrichment genes upregulated in low and high TRIB2 T-ALLs. 
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5.3 Discussion 
 
We showed TRIB2 is required to suppress T cell leukaemogenesis induced by 
NOTCH1 overexpression. A role for TRIB2 in T-ALL maintenance was 
demonstrated by Sanda and colleagues (Sanda et al., 2012) as knockdown of Trib2 
in a panel of TAL1 positive human T-ALL cell lines induced apoptosis and inhibited 
cell growth. This appears to be consistent with the role of TRIB2 in other solid 
(Zanella et al., 2010, Grandinetti et al., 2011, Wang et al., 2013a) and 
haematological (Rishi et al., 2014) malignancies that overexpression of TRIB2 
confers growth and survival advantages to tumour cells.  However, we provide 
strong evidence that TRIB2 has opposing roles in the initiation and potency of T-
ALL. In the absence of TRIB2, the latency of NOTCH1-induced T-ALL was 
shortened significantly. The tumour suppressive role of TRIB2 in the initiation of 
NOTCH1-induced T-ALL was verified by another independent study where similar 
experiments were performed using a different Trib2 knockout mouse model 
generated by the authors (Stein et al., 2016). As a cell signalling modulator and 
mediator, it is likely that TRIB2 function, whether tumour promoting or suppressing, 
is dependent on the cellular state in which it is activated, similar to what has been 
described for p53 (Kruiswijk et al., 2015). In leukaemic initiation, signalling networks 
in normal cells are perturbed by driver mutations to enable leukaemic 
transformation. However, in leukaemic maintenance, signalling networks in 
transformed cells are governed by both driver and passenger mutations to cope 
with increasing metabolic and genomic stresses. Hence, the differing roles of 
TRIB2 in T-ALL initiation and maintenance could be due to alterations in signalling 
networks during and after leukaemic transformation. 
 
We previously reported elevated TRIB2 levels in a cohort of paediatric T-ALLs 
that contain Notch1/Fbxw7 mutations compared to wild type T-ALLs and this was 
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important in the profile and phenotype of mutant NOTCH1 T-ALL (Hannon et al., 
2012). However, mutant NOTCH1 does not cluster into the aforementioned LYL1+, 
TLX1+ and TAL1+ T-ALL. Instead, aberrant NOTCH1 signalling is the unifying 
feature in all the subtypes. Hence, we performed GSEA analysis in this study to 
show TRIB2 is highly expressed in immature (LYL1+) T-ALLs that are arrested at 
the DN stage of early thymocyte development and transcriptionally related to HSCs 
and myeloid progenitors (Zhang et al., 2012c, Van Vlierberghe et al., 2013). Further 
studies of this subset of T-ALL, reviewed by Yui and Rothenberg (Yui and 
Rothenberg, 2014), indicate that leukaemic transformation is due to failure of 
uncommitted thymic progenitors to repress a ‘legacy’ stem and progenitor cell gene 
network that is inherited from multipotent precursors. These genes include but are 
not limited to MEIS1, HOXA9, LYL1, LMO2, HHEX and MYCN that are normally 
expressed only in DN1 and/or DN2a cells, and are functionally implicated as proto-
oncogenes. Furthermore, a high prevalence of AML mutations (FLT3, NRAS, 
DNMT3A, IDH1 and IDH2) (Van Vlierberghe et al., 2013) in immature (LYL1+) T-
ALLs suggests contribution of myeloid oncogenes to leukaemogenesis of this 
subset of T-ALL. In turn, TRIB2 expression is suppressed in TLX1+ human T-ALLs 
which have a mature cortical DP phenotype where the transformed cells have 
committed to the T cell lineage (Ferrando et al., 2002). We propose the role of 
TRIB2 in different subtypes of human T-ALL depends on the stage at which thymic 
progenitors undergo malignant transformation and if they have committed to T cell 
lineage. In immature T-ALL, we speculate that the oncogenic property of TRIB2 in 
myeloid leukaemia is ‘inherited’ in transformed uncommitted thymic progenitors. We 
further speculate that TRIB2 is tumour suppressing in mature T-ALL as TRIB2 
exerts its physiological role in normal T-cell development. As such, targeting of 
TRIB2 could be beneficial in the treatment of LYL1+ instead of TLX1+ T-ALLs. 
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There is a strong correlation with TRIB2 and MAPK signalling in human T-ALL 
as shown by GSEA analysis. Previously, the activation of ERK and p38 were shown 
to inversely correlate with aggressiveness of T-ALL in a model of T-ALL cell 
dormancy (Masiero et al., 2011). Furthermore, drug treatment of established human 
T-ALL cell lines was shown to induce cell death via activation of p38 and JNK (Liu 
et al., 2014, Ge et al., 2013, Jiang et al., 2013). Thus, activation of MAPK signalling 
appears to be a limiting factor, at least, in the context of T-ALL. TRIB family 
members acts as scaffold proteins for the binding of MAPK signalling complexes 
and hence modulates their activity. All TRIB family members have the conserved 
MEK1 binding motif and have been shown to interact with MEK1 (Yokoyama et al., 
2010). In human T-ALLs, upregulation of ERK1/2 signalling was found in 38% of T-
ALL patients (Gregorj et al., 2007) and MEK/ERK can be activated due to RAS 
mutations, found in about 10% of T-ALL patients (Kindler et al., 2008). Targeting of 
MEK/ERK signalling by MEK inhibition was shown to be effective in treating KRAS-
mutated T-ALL in a murine model (Dail et al., 2010). The upregulation of MAPK 
signalling in specific subtypes of T-ALL has not been studied and remains unclear. 
Here we show TRIB2 expression is high in LYL1+ immature T-ALLs enriched with 
MAPK signalling and our experimental data show defective MAPK signalling in the 
absence of TRIB2. Thus, it appears that TRIB2 functions to control T-ALL via MAPK 
modulation. 
 
 We and others (Dedhia et al., 2010, Keeshan et al., 2006) have shown that 
Trib2 is a myeloid oncogene when overexpressed in a murine BM transplant model. 
Here, loss of TRIB2 potentiated murine T-ALL induced by a T cell oncogene. Given 
that TRIB2 is expressed highest in normal T cells (Liang et al., 2013), it is not 
surprising that overexpression of Trib2 does not drive T-ALL in the BMT model, and 
our data would suggest that TRIB2 functions to suppress T-ALL. Our data provide 
insight into the understanding of the opposing leukaemogenic roles of TRIB2 in 
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myeloid and lymphoid leukaemia. However, the mechanisms that underlie whether 
TRIB2 acts as an oncogene or tumour suppressor are not well understood. It may 
be linked to its function in cell proliferation and MAPK pathway modulation, which 
could be cell context specific. Anti- and pro-proliferative effects connected with 
MAPK signalling and TRIB1 have been previously demonstrated in different cell 
contexts. In vascular smooth muscle cells, TRIB1 was shown to interact with MKK4 
which led to inhibition of JNK pathway and decreased proliferation (Sung et al., 
2007). In murine BM cells, TRIB1 was shown to interact with MEK1 which led to 
increased activation of ERK pathway and increased proliferation (Yokoyama et al., 
2010). 
 
This work is a paradigm shift in the definition of TRIB2 function in malignant 
haematopoiesis. TRIB2 is capable of driving myeloid leukaemogenesis and this 
tumour promoting function is likely to be retained in leukaemogenesis of immature 
T-ALL where the transforming thymic progenitors have not terminated properly the 
previously established legacy stem and progenitor cell transcriptional networks. 
However, in leukaemogenesis of mature T-ALL, TRIB2 is tumour suppressing owing 
to its physiological role in normal T-cell development. 
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CHAPTER SIX: EXAMINATION OF THE RELATIONSHIP OF TRIB2 WITH  
CDC25  PHOSPHATASES 
 
6.1 Introduction 
 
 
Figure 6.1 │ CDC25 family regulates cell cycle transitions. Each phase of cell 
cycle is controlled by different CDK-Cyclin complexes which are held inactive by the 
phosphorylation of two residues (for example Threonine 14 and Tyrosine 15 of 
CDK1) within the ATP binding loop. CDC25 proteins promote cell cycle progression 
by dephosphorylating these two residues. Adapted from (Brenner et al., 2014). 
 
The CDC25 family of proteins are cell cycle regulators that act as phosphatases. 
They activate cyclin-dependent kinase (CDK) complexes by dephosphorylation, 
which in turn promote cell cycle phase progression (Figure 6.1) (Brenner et al., 
2014). The functions of the CDC25 family are highly conserved across species. In 
Drosophila, String is the ortholog of CDC25 family (Edgar and O'Farrell, 1990). In 
mammalians, CDC25 family exists in three isoforms: CDC25A, CDC25B and 
CDC25C (Boutros et al., 2007). CDC25A mainly promotes G1 to S phase transition 
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by activating the CDK2-Cyclin E and CDK2-Cyclin A complexes (Blomberg and 
Hoffmann, 1999, Hoffmann et al., 1994) whereas CDC25B/C promote G2 to M 
phase transition primarily (Millar et al., 1991, Gabrielli et al., 1996). Nevertheless, 
CDC25A has also been shown to regulate G2/M phase progression (Mailand et al., 
2002) and this is supported by studies that found no apparent cell cycle phenotype 
in Cdc25b single (Lincoln et al., 2002), Cdc25C single (Chen et al., 2001) and 
Cdc25b/c double (Ferguson et al., 2005) knockout mouse models. CDC25 family 
might have a role in regulation of cell cycle entry/exit (G0 to G1 transition) as a 
recently discovered CDC25 inhibitor (NSC 119915) was found to arrest cells in the 
G0/G1 and G2/M phase transitions of the cell cycle (Lavecchia et al., 2012). 
Furthermore, regulation of Cdc25 expression has been implicated in quiescence 
(G0) maintenance and exit in naïve and activated T-cells respectively (Yusuf and 
Fruman, 2003). However, it is currently unknown if CDC25 family regulates CDK3-
Cyclin C complex which was found to be required for quiescence exit (Ren and 
Rollins, 2004).  
 
In the previous chapters, we provide evidence that TRIB2 negatively regulates 
the proliferation of immature developing thymocytes during thymopoiesis at steady 
state and under stress conditions. However, the mechanism underlying the anti-
proliferative role of TRIB2 is unknown. In Drosophila, Tribbles was shown to 
promote the proteasomal dependent degradation of String in order to coordinate cell 
division and morphogenesis during embryonic development (Grosshans and 
Wieschaus, 2000, Seher and Leptin, 2000, Mata et al., 2000). Furthermore, TRIB3 
was found to interact with CDC25A and regulate its expression (Sakai et al., 2010). 
Hence, we aimed to determine if the function of Drosophila Tribbles-mediated 
degradation of String is conserved in TRIB2. 
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6.2 Results 
 
6.2.1 TRIB2 binds to CDC25B/C but not CDC25A.  
To examine the interaction of TRIB2 with all three isoforms of CDC25 family, we 
overexpressed tagged versions of the proteins in HeLa cells and performed co-
immunoprecitation binding assays. Upon immunoprecipitation with anti-FLAG 
antibody and western blotting with anti-MYC antibody, we found that TRIB2 co-
immunoprecipitated with human CDC25B and CDC25C but not CDC25A (Figure 
6.2A). Hence, TRIB2 interaction with CDC25 family is selective and, in contrast to 
TRIB3, does not interact with CDC25A. Alignment of amino acid sequences of 
CDC25B/C between human and mouse orthologs showed that amino acid residues 
from 206 to 254 from the human CDC25C ortholog were absent in mouse (Figure 
6.2B). Nevertheless, we found that TRIB2 bound to both human and mouse 
CDC25C orthologs (Figure 6.2C). This suggests TRIB2 and CDC25C interaction is 
conserved in mouse, and rules out the region containing the 206-254 amino acid 
residues of human CDC25C as the binding site for TRIB2. Lastly, overexpressed 
TRIB2 was found to bind to the endogenously expressed CDC25C in HeLa cells 
(Figure 6.2D), showing that endogenously and exogenously expressed CDC25C 
interact with TRIB2.    
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Figure 6.2 │ TRIB2 interacts with isoform B and C of CDC25 family. (A) 
Interaction of MYC-tagged TRIB2 with different isoforms of FLAG-tagged CDC25 
family was examined by co-immunoprecipitation (co-IP). IP, immunoprecipitation. 
(B) Similarity of amino acid sequences of different orthologs (human and mouse) for 
CDC25B and CDC25C was examined by BlastP program and presented as dot 
matrix views. (C) Interaction of MYC-tagged TRIB2 with human and mouse 
orthologs of FLAG-tagged CDC25C was examined by co-IP. (D) Interaction of 
FLAG-tagged TRIB2 with endogenous CDC25C was examined by co-IP. For A, C 
and D, HeLa cells were used for the experiments. Panel C and D are 
representatives of two independent experiments.   
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6.2.2 TRIB2 promotes ubiquitination and proteasomal dependent degradation 
of CDC25C. 
To determine if TRIB2 regulates CDC25C in a similar way demonstrated in 
Drosophila (Mata et al., 2000, Seher and Leptin, 2000, Grosshans and Wieschaus, 
2000), we examined the impact of TRIB2 overexpression on CDC25C protein 
expression levels. In HeLa cells, overexpression of TRIB2 led to a decrease in 
endogenous CDC25C protein expression (Figure 6.3A) indicating TRIB2 regulates 
CDC25C turnover. In contrast to CDC25A which is primarily a nuclear protein, 
CDC25B/C are held inactive in the cytoplasm and only translocate to the nucleus 
when they are activated in order to promote cell cycle progression (Brenner et al., 
2014).On account of that, we used MG132, a proteasome inhibitor to assess 
degradation of endogenous CDC25C in both cellular compartments in the presence 
of ectopic TRIB2. Subcellular fractionation showed that endogenous CDC25C was 
located primarily in the cytoplasm consistent with the literature (Figure 6.3B). In 
vehicle-treated cells, overexpression of TRIB2 did not affect nuclear translocation of 
CDC25C as the expression of CDC25C protein in the nucleus remained similar 
compared to empty vector-transfected cells (Figure 6.3B). However, in MG132-
treated cells where proteasome was inhibited, overexpression of TRIB2 led to 
increase level of nuclear CDC25C protein (Figure 6.3B). Shabbeer and colleagues 
showed that, in response to DNA damage, breast cancer type 1 susceptibility 
protein (BRCA1) which is an E3 ubiquitin ligase polyubiquitinates CDC25C protein 
to promote its degradation (Shabbeer et al., 2013). BRCA1-mediated CDC25C 
degradation was suggested via nuclear proteasome because, upon inhibition of 
protein degradation by MG132, overexpression of BRCA1 caused stabilized 
CDC25C to retain in the nucleus (Shabbeer et al., 2013). As such, our data 
suggests that TRIB2 may regulate the turnover of CDC25C in the nucleus. 
Intriguingly, our data also suggests that TRIB2 itself is regulated in a similar fashion 
(Figure 6.3B). 
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Figure 6.3 │ TRIB2 promotes proteasomal dependent degradation of CDC25C 
in the nucleus. (A) Whole cell lysates from FLAG-TRIB2-transfected cells and 
controls (untransfected and empty vector-transfected) were analyzed by Western 
blotting. (B) Cells were treated with DMSO (vehicle) or 10 µM of MG132 for 4 hours 
before subcellular fractionation for Western blotting analysis. α-tubulin and HDAC1 
are cytoplasmic and nuclear markers respectively. For A and B, HeLa cells were 
used for the experiments. Panel A was a result from one experiment whereas panel 
B is a representative of two independent experiments.    
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TRIB2 is known to mediate the degradation of target proteins via ubiquitin 
proteasome system (Salome et al., 2015). Thus, we sought to determine if TRIB2 
promotes ubiquitination of CDC25C. Indeed, we found that TRIB2 overexpression 
caused increased ubiquitination of both human and mouse CDC25C that were 
ectopically expressed in HeLa cells (Figure 6.4A). This is in accordance with the 
results of our co-immunoprecipitation assay that TRIB2 binds to both orthologs 
(Figure 6.2C). Furthermore, we demonstrated that TRIB2 promoted lysine (K)-48-
linked polyubiquitination of endogenous CDC25C (Figure 6.4B and 6.4C). Protein 
ubiquitination via K48-linked ubiquitin chains is a specific cellular signal for 
proteasomal degradation (Komander, 2009). Hence, our results altogether suggest 
TRIB2 promotes polyubiquitination of CDC25C and this in turn increases 
proteasomal dependent degradation of CDC25C. TRIB2-mediated degradation of 
CEBPα requires the kinase-like domain and the C-terminal where COP1 binds to 
(Figure 1.3) (Keeshan et al., 2010). We performed a structure-function analysis of 
TRIB2 in HeLa cells to determine which domain of TRIB2 is essential for promotion 
of endogenous CDC25C ubiquitination. Like TRIB2 full length (FL) protein, 
overexpression of TRIB2 kinase-like domain (KD) alone was sufficient to drive 
CDC25C ubiquitination and deletion of either terminal (dN or dC) didn’t affect TRIB2 
function in this aspect (Figure 6.4D). Our preliminary result suggests only the 
kinase-like domain is crucial for TRIB2-mediated ubiquitination and possibly 
degradation of CDC25C. 
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Figure 6.4 │ TRIB2 promotes K48-linked polyubiquitination of CDC25C. Impact 
of overexpression of MYC-tagged TRIB2 on HA-tagged ubiquitination of (A) human 
and mouse orthologs of FLAG-tagged CDC25C, and (B) endogenous CDC25C. 
Impact of overexpression of (C) MYC-tagged TRIB2 wild type and (D) different 
mutants on K48-linked ubiquitination of endogenous CDC25C. FL, full length; dN, 
N-terminal deleted; KD, only kinase domain expressed; dC, C-terminal deleted. For 
A-D, HeLa cells were used for the experiments. For A and D, all samples were 
treated with 10µM of MG132 for 7 hours prior cell lysis. Panel A, B and C are 
representatives of two independent experiments. 
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6.2.3 TRIB2 is tightly regulated during cell cycle phase progression. 
Given the role of TRIB2 in regulation of CDC25B/C, we were interested to assess 
the expression of TRIB2 during cell cycle. We synchronized RPMI-8402, a T-ALL 
cell line by single thymidine block and monitored the level of TRIB2 mRNA and 
/TRIB2 protein levels as the synchronized cells resumed cell cycle following 
thymidine removal. DNA staining for samples collected at different time points 
confirmed the successful synchronization of cells. Cells were synchronized at G1 to 
S phase transition (S0) by single thymidine block (Figure 6.5A). After removal of 
thymidine, cells entered and progressed through S phase (S12 and S15) 
synchronously (Figure 6.5A). At 20 hours onwards post thymidine removal, 
increasing fraction of cells were found in G2/M and G1 phases (Figure 6.5A). This 
was confirmed with detection of increased level of phosphorylated histone H3, a 
mitosis marker, in cells collected at 22 hours (S22) post thymidine removal (Figure 
6.5B). We observed cyclic expression of TRIB2 protein despite no significant 
change at the mRNA level (Figure 6.5B and 6.5C). Increased level of TRIB2 protein 
was detected in S12, S17 and S22 where most of the synchronized cells were in S 
phase entry, S phase progression and mitotic phase respectively (Figure 6.5B). 
CDC25C protein level increased in S22 presumably due to its role in promoting 
mitotic entry (Figure 6.5B). Hence, increased expression of TRIB2 during mitotic 
phase could be important in regulating the activity of CDC25C. 
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Figure 6.5 │ TRIB2 is regulated at protein level during cell cycle phase 
progression. Asynchronous (AS) RPMI-8402 cells were arrested by single 
thymidine block (S0) followed by release (S12-S24) to allow them to progress into 
different cell cycle phase synchronously. (A) Cell cycle analysis by flow cytometry. 
Histograms of cell cycle profile for all samples were staggered offset. (B) Western 
blotting analysis with p-histone H3 signal serves as a mitosis marker. (C) 
Expression of TRIB2 measured by quantitative RT-PCR. All panels shown are 
representatives of two independent experiments.  
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6.3 Discussion 
 
The relationship between TRIB2 and CDC25 family has not been studied before. 
Here, we showed that TRIB2 interacts physically with CDC25B/C. Similar to 
Drosophila Tribbles (Mata et al., 2000, Seher and Leptin, 2000, Grosshans and 
Wieschaus, 2000), we showed that TRIB2 promotes proteasomal dependent 
degradation of CDC25C. TRIB2 appears to degrade only active CDC25C in the 
nucleus and perhaps the pool of CDC25C available for TRIB2-mediated 
degradation may be smaller. In addition to that, we found the increase of CDC25C 
turnover is due to TRIB2 mediated K48-linked polyubiquitination of CDC25C. 
Hence, the function of Drosophila Tribbles is evolutionarily conserved in TRIB2. 
 
Owing to the critical roles of CDC25 family in cell cycle regulation, the 
expression of CDC25 proteins is tightly regulated. CDC25C activity is controlled 
primarily by two mechanisms at the post-translational level. The first mechanism 
involves phosphorylation of CDC25C at Serine 216 which results in binding of 
CDC25C with 14-3-3 protein and subsequently CDC25C sequestration in the 
cytoplasm (Boutros et al., 2007). The other mechanism regulates CDC25C activity 
by proteasomal dependent degradation. Two E3 ubiquitin ligases have been 
identified so far that work independently of each other to regulate CDC25C at 
different cell cycle phase transitions. CDC25C is targeted by anaphase-promoting 
complex/cyclosome (APC/C) (Chen et al., 2002, Pfleger and Kirschner, 2000) for 
degradation upon mitotic exit whereas BRCA1 (Shabbeer et al., 2013) ubiquitinates 
CDC25C to prevent mitotic entry. We showed that TRIB2 promotes 
polyubiquitination and degradation of CDC25C. It is likely that TRIB2 functions as 
an adaptor for an as yet unidentified E3 ubiquitin ligase that ubiquitinates CDC25C. 
TRIB2 has previously been shown to function as an adaptor mediating the 
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degradation of CEBPα via COP1 E3 ligase in AML (Keeshan et al., 2010) or 
TRIM21 E3 ligase in lung cancer (Grandinetti et al., 2011). 
 
CDC25C is tightly regulated in the steady state cell cycle as well as in response 
to stress such as DNA damage that induces G2/M checkpoint (Boutros et al., 2007). 
The checkpoint following stress is important to allow cells to repair damaged DNA 
before resuming cell cycle. MAPK signalling appears to regulate CDC25C in both 
steady state cell cycle and checkpoint pathways. During cell cycle at steady state, 
phosphorylation of CDC25C at Threonine 48 by ERK leads to CDC25C activation 
and promotion of mitotic entry (Wang et al., 2007). We have shown that in cells 
lacking TRIB2 (Figure 5.4E), that there is loss of ERK activation. However, in 
response to stress and DNA damage, activated ERK has been shown to 
phosphorylate CDC25C at Serine 216 which in turn promotes CDC25C 
ubiquitination and proteasomal degradation (Eymin et al., 2006). In this study, the 
authors did not show whether the pool of ubiquitinated CDC25C was nuclear or 
cytoplasmic. JNK was shown to inactivate CDC25C by direct phosphorylation at 
Serine 168 to regulate mitotic entry and G2/M DNA damage checkpoint (Gutierrez et 
al., 2010). Lastly, p38 induces cytoplasmic sequestration and thus inactivation of 
CDC25C indirectly via MAPK-activated protein kinase 2 (MK2) in response to DNA 
damage (Manke et al., 2005). In the previous chapter, we showed that TRIB2 
controls T-ALL via MAPK modulation. Hence, further studies are warranted to 
examine TRIB2/MAPK/CDC25 axis in normal and malignant haemopoiesis.  
 
The experimental works reported in this chapter help to provide a framework for 
strategic planning in further investigation of the cellular impacts of TRIB2 and 
CDC25C interaction. It remains to be clarified if TRIB2-CDC25C interaction affects 
a specific cell cycle phase transition and if the interaction underlies the anti-
proliferative role of TRIB2 in immature developing thymocytes.  
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CHAPTER SEVEN: GENERAL DISCUSSION 
 
A recent study that showed TRIB2 is capable of auto-phosphorylation challenges 
the current classification of Tribbles family as pseudokinases (Bailey et al., 2015). 
Like CASK (Mukherjee et al., 2008), TRIB2 could be an atypical kinase with specific 
substrates. Indeed, a screen for the physiological substrates of TRIB2 has not been 
documented although TRIB3 kinase activity had been assessed by in vitro kinase 
assay with selected substrates (Bowers et al., 2003). For TRIB2, substrate 
screening has been hindered by its unknown physiological role. Now, our works 
have uncovered a role for TRIB2 in the thymus where it regulates the proliferation of 
immature developing thymocytes. Hence, substrate screening for TRIB2 could be 
examined in the thymus and in these thymocytes where the physiological TRIB2-
putative interacting proteins are expressed. This could be achieved with the recent 
development of kinase-interacting substrate screening (Amano et al., 2015) and is 
important for the elucidation of physiological TRIB2 signalling network in the 
thymus. 
 
During Drosophila embryonic development, the anti-proliferative role of Tribbles 
is necessary to coordinate cellular proliferation and morphogenesis (Mata et al., 
2000, Seher and Leptin, 2000, Grosshans and Wieschaus, 2000). In the thymus, we 
speculate that TRIB2 is important for the establishment of T-cell identity and the 
anti-proliferative role of TRIB2 is required to restrain self-renewal activity of 
uncommitted thymic progenitors (DN1 and DN2a) for T-cell specification and 
commitment. Trib2 was shown to be regulated by transcription factors (PU.1, 
NOTCH and GATA3) that control a lympho-myeloid switch during early T-cell 
development (Del Real and Rothenberg, 2013). PU.1 is a progenitor cell 
transcription factor highly expressed initially in DN1 and DN2a progenitors where 
they retain multi-lineage plasticity but are repressed in DN2b stage where the 
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progenitors become committed to T-cell lineage (Yui et al., 2010). It is required for 
the expansion of DN1 and DN2 progenitors while restraining their differentiation by 
temporally restricting activation of the T-lineage developmental programme 
(Champhekar et al., 2015). Nevertheless, forced overexpression of PU.1 can divert 
these early uncommitted progenitors to a myeloid lineage which in normal 
conditions is inhibited by thymic NOTCH signalling (Franco et al., 2006). In contrast 
to PU.1, GATA3 is a T-lineage transcription factor. Gata3 expression is turned on by 
NOTCH signalling in DN1 progenitors and remains stable at later stages (DP) of T-
cell development. GATA3 is essential for development of the T-lineage as loss of 
GATA3 affects multiple T-cell developmental stages (Rothenberg and Scripture-
Adams, 2008). To understand the myeloid versus T-cell fate choice, Del Real and 
colleagues studied the interactions between PU.1, GATA3 and NOTCH1 signalling 
in Scid.adh.2C2 cells, a DN3-like clonal early T-cell line that do not express 
endogenous PU.1 (Del Real and Rothenberg, 2013). Trib2 was downregulated in 
diverted PU.1-overexpressing Scid.adh.2C2 cells which had increased expression 
of CD11b (Del Real and Rothenberg, 2013). This indicates Trib2 is a T-lineage 
gene and is repressed by PU.1. Indeed, ChIP-seq analysis showed that Trib2 is 
bound by PU.1 in DN1 and DN2a but not in DN2b T-lineage committed progenitors 
(Zhang et al., 2012d). In contrast, Trib2 was upregulated by elevated NOTCH1 
signalling in myeloid diversion-protected Scid.adh.2C2 cells that co-overexpressed 
PU.1 and ICN1 (Del Real and Rothenberg, 2013). This is not surprising as Trib2 
has been shown previously as a direct target of NOTCH1 (Wouters et al., 2007). 
Lastly, Trib2 downregulation was dampened in PU.1-overexpressing Scid.adh.2C2 
cells which had GATA3 knockdown and were more sensitive to myeloid diversion 
(Del Real and Rothenberg, 2013). This suggests regulation of Trib2 by GATA3 and 
ChIP-seq analysis showed that Trib2 is bound by GATA3 in uncommitted DN1, 
committed DN2b progenitors and DP mature cells (Zhang et al., 2012d). 
Intriguingly, a separate study aimed to characterize T cell lineage commitment 
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found that uncommitted DN1 and DN2a progenitors undergo similar extensive 
proliferation but committed DN2b cells proliferate at a slower rate, as assessed by 
carboxyfluorescein succinimidyl ester dilution, on OP9-DL1 co-culture system (Yui 
et al., 2010). This was not pursued further in the study but it highlights a potential 
coordination between cellular proliferation and commitment as the thymic 
progenitors develop. Given the anti-proliferative role of TRIB2 in these developing 
thymocytes and the connection of Trib2 with PU.1, GATA3 and NOTCH1, future 
study is warranted to examine the role of Trib2 in T-lineage commitment.  
 
As mentioned in the third chapter, our data suggests that TRIB2 could have 
another distinct role in thymocytes beyond the DN stage. In the absence of TRIB2, 
increased number of DP thymocytes due to increased proliferation of DN 
thymocytes resulted in increased CD4 but not CD8 T cell maturation. However, this 
did not affect the size of peripheral T-cell pool. Hence, TRIB2 may impact on thymic 
selection, maturation of DP to SP thymocytes or thymic T-cell export. We speculate 
that the role of TRIB2 in the later stages of T-cell development (thymic selection and 
DP-SP maturation) is connected to its relationship with MAPK signalling. Thymic 
selection is a critical checkpoint at the DP stage for the generation of mature T-cells 
that can respond to foreign antigens without mounting an auto-immune response to 
self antigens. With low-avidity interactions between TCR and self-peptide-major 
histocompatibility complex (MHC) complexes, DP thymocytes that are normally 
destined to ‘death-by-neglect’ are signalled to survive and differentiate further 
(positive selection). However, high-avidity interactions between TCRs and self-
peptide-MHC complexes lead to apoptosis induction instead (negative selection). 
MAPK signalling, initiated by TCR-ligand interactions, appears to be important in 
both selections. Positively-selecting ligands that promote survival generate a 
weaker but sustained activation of ERK signalling whereas negatively-selecting 
ligands that induce death generate a robust but transient activation of ERK 
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signalling (Daniels et al., 2006, McNeil et al., 2005). ERK expression is 
indispensable in positive selection (Fischer et al., 2005, Pages et al., 1999) 
compared to negative selection (McGargill et al., 2009) where p38 and JNK 
activation are more critical (Sugawara et al., 1998, Rincon et al., 1998). ERK and 
p38 are also important in the maturation of thymocytes from DP to SP stage. p38 
activation (Fernandez, 2000) is required in the generation of both CD4 and CD8 SP 
T-cells whereas ERK activation (Sharp et al., 1997, Fischer et al., 2005) is important 
for the development of CD4 rather than CD8 SP T-cells. We demonstrated that 
TRIB2 is required for the regulation of MAPK signalling in leukaemic T-cells, and we 
showed reduced p38 signalling in Trib2-/- DN2 and DN3L thymocytes. Hence, future 
study should assess the impact of TRIB2 loss on thymic selection with further 
characterization of DP thymocytes (Mingueneau et al., 2013) and the MAPK status 
in these cells.  
  
TRIB2 is highly conserved in mouse and human with 99.2% of similarity in 
amino acid sequences. Hence, study of TRIB2 in the mouse organism is important 
and relevant for the elucidation of its role in the human setting. So far, Trib2 knock 
out mouse models (Trib2tm1Ryn (Takasato et al., 2008), Trib2tm1Lex (Rishi et al., 2014) 
and Trib2tm1Myam (Satoh et al., 2013)) have been generated by germline deletion of 
Trib2. Stage or cell-type specific disruption of Trib2 could be useful in dissecting the 
role of TRIB2 in the development and differentiation of a specific haematopoietic 
lineage. This could be accomplished by CRE-recombinase mediated conditional 
deletion of Lox-P site flanked Trib2 gene. Many different Cre-transgenic mouse 
lines have been developed where expression of Cre recombinase is under the 
control of cell-type specific promoter and hence enabling cell-type specific gene 
deletion. For example, Vav1 promoter driven Cre expression (Ogilvy et al., 1999) 
would allow deletion of Trib2 in HSCs and hence all their descendents whereas 
human CD2 promoter driven Cre expression (de Boer et al., 2003) would allow 
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deletion of Trib2 in T- and B-lymphoid cells. Other mouse lines that are of relevance 
to study of TRIB2 in T-cell development include Lck proximal promoter and Cd4 
promoter/enhancer/silencer driven Cre expression which enable disruption of gene 
at DN and DP stage respectively (Lee et al., 2001). 
 
In summary, the works presented in this thesis uncovered a previously 
unrecognized role for TRIB2 in negatively regulating the cell division kinetics of 
developing thymocytes. This is the first physiological role that we established for 
TRIB2 in steady state and stress haematopoiesis. We demonstrated that TRIB2 
regulates the homeostasis of intrathymic T-cell development at steady state. The 
anti-proliferative role of TRIB2 is crucial to control the response of thymocytes to 
genotoxic stress. We showed that, in the absence of TRIB2, proliferative 
thymocytes are sensitized to 5-FU-induced apoptosis. The anti-proliferative role of 
TRIB2 is also essential for proper recovery of thymopoiesis after genotoxic stress. 
We found that loss of TRIB2 causes expansion of c-Kit- DN1 thymic progenitors 
which in turn lead to accelerated thymopoietic recovery following 5-FU mediated 
genotoxic stress.  Next, using a NOTCH1-induced T-ALL BM transplantation model, 
we provided evidence that TRIB2 possesses tumour suppression function in T-cell 
leukaemogenesis. In the absence of TRIB2, NOTCH1 is more potent in driving T-
ALL initiation and the increased aggressiveness of Trib2-/- T-ALL was enhanced by 
impaired activation of MAPK signalling. We performed GSEA analysis to extrapolate 
the experimental findings of TRIB2 role in murine T-ALL to different molecular 
subtypes of human T-ALL. TRIB2 expression was elevated in LYL1+ immature 
human T-ALL enriched with MAPK signalling whereas its expression was 
suppressed in TLX1+ mature human T-ALL with defective MAPK signalling. Hence, 
TRIB2 could be tumour promoting or suppressing depending on the subtypes of T-
ALL and this is related to its capability to modulate MAPK signalling. The tumour 
suppressing function of TRIB2 is novel and is a paradigm shift in the definition of 
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TRIB2 function in malignant haematopoiesis. Last but not least, we showed that the 
function of Drosophila Tribbles in promoting degradation of String is evolutionarily 
conserved in TRIB2. We identified CDC25B/C as new interacting partners of TRIB2. 
We demonstrated that TRIB2 targets CDC25C for K48-linked polyubiquitination and 
degradation via nuclear proteasome. This adds another layer to how TRIB2 could 
regulate cellular proliferation.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
161 
 
Bibliography 
 
ADOLFSSON, J., MANSSON, R., BUZA-VIDAS, N., HULTQUIST, A., LIUBA, K., 
JENSEN, C. T., BRYDER, D., YANG, L., BORGE, O. J., THOREN, L. A., 
ANDERSON, K., SITNICKA, E., SASAKI, Y., SIGVARDSSON, M. & 
JACOBSEN, S. E. 2005. Identification of Flt3+ lympho-myeloid stem cells 
lacking erythro-megakaryocytic potential a revised road map for adult blood 
lineage commitment. Cell, 121, 295-306. 
AKASHI, K., TRAVER, D., MIYAMOTO, T. & WEISSMAN, I. L. 2000. A clonogenic 
common myeloid progenitor that gives rise to all myeloid lineages. Nature, 
404, 193-7. 
ALLMAN, D., KARNELL, F. G., PUNT, J. A., BAKKOUR, S., XU, L., MYUNG, P., 
KORETZKY, G. A., PUI, J. C., ASTER, J. C. & PEAR, W. S. 2001. 
Separation of Notch1 promoted lineage commitment and 
expansion/transformation in developing T cells. J Exp Med, 194, 99-106. 
ALTSCHUL, S. F., GISH, W., MILLER, W., MYERS, E. W. & LIPMAN, D. J. 1990. 
Basic local alignment search tool. J Mol Biol, 215, 403-10. 
AMANO, M., HAMAGUCHI, T., SHOHAG, M. H., KOZAWA, K., KATO, K., ZHANG, 
X., YURA, Y., MATSUURA, Y., KATAOKA, C., NISHIOKA, T. & KAIBUCHI, 
K. 2015. Kinase-interacting substrate screening is a novel method to identify 
kinase substrates. J Cell Biol, 209, 895-912. 
ANDERSEN, M. O., NYGAARD, J. V., BURNS, J. S., RAARUP, M. K., 
NYENGAARD, J. R., BUNGER, C., BESENBACHER, F., HOWARD, K. A., 
KASSEM, M. & KJEMS, J. 2010. siRNA nanoparticle functionalization of 
nanostructured scaffolds enables controlled multilineage differentiation of 
stem cells. Mol Ther, 18, 2018-27. 
162 
 
ANDERSON, G. & TAKAHAMA, Y. 2012. Thymic epithelial cells: working class 
heroes for T cell development and repertoire selection. Trends Immunol, 33, 
256-63. 
AQUINO ESPERANZA, J. A., AGUIRRE, M. V., AISPURU, G. R., LETTIERI, C. N., 
JUARISTI, J. A., ALVAREZ, M. A. & BRANDAN, N. C. 2008. In vivo 5-
fluorouracil-[corrected]induced apoptosis on murine thymocytes: 
involvement of FAS, Bax and Caspase3. Cell Biol Toxicol, 24, 411-22. 
ARBER, D. A., ORAZI, A., HASSERJIAN, R., THIELE, J., BOROWITZ, M. J., LE 
BEAU, M. M., BLOOMFIELD, C. D., CAZZOLA, M. & VARDIMAN, J. W. 
2016. The 2016 revision to the World Health Organization classification of 
myeloid neoplasms and acute leukemia. Blood, 127, 2391-405. 
ARGIROPOULOS, B., PALMQVIST, L., YUNG, E., KUCHENBAUER, F., HEUSER, 
M., SLY, L. M., WAN, A., KRYSTAL, G. & HUMPHRIES, R. K. 2008. 
Linkage of Meis1 leukemogenic activity to multiple downstream effectors 
including Trib2 and Ccl3. Exp Hematol, 36, 845-59. 
ASHWELL, J. D., LU, F. W. & VACCHIO, M. S. 2000. Glucocorticoids in T cell 
development and function*. Annu Rev Immunol, 18, 309-45. 
ASNAFI, V., BUZYN, A., THOMAS, X., HUGUET, F., VEY, N., BOIRON, J. M., 
REMAN, O., CAYUELA, J. M., LHERITIER, V., VERNANT, J. P., FIERE, D., 
MACINTYRE, E. & DOMBRET, H. 2005. Impact of TCR status and genotype 
on outcome in adult T-cell acute lymphoblastic leukemia: a LALA-94 study. 
Blood, 105, 3072-8. 
ASNAFI, V., RADFORD-WEISS, I., DASTUGUE, N., BAYLE, C., LEBOEUF, D., 
CHARRIN, C., GARAND, R., LAFAGE-POCHITALOFF, M., DELABESSE, 
E., BUZYN, A., TROUSSARD, X. & MACINTYRE, E. 2003. CALM-AF10 is a 
common fusion transcript in T-ALL and is specific to the TCRgammadelta 
lineage. Blood, 102, 1000-6. 
163 
 
ASTER, J. C., BODNAR, N., XU, L., KARNELL, F., MILHOLLAND, J. M., 
MAILLARD, I., HISTEN, G., NAM, Y., BLACKLOW, S. C. & PEAR, W. S. 
2011. Notch ankyrin repeat domain variation influences leukemogenesis and 
Myc transactivation. PLoS One, 6, e25645. 
ASTER, J. C., XU, L., KARNELL, F. G., PATRIUB, V., PUI, J. C. & PEAR, W. S. 
2000. Essential roles for ankyrin repeat and transactivation domains in 
induction of T-cell leukemia by notch1. Mol Cell Biol, 20, 7505-15. 
AWONG, G., LAMOTTE-MOHS, R. & ZUNIGA-PFLUCKER, J. C. 2010. Key players 
for T-cell regeneration. Curr Opin Hematol, 17, 327-32. 
BAILEY, F. P., BYRNE, D. P., ORUGANTY, K., EYERS, C. E., NOVOTNY, C. J., 
SHOKAT, K. M., KANNAN, N. & EYERS, P. A. 2015. The Tribbles 2 (TRB2) 
pseudokinase binds to ATP and autophosphorylates in a metal-independent 
manner. Biochem J, 467, 47-62. 
BASH, R. O., HALL, S., TIMMONS, C. F., CRIST, W. M., AMYLON, M., SMITH, R. 
G. & BAER, R. 1995. Does activation of the TAL1 gene occur in a majority of 
patients with T-cell acute lymphoblastic leukemia? A pediatric oncology 
group study. Blood, 86, 666-76. 
BEERMAN, I., BOCK, C., GARRISON, B. S., SMITH, Z. D., GU, H., MEISSNER, A. 
& ROSSI, D. J. 2013. Proliferation-dependent alterations of the DNA 
methylation landscape underlie hematopoietic stem cell aging. Cell Stem 
Cell, 12, 413-25. 
BEGLEY, C. G., APLAN, P. D., DAVEY, M. P., NAKAHARA, K., TCHORZ, K., 
KURTZBERG, J., HERSHFIELD, M. S., HAYNES, B. F., COHEN, D. I., 
WALDMANN, T. A. & ET AL. 1989. Chromosomal translocation in a human 
leukemic stem-cell line disrupts the T-cell antigen receptor delta-chain 
diversity region and results in a previously unreported fusion transcript. Proc 
Natl Acad Sci U S A, 86, 2031-5. 
164 
 
BENNETT, J. M., CATOVSKY, D., DANIEL, M. T., FLANDRIN, G., GALTON, D. A., 
GRALNICK, H. R. & SULTAN, C. 1991. Proposal for the recognition of 
minimally differentiated acute myeloid leukaemia (AML-MO). Br J Haematol, 
78, 325-9. 
BENZ, C. & BLEUL, C. C. 2005. A multipotent precursor in the thymus maps to the 
branching point of the T versus B lineage decision. J Exp Med, 202, 21-31. 
BENZ, C., MARTINS, V. C., RADTKE, F. & BLEUL, C. C. 2008. The stream of 
precursors that colonizes the thymus proceeds selectively through the early 
T lineage precursor stage of T cell development. J Exp Med, 205, 1187-99. 
BERGER, R., DASTUGUE, N., BUSSON, M., VAN DEN AKKER, J., PEROT, C., 
BALLERINI, P., HAGEMEIJER, A., MICHAUX, L., CHARRIN, C., PAGES, 
M. P., MUGNERET, F., ANDRIEUX, J., TALMANT, P., HELIAS, C., 
MAUVIEUX, L., LAFAGE-POCHITALOFF, M., MOZZICONACCI, M. J., 
CORNILLET-LEFEBVRE, P., RADFORD, I., ASNAFI, V., BILHOU-NABERA, 
C., NGUYEN KHAC, F., LEONARD, C., SPELEMAN, F., POPPE, B., 
BASTARD, C., TAVIAUX, S., QUILICHINI, B., HERENS, C., GREGOIRE, M. 
J., CAVE, H., BERNARD, O. A. & GROUPE FRANCAIS DE 
CYTOGENETIQUE, H. 2003. t(5;14)/HOX11L2-positive T-cell acute 
lymphoblastic leukemia. A collaborative study of the Groupe Francais de 
Cytogenetique Hematologique (GFCH). Leukemia, 17, 1851-7. 
BERGERON, J., CLAPPIER, E., RADFORD, I., BUZYN, A., MILLIEN, C., SOLER, 
G., BALLERINI, P., THOMAS, X., SOULIER, J., DOMBRET, H., 
MACINTYRE, E. A. & ASNAFI, V. 2007. Prognostic and oncogenic 
relevance of TLX1/HOX11 expression level in T-ALLs. Blood, 110, 2324-30. 
BERKOWITZ, R. D., BECKERMAN, K. P., SCHALL, T. J. & MCCUNE, J. M. 1998. 
CXCR4 and CCR5 expression delineates targets for HIV-1 disruption of T 
cell differentiation. J Immunol, 161, 3702-10. 
165 
 
BERZINS, S. P., BOYD, R. L. & MILLER, J. F. 1998. The role of the thymus and 
recent thymic migrants in the maintenance of the adult peripheral 
lymphocyte pool. J Exp Med, 187, 1839-48. 
BHANDOOLA, A. & SAMBANDAM, A. 2006. From stem cell to T cell: one route or 
many? Nat Rev Immunol, 6, 117-26. 
BLOMBERG, I. & HOFFMANN, I. 1999. Ectopic expression of Cdc25A accelerates 
the G(1)/S transition and leads to premature activation of cyclin E- and cyclin 
A-dependent kinases. Mol Cell Biol, 19, 6183-94. 
BOEHM, T. & SWANN, J. B. 2013. Thymus involution and regeneration: two sides 
of the same coin? Nat Rev Immunol, 13, 831-8. 
BOETTCHER, S., ZIEGLER, P., SCHMID, M. A., TAKIZAWA, H., VAN ROOIJEN, 
N., KOPF, M., HEIKENWALDER, M. & MANZ, M. G. 2012. Cutting edge: 
LPS-induced emergency myelopoiesis depends on TLR4-expressing 
nonhematopoietic cells. J Immunol, 188, 5824-8. 
BORGES, M., BARREIRA-SILVA, P., FLORIDO, M., JORDAN, M. B., CORREIA-
NEVES, M. & APPELBERG, R. 2012. Molecular and cellular mechanisms of 
Mycobacterium avium-induced thymic atrophy. J Immunol, 189, 3600-8. 
BOUTROS, R., LOBJOIS, V. & DUCOMMUN, B. 2007. CDC25 phosphatases in 
cancer cells: key players? Good targets? Nat Rev Cancer, 7, 495-507. 
BOWERS, A. J., SCULLY, S. & BOYLAN, J. F. 2003. SKIP3, a novel Drosophila 
tribbles ortholog, is overexpressed in human tumors and is regulated by 
hypoxia. Oncogene, 22, 2823-35. 
BREKELMANS, P., VAN SOEST, P., VOERMAN, J., PLATENBURG, P. P., 
LEENEN, P. J. & VAN EWIJK, W. 1994. Transferrin receptor expression as 
a marker of immature cycling thymocytes in the mouse. Cell Immunol, 159, 
331-9. 
166 
 
BRENET, F., KERMANI, P., SPEKTOR, R., RAFII, S. & SCANDURA, J. M. 2013. 
TGFbeta restores hematopoietic homeostasis after myelosuppressive 
chemotherapy. J Exp Med, 210, 623-39. 
BRENNER, A. K., REIKVAM, H., LAVECCHIA, A. & BRUSERUD, O. 2014. 
Therapeutic targeting the cell division cycle 25 (CDC25) phosphatases in 
human acute myeloid leukemia--the possibility to target several kinases 
through inhibition of the various CDC25 isoforms. Molecules, 19, 18414-47. 
BROWN, L., CHENG, J. T., CHEN, Q., SICILIANO, M. J., CRIST, W., BUCHANAN, 
G. & BAER, R. 1990. Site-specific recombination of the tal-1 gene is a 
common occurrence in human T cell leukemia. EMBO J, 9, 3343-51. 
BYEON, I. J., LI, H., SONG, H., GRONENBORN, A. M. & TSAI, M. D. 2005. 
Sequential phosphorylation and multisite interactions characterize specific 
target recognition by the FHA domain of Ki67. Nat Struct Mol Biol, 12, 987-
93. 
CABEZAS-WALLSCHEID, N. & TRUMPP, A. 2016. STEM CELLS. Potency finds its 
niches. Science, 351, 126-7. 
CARLSON, K. M., VIGNON, C., BOHLANDER, S., MARTINEZ-CLIMENT, J. A., LE 
BEAU, M. M. & ROWLEY, J. D. 2000. Identification and molecular 
characterization of CALM/AF10fusion products in T cell acute lymphoblastic 
leukemia and acute myeloid leukemia. Leukemia, 14, 100-4. 
CARPENTER, A. C. & BOSSELUT, R. 2010. Decision checkpoints in the thymus. 
Nat Immunol, 11, 666-73. 
CARROLL, A. J., CRIST, W. M., LINK, M. P., AMYLON, M. D., PULLEN, D. J., 
RAGAB, A. H., BUCHANAN, G. R., WIMMER, R. S. & VIETTI, T. J. 1990. 
The t(1;14)(p34;q11) is nonrandom and restricted to T-cell acute 
lymphoblastic leukemia: a Pediatric Oncology Group study. Blood, 76, 1220-
4. 
167 
 
CASERO, D., SANDOVAL, S., SEET, C. S., SCHOLES, J., ZHU, Y., HA, V. L., 
LUONG, A., PAREKH, C. & CROOKS, G. M. 2015. Long non-coding RNA 
profiling of human lymphoid progenitor cells reveals transcriptional 
divergence of B cell and T cell lineages. Nat Immunol, 16, 1282-91. 
CAUWELIER, B., CAVE, H., GERVAIS, C., LESSARD, M., BARIN, C., PEROT, C., 
VAN DEN AKKER, J., MUGNERET, F., CHARRIN, C., PAGES, M. P., 
GREGOIRE, M. J., JONVEAUX, P., LAFAGE-POCHITALOFF, M., 
MOZZICCONACCI, M. J., TERRE, C., LUQUET, I., CORNILLET-
LEFEBVRE, P., LAURENCE, B., PLESSIS, G., LEFEBVRE, C., LEROUX, 
D., ANTOINE-POIREL, H., GRAUX, C., MAUVIEUX, L., HEIMANN, P., 
CHALAS, C., CLAPPIER, E., VERHASSELT, B., BENOIT, Y., 
MOERLOOSE, B. D., POPPE, B., VAN ROY, N., KEERSMAECKER, K. D., 
COOLS, J., SIGAUX, F., SOULIER, J., HAGEMEIJER, A., PAEPE, A. D., 
DASTUGUE, N., BERGER, R. & SPELEMAN, F. 2007. Clinical, cytogenetic 
and molecular characteristics of 14 T-ALL patients carrying the TCRbeta-
HOXA rearrangement: a study of the Groupe Francophone de 
Cytogenetique Hematologique. Leukemia, 21, 121-8. 
CHAMPHEKAR, A., DAMLE, S. S., FREEDMAN, G., CAROTTA, S., NUTT, S. L. & 
ROTHENBERG, E. V. 2015. Regulation of early T-lineage gene expression 
and developmental progression by the progenitor cell transcription factor 
PU.1. Genes Dev, 29, 832-48. 
CHAUDHURY, S. S., MORISON, J. K., GIBSON, B. E. & KEESHAN, K. 2015. 
Insights into cell ontogeny, age, and acute myeloid leukemia. Exp Hematol, 
43, 745-55. 
CHEN, F., ZHANG, Z., BOWER, J., LU, Y., LEONARD, S. S., DING, M., 
CASTRANOVA, V., PIWNICA-WORMS, H. & SHI, X. 2002. Arsenite-
induced Cdc25C degradation is through the KEN-box and ubiquitin–
168 
 
proteasome pathway. Proceedings of the National Academy of Sciences, 
99, 1990-1995. 
CHEN, M. S., HUROV, J., WHITE, L. S., WOODFORD-THOMAS, T. & PIWNICA-
WORMS, H. 2001. Absence of apparent phenotype in mice lacking Cdc25C 
protein phosphatase. Mol Cell Biol, 21, 3853-61. 
CHEN, Q., CHENG, J. T., TASI, L. H., SCHNEIDER, N., BUCHANAN, G., 
CARROLL, A., CRIST, W., OZANNE, B., SICILIANO, M. J. & BAER, R. 
1990. The tal gene undergoes chromosome translocation in T cell leukemia 
and potentially encodes a helix-loop-helix protein. EMBO J, 9, 415-24. 
CHIANG, M. Y., XU, M. L., HISTEN, G., SHESTOVA, O., ROY, M., NAM, Y., 
BLACKLOW, S. C., SACKS, D. B., PEAR, W. S. & ASTER, J. C. 2006. 
Identification of a conserved negative regulatory sequence that influences 
the leukemogenic activity of NOTCH1. Mol Cell Biol, 26, 6261-71. 
CIMINO, G., SPROVIERI, T., RAPANOTTI, M. C., FOA, R., MECUCCI, C. & 
MANDELLI, F. 2001. Molecular evaluation of the NUP98/RAP1GDS1 gene 
frequency in adults with T-acute lymphoblastic leukemia. Haematologica, 86, 
436-7. 
CLAPPIER, E., CUCCUINI, W., CAYUELA, J. M., VECCHIONE, D., BARUCHEL, 
A., DOMBRET, H., SIGAUX, F. & SOULIER, J. 2006. Cyclin D2 
dysregulation by chromosomal translocations to TCR loci in T-cell acute 
lymphoblastic leukemias. Leukemia, 20, 82-6. 
CLEARY, M. L., MELLENTIN, J. D., SPIES, J. & SMITH, S. D. 1988. Chromosomal 
translocation involving the beta T cell receptor gene in acute leukemia. J 
Exp Med, 167, 682-7. 
COBALEDA, C., JOCHUM, W. & BUSSLINGER, M. 2007. Conversion of mature B 
cells into T cells by dedifferentiation to uncommitted progenitors. Nature, 
449, 473-7. 
169 
 
CREUTZIG, U., VAN DEN HEUVEL-EIBRINK, M. M., GIBSON, B., DWORZAK, M. 
N., ADACHI, S., DE BONT, E., HARBOTT, J., HASLE, H., JOHNSTON, D., 
KINOSHITA, A., LEHRNBECHER, T., LEVERGER, G., MEJSTRIKOVA, E., 
MESHINCHI, S., PESSION, A., RAIMONDI, S. C., SUNG, L., STARY, J., 
ZWAAN, C. M., KASPERS, G. J. & REINHARDT, D. 2012. Diagnosis and 
management of acute myeloid leukemia in children and adolescents: 
recommendations from an international expert panel. Blood, 120, 3187-205. 
CVETKOVIC-LOPES, V., BAYER, L., DORSAZ, S., MARET, S., PRADERVAND, 
S., DAUVILLIERS, Y., LECENDREUX, M., LAMMERS, G. J., DONJACOUR, 
C. E., DU PASQUIER, R. A., PFISTER, C., PETIT, B., HOR, H., 
MUHLETHALER, M. & TAFTI, M. 2010. Elevated Tribbles homolog 2-
specific antibody levels in narcolepsy patients. J Clin Invest, 120, 713-9. 
D'ANGIO, M., VALSECCHI, M. G., TESTI, A. M., CONTER, V., NUNES, V., 
PARASOLE, R., COLOMBINI, A., SANTORO, N., VAROTTO, S., 
CANIGLIA, M., SILVESTRI, D., CONSARINO, C., LEVATI, L., MAGRIN, E., 
LOCATELLI, F., BASSO, G., FOA, R., BIONDI, A. & CAZZANIGA, G. 2015. 
Clinical features and outcome of SIL/TAL1-positive T-cell acute 
lymphoblastic leukemia in children and adolescents: a 10-year experience of 
the AIEOP group. Haematologica, 100, e10-3. 
DAIL, M., LI, Q., MCDANIEL, A., WONG, J., AKAGI, K., HUANG, B., KANG, H. C., 
KOGAN, S. C., SHOKAT, K., WOLFF, L., BRAUN, B. S. & SHANNON, K. 
2010. Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage 
leukemogenesis and modulate responses to targeted agents. Proc Natl 
Acad Sci U S A, 107, 5106-11. 
DANIELS, M. A., TEIXEIRO, E., GILL, J., HAUSMANN, B., ROUBATY, D., 
HOLMBERG, K., WERLEN, G., HOLLANDER, G. A., GASCOIGNE, N. R. & 
PALMER, E. 2006. Thymic selection threshold defined by 
compartmentalization of Ras/MAPK signalling. Nature, 444, 724-9. 
170 
 
DE BOER, J., WILLIAMS, A., SKAVDIS, G., HARKER, N., COLES, M., TOLAINI, 
M., NORTON, T., WILLIAMS, K., RODERICK, K., POTOCNIK, A. J. & 
KIOUSSIS, D. 2003. Transgenic mice with hematopoietic and lymphoid 
specific expression of Cre. Eur J Immunol, 33, 314-25. 
DE KEERSMAECKER, K., GRAUX, C., ODERO, M. D., MENTENS, N., SOMERS, 
R., MAERTENS, J., WLODARSKA, I., VANDENBERGHE, P., 
HAGEMEIJER, A., MARYNEN, P. & COOLS, J. 2005. Fusion of EML1 to 
ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32). 
Blood, 105, 4849-52. 
DEDHIA, P. H., KEESHAN, K., ULJON, S., XU, L., VEGA, M. E., SHESTOVA, O., 
ZAKS-ZILBERMAN, M., ROMANY, C., BLACKLOW, S. C. & PEAR, W. S. 
2010. Differential ability of Tribbles family members to promote degradation 
of C/EBPalpha and induce acute myelogenous leukemia. Blood, 116, 1321-
8. 
DEL REAL, M. M. & ROTHENBERG, E. V. 2013. Architecture of a lymphomyeloid 
developmental switch controlled by PU.1, Notch and Gata3. Development, 
140, 1207-19. 
DIEHL, N. L., ENSLEN, H., FORTNER, K. A., MERRITT, C., STETSON, N., 
CHARLAND, C., FLAVELL, R. A., DAVIS, R. J. & RINCON, M. 2000. 
Activation of the p38 mitogen-activated protein kinase pathway arrests cell 
cycle progression and differentiation of immature thymocytes in vivo. J Exp 
Med, 191, 321-34. 
DUBE, I. D., KAMEL-REID, S., YUAN, C. C., LU, M., WU, X., CORPUS, G., 
RAIMONDI, S. C., CRIST, W. M., CARROLL, A. J., MINOWADA, J. & ET 
AL. 1991. A novel human homeobox gene lies at the chromosome 10 
breakpoint in lymphoid neoplasias with chromosomal translocation t(10;14). 
Blood, 78, 2996-3003. 
171 
 
DURINCK, K., GOOSSENS, S., PEIRS, S., WALLAERT, A., VAN LOOCKE, W., 
MATTHIJSSENS, F., PIETERS, T., MILANI, G., LAMMENS, T., RONDOU, 
P., VAN ROY, N., DE MOERLOOSE, B., BENOIT, Y., HAIGH, J., 
SPELEMAN, F., POPPE, B. & VAN VLIERBERGHE, P. 2015. Novel 
biological insights in T-cell acute lymphoblastic leukemia. Exp Hematol. 
EDER, K., GUAN, H., SUNG, H. Y., FRANCIS, S. E., CROSSMAN, D. C. & KISS-
TOTH, E. 2008a. LDL uptake by monocytes in response to inflammation is 
MAPK dependent but independent of tribbles protein expression. Immunol 
Lett, 116, 178-83. 
EDER, K., GUAN, H., SUNG, H. Y., WARD, J., ANGYAL, A., JANAS, M., SARMAY, 
G., DUDA, E., TURNER, M., DOWER, S. K., FRANCIS, S. E., CROSSMAN, 
D. C. & KISS-TOTH, E. 2008b. Tribbles-2 is a novel regulator of 
inflammatory activation of monocytes. Int Immunol, 20, 1543-50. 
EDGAR, B. A. & O'FARRELL, P. H. 1990. The three postblastoderm cell cycles of 
Drosophila embryogenesis are regulated in G2 by string. Cell, 62, 469-80. 
EICHHORST, S. T., MUERKOSTER, S., WEIGAND, M. A. & KRAMMER, P. H. 
2001. The chemotherapeutic drug 5-fluorouracil induces apoptosis in mouse 
thymocytes in vivo via activation of the CD95(APO-1/Fas) system. Cancer 
Res, 61, 243-8. 
ELLISEN, L. W., BIRD, J., WEST, D. C., SORENG, A. L., REYNOLDS, T. C., 
SMITH, S. D. & SKLAR, J. 1991. TAN-1, the human homolog of the 
Drosophila notch gene, is broken by chromosomal translocations in T 
lymphoblastic neoplasms. Cell, 66, 649-61. 
ERIKSON, J., FINGER, L., SUN, L., AR-RUSHDI, A., NISHIKURA, K., MINOWADA, 
J., FINAN, J., EMANUEL, B. S., NOWELL, P. C. & CROCE, C. M. 1986. 
Deregulation of c-myc by translocation of the alpha-locus of the T-cell 
receptor in T-cell leukemias. Science, 232, 884-6. 
172 
 
EYMIN, B., CLAVERIE, P., SALON, C., BRAMBILLA, C., BRAMBILLA, E. & 
GAZZERI, S. 2006. p14ARF Triggers G2 Arrest Through ERK-Mediated 
Cdc25C Phosphorylation, Ubiquitination and Proteasomal Degradation. Cell 
Cycle, 5, 759-765. 
FALINI, B., MECUCCI, C., TIACCI, E., ALCALAY, M., ROSATI, R., 
PASQUALUCCI, L., LA STARZA, R., DIVERIO, D., COLOMBO, E., 
SANTUCCI, A., BIGERNA, B., PACINI, R., PUCCIARINI, A., LISO, A., 
VIGNETTI, M., FAZI, P., MEANI, N., PETTIROSSI, V., SAGLIO, G., 
MANDELLI, F., LO-COCO, F., PELICCI, P. G. & MARTELLI, M. F. 2005. 
Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal 
karyotype. N Engl J Med, 352, 254-66. 
FERGUSON, A. M., WHITE, L. S., DONOVAN, P. J. & PIWNICA-WORMS, H. 2005. 
Normal cell cycle and checkpoint responses in mice and cells lacking 
Cdc25B and Cdc25C protein phosphatases. Mol Cell Biol, 25, 2853-60. 
FERNANDEZ, E. 2000. Thymocyte development past the CD4(+)CD8(+) stage 
requires an active p38 mitogen-activated protein kinase. Blood, 95, 1356-61. 
FERRANDO, A. A., HERBLOT, S., PALOMERO, T., HANSEN, M., HOANG, T., 
FOX, E. A. & LOOK, A. T. 2004. Biallelic transcriptional activation of 
oncogenic transcription factors in T-cell acute lymphoblastic leukemia. 
Blood, 103, 1909-11. 
FERRANDO, A. A., NEUBERG, D. S., STAUNTON, J., LOH, M. L., HUARD, C., 
RAIMONDI, S. C., BEHM, F. G., PUI, C. H., DOWNING, J. R., GILLILAND, 
D. G., LANDER, E. S., GOLUB, T. R. & LOOK, A. T. 2002. Gene expression 
signatures define novel oncogenic pathways in T cell acute lymphoblastic 
leukemia. Cancer Cell, 1, 75-87. 
FINGER, L. R., HARVEY, R. C., MOORE, R. C., SHOWE, L. C. & CROCE, C. M. 
1986. A common mechanism of chromosomal translocation in T- and B-cell 
neoplasia. Science, 234, 982-5. 
173 
 
FISCHER, A. M., KATAYAMA, C. D., PAGES, G., POUYSSEGUR, J. & HEDRICK, 
S. M. 2005. The role of erk1 and erk2 in multiple stages of T cell 
development. Immunity, 23, 431-43. 
FLACH, J., BAKKER, S. T., MOHRIN, M., CONROY, P. C., PIETRAS, E. M., 
REYNAUD, D., ALVAREZ, S., DIOLAITI, M. E., UGARTE, F., FORSBERG, 
E. C., LE BEAU, M. M., STOHR, B. A., MENDEZ, J., MORRISON, C. G. & 
PASSEGUE, E. 2014. Replication stress is a potent driver of functional 
decline in ageing haematopoietic stem cells. Nature, 512, 198-202. 
FOUDI, A., HOCHEDLINGER, K., VAN BUREN, D., SCHINDLER, J. W., 
JAENISCH, R., CAREY, V. & HOCK, H. 2009. Analysis of histone 2B-GFP 
retention reveals slowly cycling hematopoietic stem cells. Nat Biotechnol, 
27, 84-90. 
FOX, C. S., WHITE, C. C., LOHMAN, K., HEARD-COSTA, N., COHEN, P., ZHANG, 
Y., JOHNSON, A. D., EMILSSON, V., LIU, C. T., CHEN, Y. D., TAYLOR, K. 
D., ALLISON, M., BUDOFF, M., ROTTER, J. I., CARR, J. J., HOFFMANN, 
U., DING, J., CUPPLES, L. A. & LIU, Y. 2012. Genome-wide association of 
pericardial fat identifies a unique locus for ectopic fat. PLoS Genet, 8, 
e1002705. 
FRANCO, C. B., SCRIPTURE-ADAMS, D. D., PROEKT, I., TAGHON, T., WEISS, 
A. H., YUI, M. A., ADAMS, S. L., DIAMOND, R. A. & ROTHENBERG, E. V. 
2006. Notch/Delta signaling constrains reengineering of pro-T cells by PU.1. 
Proc Natl Acad Sci U S A, 103, 11993-8. 
FREIREICH, E. J., WIERNIK, P. H. & STEENSMA, D. P. 2014. The leukemias: a 
half-century of discovery. J Clin Oncol, 32, 3463-9. 
FREY, J. R., ERNST, B., SURH, C. D. & SPRENT, J. 1992. Thymus-grafted SCID 
mice show transient thymopoiesis and limited depletion of V beta 11+ T 
cells. J Exp Med, 175, 1067-71. 
174 
 
GABRIELLI, B. G., DE SOUZA, C. P., TONKS, I. D., CLARK, J. M., HAYWARD, N. 
K. & ELLEM, K. A. 1996. Cytoplasmic accumulation of cdc25B phosphatase 
in mitosis triggers centrosomal microtubule nucleation in HeLa cells. J Cell 
Sci, 109 ( Pt 5), 1081-93. 
GARCIA-CUELLAR, M. P., STEGER, J., FULLER, E., HETZNER, K. & SLANY, R. 
K. 2015. Pbx3 and Meis1 cooperate through multiple mechanisms to support 
Hox-induced murine leukemia. Haematologica, 100, 905-13. 
GE, J., LIU, Y., LI, Q., GUO, X., GU, L., MA, Z. G. & ZHU, Y. P. 2013. Resveratrol 
induces apoptosis and autophagy in T-cell acute lymphoblastic leukemia 
cells by inhibiting Akt/mTOR and activating p38-MAPK. Biomed Environ Sci, 
26, 902-11. 
GILBY, D. C., SUNG, H. Y., WINSHIP, P. R., GOODEVE, A. C., REILLY, J. T. & 
KISS-TOTH, E. 2010. Tribbles-1 and-2 are tumour suppressors, down-
regulated in human acute myeloid leukaemia. Immunology Letters, 130, 
115-124. 
GLATMAN ZARETSKY, A., ENGILES, J. B. & HUNTER, C. A. 2014. Infection-
induced changes in hematopoiesis. J Immunol, 192, 27-33. 
GODFREY, D. I., KENNEDY, J., SUDA, T. & ZLOTNIK, A. 1993. A developmental 
pathway involving four phenotypically and functionally distinct subsets of 
CD3-CD4-CD8- triple-negative adult mouse thymocytes defined by CD44 
and CD25 expression. J Immunol, 150, 4244-52. 
GOUNARI, F., AIFANTIS, I., MARTIN, C., FEHLING, H. J., HOEFLINGER, S., 
LEDER, P., VON BOEHMER, H. & REIZIS, B. 2002. Tracing lymphopoiesis 
with the aid of a pTalpha-controlled reporter gene. Nat Immunol, 3, 489-96. 
GRABHER, C., VON BOEHMER, H. & LOOK, A. T. 2006. Notch 1 activation in the 
molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat Rev 
Cancer, 6, 347-59. 
175 
 
GRANDINETTI, K. B., STEVENS, T. A., HA, S., SALAMONE, R. J., WALKER, J. R., 
ZHANG, J., AGARWALLA, S., TENEN, D. G., PETERS, E. C. & REDDY, V. 
A. 2011. Overexpression of TRIB2 in human lung cancers contributes to 
tumorigenesis through downregulation of C/EBPalpha. Oncogene, 30, 3328-
35. 
GRAUX, C., COOLS, J., MELOTTE, C., QUENTMEIER, H., FERRANDO, A., 
LEVINE, R., VERMEESCH, J. R., STUL, M., DUTTA, B., BOECKX, N., 
BOSLY, A., HEIMANN, P., UYTTEBROECK, A., MENTENS, N., SOMERS, 
R., MACLEOD, R. A., DREXLER, H. G., LOOK, A. T., GILLILAND, D. G., 
MICHAUX, L., VANDENBERGHE, P., WLODARSKA, I., MARYNEN, P. & 
HAGEMEIJER, A. 2004. Fusion of NUP214 to ABL1 on amplified episomes 
in T-cell acute lymphoblastic leukemia. Nat Genet, 36, 1084-9. 
GRAUX, C., COOLS, J., MICHAUX, L., VANDENBERGHE, P. & HAGEMEIJER, A. 
2006. Cytogenetics and molecular genetics of T-cell acute lymphoblastic 
leukemia: from thymocyte to lymphoblast. Leukemia, 20, 1496-510. 
GREENBERG, J. M., BOEHM, T., SOFRONIEW, M. V., KEYNES, R. J., BARTON, 
S. C., NORRIS, M. L., SURANI, M. A., SPILLANTINI, M. G. & RABBITTS, T. 
H. 1990. Segmental and developmental regulation of a presumptive T-cell 
oncogene in the central nervous system. Nature, 344, 158-60. 
GREGORJ, C., RICCIARDI, M. R., PETRUCCI, M. T., SCERPA, M. C., DE CAVE, 
F., FAZI, P., VIGNETTI, M., VITALE, A., MANCINI, M., CIMINO, G., 
PALMIERI, S., DI RAIMONDO, F., SPECCHIA, G., FABBIANO, F., 
CANTORE, N., MOSNA, F., CAMERA, A., LUPPI, M., ANNINO, L., 
MIRAGLIA, E., FIORITONI, G., RONCO, F., MELONI, G., MANDELLI, F., 
ANDREEFF, M., MILELLA, M., FOA, R., TAFURI, A. & PARTY, G. A. L. W. 
2007. ERK1/2 phosphorylation is an independent predictor of complete 
remission in newly diagnosed adult acute lymphoblastic leukemia. Blood, 
109, 5473-6. 
176 
 
GRIMWADE, D., IVEY, A. & HUNTLY, B. J. 2016. Molecular landscape of acute 
myeloid leukemia in younger adults and its clinical relevance. Blood, 127, 
29-41. 
GROSSHANS, J. & WIESCHAUS, E. 2000. A genetic link between morphogenesis 
and cell division during formation of the ventral furrow in Drosophila. Cell, 
101, 523-31. 
GUTIERREZ, G. J., TSUJI, T., CROSS, J. V., DAVIS, R. J., TEMPLETON, D. J., 
JIANG, W. & RONAI, Z. A. 2010. JNK-mediated phosphorylation of Cdc25C 
regulates cell cycle entry and G(2)/M DNA damage checkpoint. J Biol Chem, 
285, 14217-28. 
HAAS, S., HANSSON, J., KLIMMECK, D., LOEFFLER, D., VELTEN, L., 
UCKELMANN, H., WURZER, S., PRENDERGAST, A. M., SCHNELL, A., 
HEXEL, K., SANTARELLA-MELLWIG, R., BLASZKIEWICZ, S., KUCK, A., 
GEIGER, H., MILSOM, M. D., STEINMETZ, L. M., SCHROEDER, T., 
TRUMPP, A., KRIJGSVELD, J. & ESSERS, M. A. 2015. Inflammation-
Induced Emergency Megakaryopoiesis Driven by Hematopoietic Stem Cell-
like Megakaryocyte Progenitors. Cell Stem Cell, 17, 422-34. 
HAFERLACH, T., KOHLMANN, A., WIECZOREK, L., BASSO, G., KRONNIE, G. T., 
BENE, M. C., DE VOS, J., HERNANDEZ, J. M., HOFMANN, W. K., MILLS, 
K. I., GILKES, A., CHIARETTI, S., SHURTLEFF, S. A., KIPPS, T. J., 
RASSENTI, L. Z., YEOH, A. E., PAPENHAUSEN, P. R., LIU, W. M., 
WILLIAMS, P. M. & FOA, R. 2010. Clinical utility of microarray-based gene 
expression profiling in the diagnosis and subclassification of leukemia: report 
from the International Microarray Innovations in Leukemia Study Group. J 
Clin Oncol, 28, 2529-37. 
HAGEMEIJER, A. & GRAUX, C. 2010. ABL1 rearrangements in T-cell acute 
lymphoblastic leukemia. Genes Chromosomes Cancer, 49, 299-308. 
177 
 
HANAHAN, D. & WEINBERG, R. A. 2011. Hallmarks of cancer: the next generation. 
Cell, 144, 646-74. 
HANNON, M. M., LOHAN, F., ERBILGIN, Y., SAYITOGLU, M., O'HAGAN, K., 
MILLS, K., OZBEK, U. & KEESHAN, K. 2012. Elevated TRIB2 with NOTCH1 
activation in paediatric/adult T-ALL. Br J Haematol, 158, 626-34. 
HANSEN-HAGGE, T. E., SCHAFER, M., KIYOI, H., MORRIS, S. W., WHITLOCK, 
J. A., KOCH, P., BOHLMANN, I., MAHOTKA, C., BARTRAM, C. R. & 
JANSSEN, J. W. 2002. Disruption of the RanBP17/Hox11L2 region by 
recombination with the TCRdelta locus in acute lymphoblastic leukemias 
with t(5;14)(q34;q11). Leukemia, 16, 2205-12. 
HARRISON, D. E. & LERNER, C. P. 1991. Most primitive hematopoietic stem cells 
are stimulated to cycle rapidly after treatment with 5-fluorouracil. Blood, 78, 
1237-40. 
HATANO, M., ROBERTS, C. W., MINDEN, M., CRIST, W. M. & KORSMEYER, S. 
J. 1991. Deregulation of a homeobox gene, HOX11, by the t(10;14) in T cell 
leukemia. Science, 253, 79-82. 
HEBESTREIT, K., GROTTRUP, S., EMDEN, D., VEERKAMP, J., RUCKERT, C., 
KLEIN, H. U., MULLER-TIDOW, C. & DUGAS, M. 2012. Leukemia gene 
atlas--a public platform for integrative exploration of genome-wide molecular 
data. PLoS One, 7, e39148. 
HENG, T. S., GOLDBERG, G. L., GRAY, D. H., SUTHERLAND, J. S., CHIDGEY, A. 
P. & BOYD, R. L. 2005. Effects of castration on thymocyte development in 
two different models of thymic involution. J Immunol, 175, 2982-93. 
HILL, R., KALATHUR, R. K., COLACO, L., BRANDAO, R., UGUREL, S., 
FUTSCHIK, M. & LINK, W. 2015. TRIB2 as a biomarker for diagnosis and 
progression of melanoma. Carcinogenesis, 36, 469-77. 
HOFFMAN, E. S., PASSONI, L., CROMPTON, T., LEU, T. M., SCHATZ, D. G., 
KOFF, A., OWEN, M. J. & HAYDAY, A. C. 1996. Productive T-cell receptor 
178 
 
beta-chain gene rearrangement: coincident regulation of cell cycle and 
clonality during development in vivo. Genes & Development, 10, 948-962. 
HOFFMANN, I., DRAETTA, G. & KARSENTI, E. 1994. Activation of the 
phosphatase activity of human cdc25A by a cdk2-cyclin E dependent 
phosphorylation at the G1/S transition. EMBO J, 13, 4302-10. 
HOMMINGA, I., VUERHARD, M. J., LANGERAK, A. W., BUIJS-GLADDINES, J., 
PIETERS, R. & MEIJERINK, J. P. 2012. Characterization of a pediatric T-
cell acute lymphoblastic leukemia patient with simultaneous LYL1 and LMO2 
rearrangements. Haematologica, 97, 258-61. 
HUSSEY, D. J., NICOLA, M., MOORE, S., PETERS, G. B. & DOBROVIC, A. 1999. 
The (4;11)(q21;p15) translocation fuses the NUP98 and RAP1GDS1 genes 
and is recurrent in T-cell acute lymphocytic leukemia. Blood, 94, 2072-9. 
ISLAM, Z., NAGASE, M., YOSHIZAWA, T., YAMAUCHI, K. & SAKATO, N. 1998. T-
2 toxin induces thymic apoptosis in vivo in mice. Toxicol Appl Pharmacol, 
148, 205-14. 
IZRAILIT, J., BERMAN, H. K., DATTI, A., WRANA, J. L. & REEDIJK, M. 2013. High 
throughput kinase inhibitor screens reveal TRB3 and MAPK-ERK/TGFbeta 
pathways as fundamental Notch regulators in breast cancer. Proc Natl Acad 
Sci U S A, 110, 1714-9. 
JIANG, Q., LI, F., SHI, K., WU, P., AN, J., YANG, Y. & XU, C. 2013. ATF4 activation 
by the p38MAPK-eIF4E axis mediates apoptosis and autophagy induced by 
selenite in Jurkat cells. FEBS Lett, 587, 2420-9. 
KATZAV, A., ARANGO, M. T., KIVITY, S., TANAKA, S., GIVATY, G., AGMON-
LEVIN, N., HONDA, M., ANAYA, J. M., CHAPMAN, J. & SHOENFELD, Y. 
2013. Passive transfer of narcolepsy: anti-TRIB2 autoantibody positive 
patient IgG causes hypothalamic orexin neuron loss and sleep attacks in 
mice. J Autoimmun, 45, 24-30. 
179 
 
KAWAKAMI, M., TSUTSUMI, H., KUMAKAWA, T., ABE, H., HIRAI, M., 
KUROSAWA, S., MORI, M. & FUKUSHIMA, M. 1990. Levels of serum 
granulocyte colony-stimulating factor in patients with infections. Blood, 76, 
1962-4. 
KAWASHIMA, M., LIN, L., TANAKA, S., JENNUM, P., KNUDSEN, S., 
NEVSIMALOVA, S., PLAZZI, G. & MIGNOT, E. 2010. Anti-Tribbles homolog 
2 (TRIB2) autoantibodies in narcolepsy are associated with recent onset of 
cataplexy. Sleep, 33, 869-74. 
KEESHAN, K., BAILIS, W., DEDHIA, P. H., VEGA, M. E., SHESTOVA, O., XU, L. 
W., TOSCANO, K., ULJON, S. N., BLACKLOW, S. C. & PEAR, W. S. 2010. 
Transformation by Tribbles homolog 2 (Trib2) requires both the Trib2 kinase 
domain and COP1 binding. Blood, 116, 4948-4957. 
KEESHAN, K., HE, Y., WOUTERS, B. J., SHESTOVA, O., XU, L., SAI, H., 
RODRIGUEZ, C. G., MAILLARD, I., TOBIAS, J. W., VALK, P., CARROLL, 
M., ASTER, J. C., DELWEL, R. & PEAR, W. S. 2006. Tribbles homolog 2 
inactivates C/EBPalpha and causes acute myelogenous leukemia. Cancer 
Cell, 10, 401-11. 
KEESHAN, K., SHESTOVA, O., USSIN, L. & PEAR, W. S. 2008. Tribbles homolog 
2 (Trib2) and HoxA9 cooperate to accelerate acute myelogenous leukemia. 
Blood Cells Molecules and Diseases, 40, 119-121. 
KENNEDY, M. A., GONZALEZ-SARMIENTO, R., KEES, U. R., LAMPERT, F., 
DEAR, N., BOEHM, T. & RABBITTS, T. H. 1991. HOX11, a homeobox-
containing T-cell oncogene on human chromosome 10q24. Proc Natl Acad 
Sci U S A, 88, 8900-4. 
KINDLER, T., CORNEJO, M. G., SCHOLL, C., LIU, J., LEEMAN, D. S., HAYDU, J. 
E., FROHLING, S., LEE, B. H. & GILLILAND, D. G. 2008. K-RasG12D-
induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations 
and are sensitive to gamma-secretase inhibitors. Blood, 112, 3373-82. 
180 
 
KOMANDER, D. 2009. The emerging complexity of protein ubiquitination. Biochem 
Soc Trans, 37, 937-53. 
KONDO, M., WEISSMAN, I. L. & AKASHI, K. 1997. Identification of clonogenic 
common lymphoid progenitors in mouse bone marrow. Cell, 91, 661-72. 
KOSCHMIEDER, S., HALMOS, B., LEVANTINI, E. & TENEN, D. G. 2009. 
Dysregulation of the C/EBPalpha differentiation pathway in human cancer. J 
Clin Oncol, 27, 619-28. 
KRISTJANSDOTTIR, K. & RUDOLPH, J. 2004. Cdc25 phosphatases and cancer. 
Chem Biol, 11, 1043-51. 
KRUISWIJK, F., LABUSCHAGNE, C. F. & VOUSDEN, K. H. 2015. p53 in survival, 
death and metabolic health: a lifeguard with a licence to kill. Nat Rev Mol 
Cell Biol, 16, 393-405. 
LACRONIQUE, V., BOUREUX, A., VALLE, V. D., POIREL, H., QUANG, C. T., 
MAUCHAUFFE, M., BERTHOU, C., LESSARD, M., BERGER, R., 
GHYSDAEL, J. & BERNARD, O. A. 1997. A TEL-JAK2 fusion protein with 
constitutive kinase activity in human leukemia. Science, 278, 1309-12. 
LAVECCHIA, A., DI GIOVANNI, C., PESAPANE, A., MONTUORI, N., RAGNO, P., 
MARTUCCI, N. M., MASULLO, M., DE VENDITTIS, E. & NOVELLINO, E. 
2012. Discovery of new inhibitors of Cdc25B dual specificity phosphatases 
by structure-based virtual screening. J Med Chem, 55, 4142-58. 
LEE, P. P., FITZPATRICK, D. R., BEARD, C., JESSUP, H. K., LEHAR, S., MAKAR, 
K. W., PEREZ-MELGOSA, M., SWEETSER, M. T., SCHLISSEL, M. S., 
NGUYEN, S., CHERRY, S. R., TSAI, J. H., TUCKER, S. M., WEAVER, W. 
M., KELSO, A., JAENISCH, R. & WILSON, C. B. 2001. A critical role for 
Dnmt1 and DNA methylation in T cell development, function, and survival. 
Immunity, 15, 763-74. 
181 
 
LI, X., GOUNARI, F., PROTOPOPOV, A., KHAZAIE, K. & VON BOEHMER, H. 
2008. Oncogenesis of T-ALL and nonmalignant consequences of 
overexpressing intracellular NOTCH1. J Exp Med, 205, 2851-61. 
LI, X. & SLAYTON, W. B. 2013. Molecular mechanisms of platelet and stem cell 
rebound after 5-fluorouracil treatment. Exp Hematol, 41, 635-645 e3. 
LI, Z., DORDAI, D. I., LEE, J. & DESIDERIO, S. 1996. A conserved degradation 
signal regulates RAG-2 accumulation during cell division and links V(D)J 
recombination to the cell cycle. Immunity, 5, 575-89. 
LIANG, K. L., RISHI, L. & KEESHAN, K. 2013. Tribbles in acute leukemia. Blood, 
121, 4265-70. 
LIN, K. R., LEE, S. F., HUNG, C. M., LI, C. L., YANG-YEN, H. F. & YEN, J. J. 2007. 
Survival factor withdrawal-induced apoptosis of TF-1 cells involves a TRB2-
Mcl-1 axis-dependent pathway. J Biol Chem, 282, 21962-72. 
LIN, W. C. & DESIDERIO, S. 1994. Cell cycle regulation of V(D)J recombination-
activating protein RAG-2. Proc Natl Acad Sci U S A, 91, 2733-7. 
LINCOLN, A. J., WICKRAMASINGHE, D., STEIN, P., SCHULTZ, R. M., PALKO, M. 
E., DE MIGUEL, M. P., TESSAROLLO, L. & DONOVAN, P. J. 2002. Cdc25b 
phosphatase is required for resumption of meiosis during oocyte maturation. 
Nat Genet, 30, 446-9. 
LITZOW, M. R. & FERRANDO, A. A. 2015. How we treat T-cell acute lymphoblastic 
leukemia in adults. Blood. 
LIU, Y., GE, J., LI, Q., GUO, X., GU, L., MA, Z. G., LI, X. H. & ZHU, Y. P. 2014. 
Low-dose anisomycin sensitizes glucocorticoid-resistant T-acute 
lymphoblastic leukemia CEM-C1 cells to dexamethasone-induced apoptosis 
through activation of glucocorticoid receptor and p38-MAPK/JNK. Leuk 
Lymphoma, 55, 2179-88. 
LONGLEY, D. B., HARKIN, D. P. & JOHNSTON, P. G. 2003. 5-fluorouracil: 
mechanisms of action and clinical strategies. Nat Rev Cancer, 3, 330-8. 
182 
 
LU, M., GONG, Z. Y., SHEN, W. F. & HO, A. D. 1991. The tcl-3 proto-oncogene 
altered by chromosomal translocation in T-cell leukemia codes for a 
homeobox protein. EMBO J, 10, 2905-10. 
LUC, S., LUIS, T. C., BOUKARABILA, H., MACAULAY, I. C., BUZA-VIDAS, N., 
BOURIEZ-JONES, T., LUTTEROPP, M., WOLL, P. S., LOUGHRAN, S. J., 
MEAD, A. J., HULTQUIST, A., BROWN, J., MIZUKAMI, T., MATSUOKA, S., 
FERRY, H., ANDERSON, K., DUARTE, S., ATKINSON, D., SONEJI, S., 
DOMANSKI, A., FARLEY, A., SANJUAN-PLA, A., CARELLA, C., PATIENT, 
R., DE BRUIJN, M., ENVER, T., NERLOV, C., BLACKBURN, C., GODIN, I. 
& JACOBSEN, S. E. 2012. The earliest thymic T cell progenitors sustain B 
cell and myeloid lineage potential. Nat Immunol, 13, 412-9. 
MAILAND, N., PODTELEJNIKOV, A. V., GROTH, A., MANN, M., BARTEK, J. & 
LUKAS, J. 2002. Regulation of G(2)/M events by Cdc25A through 
phosphorylation-dependent modulation of its stability. EMBO J, 21, 5911-20. 
MANCINI, E., SANJUAN-PLA, A., LUCIANI, L., MOORE, S., GROVER, A., ZAY, A., 
RASMUSSEN, K. D., LUC, S., BILBAO, D., O'CARROLL, D., JACOBSEN, 
S. E. & NERLOV, C. 2012. FOG-1 and GATA-1 act sequentially to specify 
definitive megakaryocytic and erythroid progenitors. EMBO J, 31, 351-65. 
MANKE, I. A., NGUYEN, A., LIM, D., STEWART, M. Q., ELIA, A. E. & YAFFE, M. B. 
2005. MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the 
G2/M transition and S phase progression in response to UV irradiation. Mol 
Cell, 17, 37-48. 
MANNING, G., WHYTE, D. B., MARTINEZ, R., HUNTER, T. & SUDARSANAM, S. 
2002. The protein kinase complement of the human genome. Science, 298, 
1912-34. 
MANZ, M. G. & BOETTCHER, S. 2014. Emergency granulopoiesis. Nat Rev 
Immunol, 14, 302-14. 
183 
 
MARTINS, V. C., BUSCH, K., JURAEVA, D., BLUM, C., LUDWIG, C., RASCHE, V., 
LASITSCHKA, F., MASTITSKY, S. E., BRORS, B., HIELSCHER, T., 
FEHLING, H. J. & RODEWALD, H. R. 2014. Cell competition is a tumour 
suppressor mechanism in the thymus. Nature, 509, 465-70. 
MARTINS, V. C., RUGGIERO, E., SCHLENNER, S. M., MADAN, V., SCHMIDT, M., 
FINK, P. J., VON KALLE, C. & RODEWALD, H. R. 2012. Thymus-
autonomous T cell development in the absence of progenitor import. J Exp 
Med, 209, 1409-17. 
MASIERO, M., MINUZZO, S., PUSCEDDU, I., MOSERLE, L., PERSANO, L., 
AGNUSDEI, V., TOSELLO, V., BASSO, G., AMADORI, A. & INDRACCOLO, 
S. 2011. Notch3-mediated regulation of MKP-1 levels promotes survival of T 
acute lymphoblastic leukemia cells. Leukemia, 25, 588-98. 
MATA, J., CURADO, S., EPHRUSSI, A. & RORTH, P. 2000. Tribbles coordinates 
mitosis and morphogenesis in Drosophila by regulating string/CDC25 
proteolysis. Cell, 101, 511-22. 
MAUCH, P., CONSTINE, L., GREENBERGER, J., KNOSPE, W., SULLIVAN, J., 
LIESVELD, J. L. & DEEG, H. J. 1995. Hematopoietic stem cell compartment: 
acute and late effects of radiation therapy and chemotherapy. Int J Radiat 
Oncol Biol Phys, 31, 1319-39. 
MCGARGILL, M. A., CH'EN, I. L., KATAYAMA, C. D., PAGES, G., POUYSSEGUR, 
J. & HEDRICK, S. M. 2009. Cutting edge: Extracellular signal-related kinase 
is not required for negative selection of developing T cells. J Immunol, 183, 
4838-42. 
MCGUIRE, E. A., HOCKETT, R. D., POLLOCK, K. M., BARTHOLDI, M. F., 
O'BRIEN, S. J. & KORSMEYER, S. J. 1989. The t(11;14)(p15;q11) in a T-
cell acute lymphoblastic leukemia cell line activates multiple transcripts, 
including Ttg-1, a gene encoding a potential zinc finger protein. Mol Cell 
Biol, 9, 2124-32. 
184 
 
MCKEITHAN, T. W., SHIMA, E. A., LE BEAU, M. M., MINOWADA, J., ROWLEY, J. 
D. & DIAZ, M. O. 1986. Molecular cloning of the breakpoint junction of a 
human chromosomal 8;14 translocation involving the T-cell receptor alpha-
chain gene and sequences on the 3' side of MYC. Proc Natl Acad Sci U S A, 
83, 6636-40. 
MCNEIL, L. K., STARR, T. K. & HOGQUIST, K. A. 2005. A requirement for 
sustained ERK signaling during thymocyte positive selection in vivo. Proc 
Natl Acad Sci U S A, 102, 13574-9. 
MELKUN, E., PILIONE, M. & PAULSON, R. F. 2002. A naturally occurring point 
substitution in Cdc25A, and not Fv2/Stk, is associated with altered cell-cycle 
status of early erythroid progenitor cells. Blood, 100, 3804-11. 
MELLENTIN, J. D., SMITH, S. D. & CLEARY, M. L. 1989. lyl-1, a novel gene altered 
by chromosomal translocation in T cell leukemia, codes for a protein with a 
helix-loop-helix DNA binding motif. Cell, 58, 77-83. 
MILLAR, J. B., BLEVITT, J., GERACE, L., SADHU, K., FEATHERSTONE, C. & 
RUSSELL, P. 1991. p55CDC25 is a nuclear protein required for the initiation 
of mitosis in human cells. Proc Natl Acad Sci U S A, 88, 10500-4. 
MIN, H., MONTECINO-RODRIGUEZ, E. & DORSHKIND, K. 2004. Reduction in the 
developmental potential of intrathymic T cell progenitors with age. J 
Immunol, 173, 245-50. 
MINGUENEAU, M., KRESLAVSKY, T., GRAY, D., HENG, T., CRUSE, R., 
ERICSON, J., BENDALL, S., SPITZER, M. H., NOLAN, G. P., KOBAYASHI, 
K., VON BOEHMER, H., MATHIS, D., BENOIST, C., BEST, A. J., KNELL, 
J., GOLDRATH, A., JOIC, V., KOLLER, D., SHAY, T., REGEV, A., COHEN, 
N., BRENNAN, P., BRENNER, M., KIM, F., NAGESWARA RAO, T., 
WAGERS, A., ROTHAMEL, K., ORTIZ-LOPEZ, A., BEZMAN, N. A., SUN, J. 
C., MIN-OO, G., KIM, C. C., LANIER, L. L., MILLER, J., BROWN, B., 
MERAD, M., GAUTIER, E. L., JAKUBZICK, C., RANDOLPH, G. J., 
185 
 
MONACH, P., BLAIR, D. A., DUSTIN, M. L., SHINTON, S. A., HARDY, R. 
R., LAIDLAW, D., COLLINS, J., GAZIT, R., ROSSI, D. J., MALHOTRA, N., 
SYLVIA, K., KANG, J., FLETCHER, A., ELPEK, K., BELLEMARE-
PELLETIER, A., MALHOTRA, D. & TURLEY, S. 2013. The transcriptional 
landscape of alphabeta T cell differentiation. Nat Immunol, 14, 619-32. 
MOORE, A. J., SARMIENTO, J., MOHTASHAMI, M., BRAUNSTEIN, M., ZUNIGA-
PFLUCKER, J. C. & ANDERSON, M. K. 2012. Transcriptional priming of 
intrathymic precursors for dendritic cell development. Development, 139, 
373-84. 
MUKHERJEE, K., SHARMA, M., JAHN, R., WAHL, M. C. & SUDHOF, T. C. 2010. 
Evolution of CASK into a Mg2+-sensitive kinase. Sci Signal, 3, ra33. 
MUKHERJEE, K., SHARMA, M., URLAUB, H., BOURENKOV, G. P., JAHN, R., 
SUDHOF, T. C. & WAHL, M. C. 2008. CASK Functions as a Mg2+-
independent neurexin kinase. Cell, 133, 328-39. 
NAGEL, S., VENTURINI, L., PRZYBYLSKI, G. K., GRABARCZYK, P., 
SCHNEIDER, B., MEYER, C., KAUFMANN, M., SCHMIDT, C. A., SCHERR, 
M., DREXLER, H. G. & MACLEOD, R. A. 2011. Activation of Paired-
homeobox gene PITX1 by del(5)(q31) in T-cell acute lymphoblastic 
leukemia. Leuk Lymphoma, 52, 1348-59. 
NAIKI, T., SAIJOU, E., MIYAOKA, Y., SEKINE, K. & MIYAJIMA, A. 2007. TRB2, a 
mouse Tribbles ortholog, suppresses adipocyte differentiation by inhibiting 
AKT and C/EBPbeta. J Biol Chem, 282, 24075-82. 
NAKAYAMA, K., OGAWA, A., MIYASHITA, H., TABARA, Y., IGASE, M., KOHARA, 
K., MIKI, T., KAGAWA, Y., YANAGISAWA, Y., KATASHIMA, M., ONDA, T., 
OKADA, K., FUKUSHIMA, S. & IWAMOTO, S. 2013. Positive natural 
selection of TRIB2, a novel gene that influences visceral fat accumulation, in 
East Asia. Hum Genet, 132, 201-17. 
186 
 
NAKAYAMA, T., KASPROWICZ, D. J., YAMASHITA, M., SCHUBERT, L. A., 
GILLARD, G., KIMURA, M., DIDIERLAURENT, A., KOSEKI, H. & ZIEGLER, 
S. F. 2002. The generation of mature, single-positive thymocytes in vivo is 
dysregulated by CD69 blockade or overexpression. J Immunol, 168, 87-94. 
NOTTA, F., ZANDI, S., TAKAYAMA, N., DOBSON, S., GAN, O. I., WILSON, G., 
KAUFMANN, K. B., MCLEOD, J., LAURENTI, E., DUNANT, C. F., 
MCPHERSON, J. D., STEIN, L. D., DROR, Y. & DICK, J. E. 2016. Distinct 
routes of lineage development reshape the human blood hierarchy across 
ontogeny. Science, 351, aab2116. 
NUNES-ALVES, C., NOBREGA, C., BEHAR, S. M. & CORREIA-NEVES, M. 2013. 
Tolerance has its limits: how the thymus copes with infection. Trends 
Immunol, 34, 502-10. 
OGILVY, S., METCALF, D., GIBSON, L., BATH, M. L., HARRIS, A. W. & ADAMS, 
J. M. 1999. Promoter elements of vav drive transgene expression in vivo 
throughout the hematopoietic compartment. Blood, 94, 1855-63. 
OKAMOTO, H., LATRES, E., LIU, R., THABET, K., MURPHY, A., VALENZEULA, 
D., YANCOPOULOS, G. D., STITT, T. N., GLASS, D. J. & SLEEMAN, M. W. 
2007. Genetic deletion of Trb3, the mammalian Drosophila tribbles homolog, 
displays normal hepatic insulin signaling and glucose homeostasis. 
Diabetes, 56, 1350-6. 
ORD, T., ORD, D., KUUSE, S. & PLAAS, M. 2012. Trib3 is regulated by IL-3 and 
affects bone marrow-derived mast cell survival and function. Cell Immunol, 
280, 68-75. 
OZEKI, Y., KANEDA, K., FUJIWARA, N., MORIMOTO, M., OKA, S. & YANO, I. 
1997. In vivo induction of apoptosis in the thymus by administration of 
mycobacterial cord factor (trehalose 6,6'-dimycolate). Infect Immun, 65, 
1793-9. 
187 
 
PAGES, G., GUERIN, S., GRALL, D., BONINO, F., SMITH, A., ANJUERE, F., 
AUBERGER, P. & POUYSSEGUR, J. 1999. Defective thymocyte maturation 
in p44 MAP kinase (Erk 1) knockout mice. Science, 286, 1374-7. 
PALMA, C. A., AL SHEIKHA, D., LIM, T. K., BRYANT, A., VU, T. T., JAYASWAL, V. 
& MA, D. D. 2014. MicroRNA-155 as an inducer of apoptosis and cell 
differentiation in Acute Myeloid Leukaemia. Mol Cancer, 13, 79. 
PALMER, D. B. 2013. The Effect of Age on Thymic Function. Front Immunol, 4, 
316. 
PANG, W. W., PRICE, E. A., SAHOO, D., BEERMAN, I., MALONEY, W. J., ROSSI, 
D. J., SCHRIER, S. L. & WEISSMAN, I. L. 2011. Human bone marrow 
hematopoietic stem cells are increased in frequency and myeloid-biased 
with age. Proc Natl Acad Sci U S A, 108, 20012-7. 
PAUL, F., ARKIN, Y., GILADI, A., JAITIN, D. A., KENIGSBERG, E., KEREN-
SHAUL, H., WINTER, D., LARA-ASTIASO, D., GURY, M., WEINER, A., 
DAVID, E., COHEN, N., LAURIDSEN, F. K., HAAS, S., SCHLITZER, A., 
MILDNER, A., GINHOUX, F., JUNG, S., TRUMPP, A., PORSE, B. T., 
TANAY, A. & AMIT, I. 2015. Transcriptional Heterogeneity and Lineage 
Commitment in Myeloid Progenitors. Cell, 163, 1663-77. 
PEAR, W. S., ASTER, J. C., SCOTT, M. L., HASSERJIAN, R. P., SOFFER, B., 
SKLAR, J. & BALTIMORE, D. 1996. Exclusive development of T cell 
neoplasms in mice transplanted with bone marrow expressing activated 
Notch alleles. J Exp Med, 183, 2283-91. 
PEAUDECERF, L., LEMOS, S., GALGANO, A., KRENN, G., VASSEUR, F., DI 
SANTO, J. P., EZINE, S. & ROCHA, B. 2012. Thymocytes may persist and 
differentiate without any input from bone marrow progenitors. J Exp Med, 
209, 1401-8. 
PFLEGER, C. M. & KIRSCHNER, M. W. 2000. The KEN box: an APC recognition 
signal distinct from the D box targeted by Cdh1. Genes Dev, 14, 655-65. 
188 
 
PORRITT, H. E., RUMFELT, L. L., TABRIZIFARD, S., SCHMITT, T. M., ZUNIGA-
PFLUCKER, J. C. & PETRIE, H. T. 2004. Heterogeneity among DN1 
prothymocytes reveals multiple progenitors with different capacities to 
generate T cell and non-T cell lineages. Immunity, 20, 735-45. 
PRINZ, I., SANSONI, A., KISSENPFENNIG, A., ARDOUIN, L., MALISSEN, M. & 
MALISSEN, B. 2006. Visualization of the earliest steps of gammadelta T cell 
development in the adult thymus. Nat Immunol, 7, 995-1003. 
PUI, J. C., ALLMAN, D., XU, L., DEROCCO, S., KARNELL, F. G., BAKKOUR, S., 
LEE, J. Y., KADESCH, T., HARDY, R. R., ASTER, J. C. & PEAR, W. S. 
1999. Notch1 expression in early lymphopoiesis influences B versus T 
lineage determination. Immunity, 11, 299-308. 
QI, L., HEREDIA, J. E., ALTAREJOS, J. Y., SCREATON, R., GOEBEL, N., 
NIESSEN, S., MACLEOD, I. X., LIEW, C. W., KULKARNI, R. N., BAIN, J., 
NEWGARD, C., NELSON, M., EVANS, R. M., YATES, J. & MONTMINY, M. 
2006. TRB3 links the E3 ubiquitin ligase COP1 to lipid metabolism. Science, 
312, 1763-6. 
QIAO, Y., ZHANG, Y. & WANG, J. 2013. Ubiquitin E3 ligase SCF(beta-TRCP) 
regulates TRIB2 stability in liver cancer cells. Biochem Biophys Res 
Commun, 441, 555-9. 
RADTKE, F., WILSON, A., STARK, G., BAUER, M., VAN MEERWIJK, J., 
MACDONALD, H. R. & AGUET, M. 1999. Deficient T cell fate specification in 
mice with an induced inactivation of Notch1. Immunity, 10, 547-58. 
RANDALL, T. D. & WEISSMAN, I. L. 1997. Phenotypic and functional changes 
induced at the clonal level in hematopoietic stem cells after 5-fluorouracil 
treatment. Blood, 89, 3596-606. 
RANDLE-BARRETT, E. S. & BOYD, R. L. 1995. Thymic microenvironment and 
lymphoid responses to sublethal irradiation. Dev Immunol, 4, 101-16. 
189 
 
REN, S. & ROLLINS, B. J. 2004. Cyclin C/cdk3 promotes Rb-dependent G0 exit. 
Cell, 117, 239-51. 
REYA, T., MORRISON, S. J., CLARKE, M. F. & WEISSMAN, I. L. 2001. Stem cells, 
cancer, and cancer stem cells. Nature, 414, 105-11. 
RINCON, M., WHITMARSH, A., YANG, D. D., WEISS, L., DERIJARD, B., 
JAYARAJ, P., DAVIS, R. J. & FLAVELL, R. A. 1998. The JNK pathway 
regulates the In vivo deletion of immature CD4(+)CD8(+) thymocytes. J Exp 
Med, 188, 1817-30. 
RISHI, L., HANNON, M., SALOME, M., HASEMANN, M., FRANK, A. K., CAMPOS, 
J., TIMONEY, J., O'CONNOR, C., CAHILL, M. R., PORSE, B. & KEESHAN, 
K. 2014. Regulation of Trib2 by an E2F1-C/EBPalpha feedback loop in AML 
cell proliferation. Blood, 123, 2389-400. 
RORTH, P., SZABO, K. & TEXIDO, G. 2000. The level of C/EBP protein is critical 
for cell migration during Drosophila oogenesis and is tightly controlled by 
regulated degradation. Mol Cell, 6, 23-30. 
ROSSI, D. J., BRYDER, D., ZAHN, J. M., AHLENIUS, H., SONU, R., WAGERS, A. 
J. & WEISSMAN, I. L. 2005. Cell intrinsic alterations underlie hematopoietic 
stem cell aging. Proc Natl Acad Sci U S A, 102, 9194-9. 
ROTHENBERG, E. V. & SCRIPTURE-ADAMS, D. D. 2008. Competition and 
collaboration: GATA-3, PU.1, and Notch signaling in early T-cell fate 
determination. Semin Immunol, 20, 236-46. 
SAKA, Y. & SMITH, J. C. 2004. A Xenopus tribbles orthologue is required for the 
progression of mitosis and for development of the nervous system. Dev Biol, 
273, 210-25. 
SAKAI, S., OHOKA, N., ONOZAKI, K., KITAGAWA, M., NAKANISHI, M. & 
HAYASHI, H. 2010. Dual mode of regulation of cell division cycle 25 A 
protein by TRB3. Biol Pharm Bull, 33, 1112-6. 
190 
 
SALLAN, S. E. 2006. Myths and lessons from the adult/pediatric interface in acute 
lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program, 128-
32. 
SALOME, M., CAMPOS, J. & KEESHAN, K. 2015. TRIB2 and the ubiquitin 
proteasome system in cancer. Biochem Soc Trans, 43, 1089-94. 
SANDA, T., LAWTON, L. N., BARRASA, M. I., FAN, Z. P., KOHLHAMMER, H., 
GUTIERREZ, A., MA, W., TATAREK, J., AHN, Y., KELLIHER, M. A., 
JAMIESON, C. H., STAUDT, L. M., YOUNG, R. A. & LOOK, A. T. 2012. 
Core transcriptional regulatory circuit controlled by the TAL1 complex in 
human T cell acute lymphoblastic leukemia. Cancer Cell, 22, 209-21. 
SATOH, T., KIDOYA, H., NAITO, H., YAMAMOTO, M., TAKEMURA, N., 
NAKAGAWA, K., YOSHIOKA, Y., MORII, E., TAKAKURA, N., TAKEUCHI, 
O. & AKIRA, S. 2013. Critical role of Trib1 in differentiation of tissue-resident 
M2-like macrophages. Nature, 495, 524-8. 
SCHLENNER, S. M., MADAN, V., BUSCH, K., TIETZ, A., LAUFLE, C., COSTA, C., 
BLUM, C., FEHLING, H. J. & RODEWALD, H. R. 2010. Fate mapping 
reveals separate origins of T cells and myeloid lineages in the thymus. 
Immunity, 32, 426-36. 
SCHOOLMEESTERS, A., BROWN, D. D. & FEDOROV, Y. 2012. Kinome-wide 
functional genomics screen reveals a novel mechanism of TNFalpha-
induced nuclear accumulation of the HIF-1alpha transcription factor in 
cancer cells. PLoS One, 7, e31270. 
SEHER, T. C. & LEPTIN, M. 2000. Tribbles, a cell-cycle brake that coordinates 
proliferation and morphogenesis during Drosophila gastrulation. Curr Biol, 
10, 623-9. 
SEITAN, V. C., HAO, B., TACHIBANA-KONWALSKI, K., LAVAGNOLLI, T., MIRA-
BONTENBAL, H., BROWN, K. E., TENG, G., CARROLL, T., TERRY, A., 
HORAN, K., MARKS, H., ADAMS, D. J., SCHATZ, D. G., ARAGON, L., 
191 
 
FISHER, A. G., KRANGEL, M. S., NASMYTH, K. & MERKENSCHLAGER, 
M. 2011. A role for cohesin in T-cell-receptor rearrangement and thymocyte 
differentiation. Nature, 476, 467-71. 
SERWOLD, T., EHRLICH, L. I. & WEISSMAN, I. L. 2009. Reductive isolation from 
bone marrow and blood implicates common lymphoid progenitors as the 
major source of thymopoiesis. Blood, 113, 807-15. 
SHABBEER, S., OMER, D., BERNEMAN, D., WEITZMAN, O., ALPAUGH, A., 
PIETRASZKIEWICZ, A., METSUYANIM, S., SHAINSKAYA, A., PAPA, M. Z. 
& YARDEN, R. I. 2013. BRCA1 targets G2/M cell cycle proteins for 
ubiquitination and proteasomal degradation. Oncogene, 32, 5005-16. 
SHAO, L., FENG, W., LI, H., GARDNER, D., LUO, Y., WANG, Y., LIU, L., MENG, 
A., SHARPLESS, N. E. & ZHOU, D. 2014. Total body irradiation causes 
long-term mouse BM injury via induction of HSC premature senescence in 
an Ink4a- and Arf-independent manner. Blood, 123, 3105-15. 
SHARP, L. L., SCHWARZ, D. A., BOTT, C. M., MARSHALL, C. J. & HEDRICK, S. 
M. 1997. The influence of the MAPK pathway on T cell lineage commitment. 
Immunity, 7, 609-18. 
SHIMA, E. A., LE BEAU, M. M., MCKEITHAN, T. W., MINOWADA, J., SHOWE, L. 
C., MAK, T. W., MINDEN, M. D., ROWLEY, J. D. & DIAZ, M. O. 1986. Gene 
encoding the alpha chain of the T-cell receptor is moved immediately 
downstream of c-myc in a chromosomal 8;14 translocation in a cell line from 
a human T-cell leukemia. Proc Natl Acad Sci U S A, 83, 3439-43. 
SHIN, J. Y., HU, W., NARAMURA, M. & PARK, C. Y. 2014. High c-Kit expression 
identifies hematopoietic stem cells with impaired self-renewal and 
megakaryocytic bias. J Exp Med, 211, 217-31. 
SMITH, S. D., MORGAN, R., GEMMELL, R., AMYLON, M. D., LINK, M. P., 
LINKER, C., HECHT, B. K., WARNKE, R., GLADER, B. E. & HECHT, F. 
192 
 
1988. Clinical and biologic characterization of T-cell neoplasias with 
rearrangements of chromosome 7 band q34. Blood, 71, 395-402. 
SOULIER, J., CLAPPIER, E., CAYUELA, J. M., REGNAULT, A., GARCIA-
PEYDRO, M., DOMBRET, H., BARUCHEL, A., TORIBIO, M. L. & SIGAUX, 
F. 2005. HOXA genes are included in genetic and biologic networks defining 
human acute T-cell leukemia (T-ALL). Blood, 106, 274-86. 
SPELEMAN, F., CAUWELIER, B., DASTUGUE, N., COOLS, J., VERHASSELT, B., 
POPPE, B., VAN ROY, N., VANDESOMPELE, J., GRAUX, C., 
UYTTEBROECK, A., BOOGAERTS, M., DE MOERLOOSE, B., BENOIT, Y., 
SELLESLAG, D., BILLIET, J., ROBERT, A., HUGUET, F., 
VANDENBERGHE, P., DE PAEPE, A., MARYNEN, P. & HAGEMEIJER, A. 
2005. A new recurrent inversion, inv(7)(p15q34), leads to transcriptional 
activation of HOXA10 and HOXA11 in a subset of T-cell acute lymphoblastic 
leukemias. Leukemia, 19, 358-66. 
SPITS, H. 2002. Development of alphabeta T cells in the human thymus. Nat Rev 
Immunol, 2, 760-72. 
STEIN, E. M. & TALLMAN, M. S. 2016. Emerging therapeutic drugs for AML. Blood, 
127, 71-8. 
STEIN, S. J., MACK, E. A., ROME, K. S., PAJCINI, K. V., OHTANI, T., XU, L., LI, 
Y., MEIJERINK, J. P., FARYABI, R. B. & PEAR, W. S. 2016. Trib2 
Suppresses Tumor Initiation in Notch-Driven T-ALL. PLoS One, 11, 
e0155408. 
SUBRAMANIAN, A., TAMAYO, P., MOOTHA, V. K., MUKHERJEE, S., EBERT, B. 
L., GILLETTE, M. A., PAULOVICH, A., POMEROY, S. L., GOLUB, T. R., 
LANDER, E. S. & MESIROV, J. P. 2005. Gene set enrichment analysis: a 
knowledge-based approach for interpreting genome-wide expression 
profiles. Proc Natl Acad Sci U S A, 102, 15545-50. 
193 
 
SUDO, K., EMA, H., MORITA, Y. & NAKAUCHI, H. 2000. Age-associated 
characteristics of murine hematopoietic stem cells. J Exp Med, 192, 1273-
80. 
SUGAWARA, T., MORIGUCHI, T., NISHIDA, E. & TAKAHAMA, Y. 1998. 
Differential roles of ERK and p38 MAP kinase pathways in positive and 
negative selection of T lymphocytes. Immunity, 9, 565-74. 
SUN, D., LUO, M., JEONG, M., RODRIGUEZ, B., XIA, Z., HANNAH, R., WANG, H., 
LE, T., FAULL, K. F., CHEN, R., GU, H., BOCK, C., MEISSNER, A., 
GOTTGENS, B., DARLINGTON, G. J., LI, W. & GOODELL, M. A. 2014. 
Epigenomic profiling of young and aged HSCs reveals concerted changes 
during aging that reinforce self-renewal. Cell Stem Cell, 14, 673-88. 
SUNG, H. Y., GUAN, H., CZIBULA, A., KING, A. R., EDER, K., HEATH, E., 
SUVARNA, S. K., DOWER, S. K., WILSON, A. G., FRANCIS, S. E., 
CROSSMAN, D. C. & KISS-TOTH, E. 2007. Human tribbles-1 controls 
proliferation and chemotaxis of smooth muscle cells via MAPK signaling 
pathways. J Biol Chem, 282, 18379-87. 
TAGHON, T., WAEGEMANS, E. & VAN DE WALLE, I. 2012. Notch signaling during 
human T cell development. Curr Top Microbiol Immunol, 360, 75-97. 
TAGHON, T., YUI, M. A., PANT, R., DIAMOND, R. A. & ROTHENBERG, E. V. 
2006. Developmental and molecular characterization of emerging beta- and 
gammadelta-selected pre-T cells in the adult mouse thymus. Immunity, 24, 
53-64. 
TAKASATO, M., KOBAYASHI, C., OKABAYASHI, K., KIYONARI, H., OSHIMA, N., 
ASASHIMA, M. & NISHINAKAMURA, R. 2008. Trb2, a mouse homolog of 
tribbles, is dispensable for kidney and mouse development. Biochem 
Biophys Res Commun, 373, 648-52. 
TAKEDA, S., RODEWALD, H. R., ARAKAWA, H., BLUETHMANN, H. & SHIMIZU, 
T. 1996. MHC class II molecules are not required for survival of newly 
194 
 
generated CD4+ T cells, but affect their long-term life span. Immunity, 5, 
217-28. 
TAN, S. H., YAM, A. W., LAWTON, L. N., WONG, R. W., YOUNG, R. A., LOOK, T. 
A. & SANDA, T. 2015. TRIB2 reinforces the oncogenic transcriptional 
program controlled by the TAL1 complex in T-cell acute lymphoblastic 
leukemia. Leukemia. 
TOYODA, H., TANAKA, S., MIYAGAWA, T., HONDA, Y., TOKUNAGA, K. & 
HONDA, M. 2010. Anti-Tribbles homolog 2 autoantibodies in Japanese 
patients with narcolepsy. Sleep, 33, 875-8. 
TYCKO, B., SMITH, S. D. & SKLAR, J. 1991. Chromosomal translocations joining 
LCK and TCRB loci in human T cell leukemia. J Exp Med, 174, 867-73. 
VAN LIMBERGEN, H., BEVERLOO, H. B., VAN DRUNEN, E., JANSSENS, A., 
HAHLEN, K., POPPE, B., VAN ROY, N., MARYNEN, P., DE PAEPE, A., 
SLATER, R. & SPELEMAN, F. 2001. Molecular cytogenetic and clinical 
findings in ETV6/ABL1-positive leukemia. Genes Chromosomes Cancer, 30, 
274-82. 
VAN VLIERBERGHE, P., AMBESI-IMPIOMBATO, A., DE KEERSMAECKER, K., 
HADLER, M., PAIETTA, E., TALLMAN, M. S., ROWE, J. M., FORNE, C., 
RUE, M. & FERRANDO, A. A. 2013. Prognostic relevance of integrated 
genetic profiling in adult T-cell acute lymphoblastic leukemia. Blood, 122, 74-
82. 
VAN VLIERBERGHE, P. & FERRANDO, A. 2012. The molecular basis of T cell 
acute lymphoblastic leukemia. J Clin Invest, 122, 3398-406. 
VAN VLIERBERGHE, P., VAN GROTEL, M., BEVERLOO, H. B., LEE, C., 
HELGASON, T., BUIJS-GLADDINES, J., PASSIER, M., VAN WERING, E. 
R., VEERMAN, A. J., KAMPS, W. A., MEIJERINK, J. P. & PIETERS, R. 
2006. The cryptic chromosomal deletion del(11)(p12p13) as a new activation 
195 
 
mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia. Blood, 
108, 3520-9. 
VARDIMAN, J. W., HARRIS, N. L. & BRUNNING, R. D. 2002. The World Health 
Organization (WHO) classification of the myeloid neoplasms. Blood, 100, 
2292-302. 
VARDIMAN, J. W., THIELE, J., ARBER, D. A., BRUNNING, R. D., BOROWITZ, M. 
J., PORWIT, A., HARRIS, N. L., LE BEAU, M. M., HELLSTROM-
LINDBERG, E., TEFFERI, A. & BLOOMFIELD, C. D. 2009. The 2008 
revision of the World Health Organization (WHO) classification of myeloid 
neoplasms and acute leukemia: rationale and important changes. Blood, 
114, 937-51. 
VOGEL, A. B., HAASBACH, E., REILING, S. J., DROEBNER, K., KLINGEL, K. & 
PLANZ, O. 2010. Highly pathogenic influenza virus infection of the thymus 
interferes with T lymphocyte development. J Immunol, 185, 4824-34. 
WANG, J., JANI-SAIT, S. N., ESCALON, E. A., CARROLL, A. J., DE JONG, P. J., 
KIRSCH, I. R. & APLAN, P. D. 2000. The t(14;21)(q11.2;q22) chromosomal 
translocation associated with T-cell acute lymphoblastic leukemia activates 
the BHLHB1 gene. Proc Natl Acad Sci U S A, 97, 3497-502. 
WANG, J., PARK, J. S., WEI, Y., RAJURKAR, M., COTTON, J. L., FAN, Q., LEWIS, 
B. C., JI, H. & MAO, J. 2013a. TRIB2 acts downstream of Wnt/TCF in liver 
cancer cells to regulate YAP and C/EBPalpha function. Mol Cell, 51, 211-25. 
WANG, J., ZHANG, Y., WENG, W., QIAO, Y., MA, L., XIAO, W., YU, Y., PAN, Q. & 
SUN, F. 2013b. Impaired phosphorylation and ubiquitination by p70 S6 
kinase (p70S6K) and Smad ubiquitination regulatory factor 1 (Smurf1) 
promote tribbles homolog 2 (TRIB2) stability and carcinogenic property in 
liver cancer. J Biol Chem, 288, 33667-81. 
WANG, P. Y., SUN, Y. X., ZHANG, S., PANG, M., ZHANG, H. H., GAO, S. Y., 
ZHANG, C., LV, C. J. & XIE, S. Y. 2013c. Let-7c inhibits A549 cell 
196 
 
proliferation through oncogenic TRIB2 related factors. FEBS Lett, 587, 2675-
81. 
WANG, R., HE, G., NELMAN-GONZALEZ, M., ASHORN, C. L., GALLICK, G. E., 
STUKENBERG, P. T., KIRSCHNER, M. W. & KUANG, J. 2007. Regulation 
of Cdc25C by ERK-MAP kinases during the G2/M transition. Cell, 128, 
1119-32. 
WANG, X., XIAO, G., ZHANG, Y., WEN, X., GAO, X., OKADA, S. & LIU, X. 2008. 
Regulation of Tcrb recombination ordering by c-Fos-dependent RAG 
deposition. Nat Immunol, 9, 794-801. 
WEI, S. C., ROSENBERG, I. M., CAO, Z., HUETT, A. S., XAVIER, R. J. & 
PODOLSKY, D. K. 2012. Tribbles 2 (Trib2) is a novel regulator of toll-like 
receptor 5 signaling. Inflamm Bowel Dis, 18, 877-88. 
WENG, A. P., FERRANDO, A. A., LEE, W., MORRIS, J. P. T., SILVERMAN, L. B., 
SANCHEZ-IRIZARRY, C., BLACKLOW, S. C., LOOK, A. T. & ASTER, J. C. 
2004. Activating mutations of NOTCH1 in human T cell acute lymphoblastic 
leukemia. Science, 306, 269-71. 
WILSON, A., LAURENTI, E., OSER, G., VAN DER WATH, R. C., BLANCO-BOSE, 
W., JAWORSKI, M., OFFNER, S., DUNANT, C. F., ESHKIND, L., 
BOCKAMP, E., LIO, P., MACDONALD, H. R. & TRUMPP, A. 2008. 
Hematopoietic stem cells reversibly switch from dormancy to self-renewal 
during homeostasis and repair. Cell, 135, 1118-29. 
WOUTERS, B. J., JORDA, M. A., KEESHAN, K., LOUWERS, I., ERPELINCK-
VERSCHUEREN, C. A., TIELEMANS, D., LANGERAK, A. W., HE, Y., 
YASHIRO-OHTANI, Y., ZHANG, P., HETHERINGTON, C. J., VERHAAK, R. 
G., VALK, P. J., LOWENBERG, B., TENEN, D. G., PEAR, W. S. & 
DELWEL, R. 2007. Distinct gene expression profiles of acute myeloid/T-
lymphoid leukemia with silenced CEBPA and mutations in NOTCH1. Blood, 
110, 3706-14. 
197 
 
XIA, Y., BROWN, L., YANG, C. Y., TSAN, J. T., SICILIANO, M. J., ESPINOSA, R., 
3RD, LE BEAU, M. M. & BAER, R. J. 1991. TAL2, a helix-loop-helix gene 
activated by the (7;9)(q34;q32) translocation in human T-cell leukemia. Proc 
Natl Acad Sci U S A, 88, 11416-20. 
XIE, S., XIE, N., LI, Y., WANG, P., ZHANG, C., LI, Q., LIU, X., DENG, J., ZHANG, 
C. & LV, C. 2012. Upregulation of TRB2 induced by miR-98 in the early 
lesions of large artery of type-2 diabetic rat. Molecular and Cellular 
Biochemistry, 361, 305-314. 
XIN, J. X., YUE, Z., ZHANG, S., JIANG, Z. H., WANG, P. Y., LI, Y. J., PANG, M. & 
XIE, S. Y. 2013. miR-99 inhibits cervical carcinoma cell proliferation by 
targeting TRIB2. Oncol Lett, 6, 1025-1030. 
YAMAMOTO, R., MORITA, Y., OOEHARA, J., HAMANAKA, S., ONODERA, M., 
RUDOLPH, K. L., EMA, H. & NAKAUCHI, H. 2013. Clonal analysis unveils 
self-renewing lineage-restricted progenitors generated directly from 
hematopoietic stem cells. Cell, 154, 1112-26. 
YOKOYAMA, T., KANNO, Y., YAMAZAKI, Y., TAKAHARA, T., MIYATA, S. & 
NAKAMURA, T. 2010. Trib1 links the MEK1/ERK pathway in myeloid 
leukemogenesis. Blood, 116, 2768-75. 
YOKOYAMA, T. & NAKAMURA, T. 2011. Tribbles in disease: Signaling pathways 
important for cellular function and neoplastic transformation. Cancer Sci, 
102, 1115-22. 
YOKOYAMA, T., TOKI, T., AOKI, Y., KANEZAKI, R., PARK, M. J., KANNO, Y., 
TAKAHARA, T., YAMAZAKI, Y., ITO, E., HAYASHI, Y. & NAKAMURA, T. 
2012. Identification of TRIB1 R107L gain-of-function mutation in human 
acute megakaryocytic leukemia. Blood, 119, 2608-11. 
YOSHIMURA, F. K., WANG, T. & CANKOVIC, M. 1999. Sequences between the 
enhancer and promoter in the long terminal repeat affect murine leukemia 
virus pathogenicity and replication in the thymus. J Virol, 73, 4890-8. 
198 
 
YUI, M. A., FENG, N. & ROTHENBERG, E. V. 2010. Fine-scale staging of T cell 
lineage commitment in adult mouse thymus. J Immunol, 185, 284-93. 
YUI, M. A. & ROTHENBERG, E. V. 2014. Developmental gene networks: a triathlon 
on the course to T cell identity. Nat Rev Immunol, 14, 529-45. 
YUSUF, I. & FRUMAN, D. A. 2003. Regulation of quiescence in lymphocytes. 
Trends Immunol, 24, 380-6. 
ZANELLA, F., RENNER, O., GARCIA, B., CALLEJAS, S., DOPAZO, A., 
PEREGRINA, S., CARNERO, A. & LINK, W. 2010. Human TRIB2 is a 
repressor of FOXO that contributes to the malignant phenotype of 
melanoma cells. Oncogene, 29, 2973-82. 
ZEDIAK, V. P., MAILLARD, I. & BHANDOOLA, A. 2007. Multiple prethymic defects 
underlie age-related loss of T progenitor competence. Blood, 110, 1161-7. 
ZHANG, C., CHI, Y. L., WANG, P. Y., WANG, Y. Q., ZHANG, Y. X., DENG, J., LV, 
C. J. & XIE, S. Y. 2012a. miR-511 and miR-1297 inhibit human lung 
adenocarcinoma cell proliferation by targeting oncogene TRIB2. PLoS One, 
7, e46090. 
ZHANG, H., PHOTIOU, A., GROTHEY, A., STEBBING, J. & GIAMAS, G. 2012b. 
The role of pseudokinases in cancer. Cell Signal, 24, 1173-1184. 
ZHANG, H. H., PANG, M., DONG, W., XIN, J. X., LI, Y. J., ZHANG, Z. C., YU, L., 
WANG, P. Y., LI, B. S. & XIE, S. Y. 2014. miR-511 induces the apoptosis of 
radioresistant lung adenocarcinoma cells by triggering BAX. Oncol Rep, 31, 
1473-9. 
ZHANG, J., DING, L., HOLMFELDT, L., WU, G., HEATLEY, S. L., PAYNE-
TURNER, D., EASTON, J., CHEN, X., WANG, J., RUSCH, M., LU, C., 
CHEN, S. C., WEI, L., COLLINS-UNDERWOOD, J. R., MA, J., ROBERTS, 
K. G., POUNDS, S. B., ULYANOV, A., BECKSFORT, J., GUPTA, P., 
HUETHER, R., KRIWACKI, R. W., PARKER, M., MCGOLDRICK, D. J., 
ZHAO, D., ALFORD, D., ESPY, S., BOBBA, K. C., SONG, G., PEI, D., 
199 
 
CHENG, C., ROBERTS, S., BARBATO, M. I., CAMPANA, D., COUSTAN-
SMITH, E., SHURTLEFF, S. A., RAIMONDI, S. C., KLEPPE, M., COOLS, J., 
SHIMANO, K. A., HERMISTON, M. L., DOULATOV, S., EPPERT, K., 
LAURENTI, E., NOTTA, F., DICK, J. E., BASSO, G., HUNGER, S. P., LOH, 
M. L., DEVIDAS, M., WOOD, B., WINTER, S., DUNSMORE, K. P., 
FULTON, R. S., FULTON, L. L., HONG, X., HARRIS, C. C., DOOLING, D. 
J., OCHOA, K., JOHNSON, K. J., OBENAUER, J. C., EVANS, W. E., PUI, 
C. H., NAEVE, C. W., LEY, T. J., MARDIS, E. R., WILSON, R. K., 
DOWNING, J. R. & MULLIGHAN, C. G. 2012c. The genetic basis of early T-
cell precursor acute lymphoblastic leukaemia. Nature, 481, 157-63. 
ZHANG, J. A., MORTAZAVI, A., WILLIAMS, B. A., WOLD, B. J. & ROTHENBERG, 
E. V. 2012d. Dynamic transformations of genome-wide epigenetic marking 
and transcriptional control establish T cell identity. Cell, 149, 467-82. 
ZHANG, L., LI, X., KE, Z., HUANG, L., LIANG, Y., WU, J., ZHANG, X., CHEN, Y., 
ZHANG, H. & LUO, X. 2013. MiR-99a may serve as a potential oncogene in 
pediatric myeloid leukemia. Cancer Cell Int, 13, 110. 
ZHANG, P., NELSON, S., BAGBY, G. J., SIGGINS, R., 2ND, SHELLITO, J. E. & 
WELSH, D. A. 2008. The lineage-c-Kit+Sca-1+ cell response to Escherichia 
coli bacteremia in Balb/c mice. Stem Cells, 26, 1778-86. 
ZHANG, Y., DAVIS, J. L. & LI, W. 2005. Identification of tribbles homolog 2 as an 
autoantigen in autoimmune uveitis by phage display. Mol Immunol, 42, 
1275-81. 
ZHENG, Y. S., ZHANG, H., ZHANG, X. J., FENG, D. D., LUO, X. Q., ZENG, C. W., 
LIN, K. Y., ZHOU, H., QU, L. H., ZHANG, P. & CHEN, Y. Q. 2012. MiR-100 
regulates cell differentiation and survival by targeting RBSP3, a 
phosphatase-like tumor suppressor in acute myeloid leukemia. Oncogene, 
31, 80-92. 
200 
 
ZHOU, M. H., GAO, L., JING, Y., XU, Y. Y., DING, Y., WANG, N., WANG, W., LI, M. 
Y., HAN, X. P., SUN, J. Z., WANG, L. L. & YU, L. 2012. Detection of ETV6 
gene rearrangements in adult acute lymphoblastic leukemia. Ann Hematol, 
91, 1235-43. 
ZUNA, J., ZALIOVA, M., MUZIKOVA, K., MEYER, C., LIZCOVA, L., ZEMANOVA, 
Z., BREZINOVA, J., VOTAVA, F., MARSCHALEK, R., STARY, J. & TRKA, 
J. 2010. Acute leukemias with ETV6/ABL1 (TEL/ABL) fusion: poor prognosis 
and prenatal origin. Genes Chromosomes Cancer, 49, 873-84. 
 
201 
 
 
